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Resumo 
O nicho das células hematopoiéticas estaminais (CHE) na medula óssea (MO) é um microambiente 
protetor de difícil acesso, tornando-se difícil de modular no contexto de transplante de CHE e doenças 
hematopoiéticas. Nesta tese, desenvolvemos novas estratégias para ultrapassar estes obstáculos, 
utilizando uma combinação de ferramentas de nanomedicina com células, utilizadas como veículo. No 
contexto da leucemia, acredita-se que as células resistentes às terapias convencionais residam em nichos 
protetores. Aqui, descrevemos nanopartículas (NP) poliméricas induzíveis por luz que contêm ácido 
retinóico (RA). Estas NPs têm a capacidade de se acumular no citoplasma das células leucêmicas (CL) 
durante vários dias enquanto mantêm a capacidade de libertar grandes quantidade de RA, poucos 
minutos após exposição à luz azul / Ultravioleta. Quando comparadas com NPs não ativadas pela 
exposição à luz, RA+NPs reduzem mais eficientemente a clonogenicidade de CL da MO de pacientes 
com Leucemia mieloide aguda (LMA) e induzem a diferenciação de CL com sensibilidade ao RA 
reduzida. Adicionalmente, nós demostramos in vivo que as CL transfectadas com RA+NPs 
fotossensíveis podem enxertar a MO na proximidade de outras CL, induzir a diferenciação após 
exposição à luz azul e libertar fatores parácrinos que modulam as células na proximidade das células 
utilizadas como veículo. Esta capacidade de modular remotamente o nicho leucémico foi testada num 
modelo animal de LMA com sucesso. As RA+NPs induziram a diferenciação de LMA na linhagem 
monocítica / macrofágica no modelo animal em murganhos de LMA contendo o oncogene MLL-AF9. 
Além disso, demostramos in vitro que as RA+NPs estimulam a ativação de macrófagos M1, com 
capacidades anti-tumorais. Esta indução de diferenciação em macrófagos in vivo parece ter efeito anti- 
leucêmico “sistêmico” dentro do nicho leucêmico da BM, pois observamos uma redução significativa 
de CL na MO de animais tratados com RA+NPs quando comparados com animais tratados com NPs 
vazias (RA-NPs). Por último, foram feitos estudos prospetivos tendo como objectivo o uso de CHEs 
saudáveis como transportadoras de NP. Os nossos resultados mostraram que, apesar de serem um tipo 
celular mais sensível, as células UCB CD34+ podem ser carregadas com RA+NPs e, após a libertação 
de RA induzida pela luz, observamos um aumento de expressão de CD38. No contexto de utilização 
deste tipo de ferramentas na modulação do enxerto de CHE no contexto de transplante medular,  fomos 
capazes de produzir HOXB4 funcional, um fator de transcrição fundamental para o normal 
funcionamento e expansão de CHE,  através da indução dum estado de quiescência e paragens do ciclo 
celular em G0. Contudo a funcionalização de NP com este tipo de molécula constitui um desafio e 
poderá ser tema de trabalho futuro. 
 
Palavras-chave: Nanopartículas, Administração direcionada de fármacos; Activação por luz; 
Leucemia Mieloide Aguda; células transportadoras 
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Abstract 
 
The bone-marrow haematopoietic stem cell niche is a protective hard to reach microenvironment 
that is difficult to modulate in the context of HSC transplant and malignant haematopoietic disease. In 
this thesis we developed new strategies to tackle this by the use of a combination of nanomedicine tools 
and cell-mediated delivery systems. In the context of leukaemia, cells that are resistant to conventional 
therapies are thought to reside in protective niches. Here, we describe light-inducible polymeric retinoic 
acid (RA)-containing nanoparticles (NPs) with the capacity to accumulate in the cytoplasm of leukaemia 
cells for several days and release their RA payloads within a few minutes upon exposure to blue/UV 
light. Compared to NPs that are not activated by light exposure, these NPs more efficiently reduce the 
clonogenicity of bone marrow cancer cells from patients with AML and induce the differentiation of 
RA-low sensitive leukaemia cells. Importantly, we show that leukaemia cells transfected with light-
inducible NPs containing RA can engraft into bone marrow in vivo in the proximity of other leukaemic 
cells, differentiate upon exposure to blue light and release paracrine factors that modulate nearby cells. 
This capacity of remotely modulating the leukaemic niche has been tested in an AML disease animal 
model with success. RA+NPs induced AML differentiation towards monocytic/macrophage lineage in 
the MLL-AF9 mouse model of AML. Also, we have shown in vitro that RA+NPs stimulate antitumoral 
M1 macrophage activation. This macrophage induced differentiation in vivo seems to have “systemic” 
anti-leukemic effect within the BM leukemic niche, as we observed a significant reduction of leukemic 
cells in the BM of animals treated with RA+NPs when compared with animals treated with empty NPs 
(RA-NPs). Finally, prospective studies on the use of healthy HSCs as carriers have shown that despite 
having a more sensitive behaviour UCB CD34+cells can be loaded with RA+NP and after light-activated 
release of RA, induce CD38 expression and differentiate. Towards the use of this type of tools in the 
context of HSC transplant engraftment modulation we were able to produce functional HOXB4, a 
pivotal transcription factor for HSC potency, that was able to induce G0 quiescence, but NP-
functionalization with this molecule remains a challenge and is the subject of future work. 
 
Keywords: Nanoparticles; Targeted drug delivery; Light activation; Acute Myeloid Leukaemia; 
Carrier cells 
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• FGF1 - fibroblast growth factor 1  
• FGF2 - fibroblast growth factor 2 
• FGFR - FGF receptor 
• FITC - Fluorescein isothiocyanate 
• FLT3 - FMS-related tyrosine kinase 3 
• FLT3-ID - FMS-like tyrosine kinase 3/internal tandem duplication 
• FRET, fluorescence energy transfer 
• FR-β - folate receptor-β 
• FSC/SSC - Forward-scattered light / Side-scattered light 
• G-CSF - granulocyte colony-stimulating factor 
• GFP - green fluorescent protein  
• GMPs - granulocyte-macrophage progenitors 
• GVHD - Graft-versus-host disease 
• H2O - water 
• HA – hydroxyapatite 
• HCT-CI - Haematopoietic Cell Transplantation Co-morbidity Index 
• HEPES - hydroxyethyl piperazineethanesulfonic acid 
• HGF - hepatocyte growth factor 
• HLA - Human leukocyte antigen 
• HSCs - Haematopoietic stem cells 
• HSCT - haematopoietic stem cell transplantations 
• HUVECs – human vein umbilical endothelial cells 
• ICP-MS - inductively coupled plasma mass spectrometry 
• IDH - isocitrate dehydrogenase 
 3 
 
• IDH1 - isocitrate dehydrogenase 1 
• IFN-γ - interferon 
• IGF1 - insulin-like growth factor 1 
• IGF1R - IGF1 receptor 
• IGF2 - insulin-like growth factor 2 
• IL-1α - interleukin-1α 
• IL-3 - interleukin 3 
• IL-6 - interleukin-6 
• IMDM - Iscove's Modified Dulbecco's Medium 
• ISH - in situ hybridization 
• ITD - internal tandem duplication 
• IT-HSC - intermediate-term haematopoietic stem cells 
• JAK2 - Janus kinase 2 
• KCl - Potassium chlorate 
• Kcps - kilo counts per second 
• KSP - kinesin spindle protein (also known as KIF11) 
• LDLR - low-density lipoprotein receptor 
• LepR- leptin receptor 
• lncRNA - long non-coding RNA 
• LNP - lipid NP 
• LSCs - leukaemia Stem Cells 
• LSK - lineage−SCA1+KIT+ 
• LT - long-term 
• LTC-IC - long-term culture-initiating cell 
• LT-HSC - long-term haematopoietic stem cells 
• M.F.I - mean fluorescence intensity 
• MAFIA - macrophage-Fas-induced apoptosis transgenic  
• mCRPC - metastatic castration resistant prostate cancer 
• MDS - myelodysplastic syndrome  
• MEPs - megakaryocyte/erythroid progenitors 
• MIP-1α - macrophage inflammatory protein-1α 
• miR - microRNA 
• MKL1 - megakaryoblastic leukaemia (translocation) 1 
• MKs - megakaryocytes  
• MLL - myeloid/lymphoid or mixed-lineage leukaemia (also known as KMT2A) 
• MLL-AF9 YFP cells 
• MLLT3 - MLL translocated to 3 
• MNPs - magnetic nanoparticles 
• MPB - mobilized peripheral blood 
• MPL - myeloproliferative leukaemia protein 
• MPN - myeloproliferative neoplasm phenotype 
• MPS - mononuclear phagocyte system 
• MPS - myeloproliferative syndrome 
• MRD - minimal residual disease 
• MRI - magnetic resonance imaging 
• MS-5 - murine MS-5 stromal cell line 
• MSC - mesenchymal stem cell 
• MSN - mesoporous silica NP 
• mTOR - mammalian target of rapamycin 
• MUC1 - membrane bound mucin 1 
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• MYH11 - myosin heavy chain 11 smooth muscle 
• NA- not applicable 
• nab - nanoparticle albumin bound 
• NaCl - Sodium chloride 
• NC – nanocrystal 
• NIR - near infrared regions 
• NK - normal karyotype 
• NMR - Nuclear magnetic resonance 
• NP – nanoparticles 
• NPM1 - nucleophosmin 
• NPY - neuropeptide Y  
• NSCLC - non small cell lung cancer 
• NSCs - neural stem cells 
• NSG - Nod-Scid-gamma 
• NUP214 - nucleoporin 214kDa 
• OBC - osteoblastic lineage cells 
• OPN - osteopontin 
• P - pellets 
• PB - peripheral blood 
• PBS - Phosphate-buffered saline 
• PcG - Polycomb group family 
• PCL - photocleavable linker 
• PCS - photon correlation spectroscopy 
• PDGF- β - platelet-derived growth factor-β  
• PDMS - poly(dimethylsiloxane) 
• PdPc(OBu)8 - 1,4,8,11,15,18,22,25-octabutoxyphthalocyaninato-palladium-(II) 
• PEComa - perivascular epithelioid cell tumours 
• PEG - poly(ethylene glycol) 
• PEI - poly(ethyleneimine) 
• Pen-Strep - Penicillin Streptomycin 
• P-gp - P-glycoprotein 
• pI - isoelectric point 
• PLGA - poly(lactic acid-co-glycolic acid) 
• PLK1 - polo like kinase 1 
• PMF - primary myelofibrosis  
• PML - promyelocytic leukaemia 
• PNIPAM - poly(N-isopropylacrylamide) 
• polyArg - peptide sequence with nine arginines; 
• Prx-1 - paired related homeobox-1  
• PSMA - prostate specific membrane antigen 
• PTC - Pseudotumour cerebri 
• PTK7 - protein tyrosine kinase 7 
• PTX - paclitaxel 
• QD - quantum dot 
• q-RT-PCR – quantative Reverse transcription polymerase chain reaction 
• RA - retinoic acid 
• RAREs - retinoic acid response elements 
• RARs - retinoic acid receptors 
• RARα or RARA - retinoic receptor α 
• Rarγ - retinoic acid receptor γ  
 5 
 
• Rb - retinoblastoma  
• RBC - red blood cells 
• RBM15 - RNA-binding motif protein 15 
• RES - reticulo-endothelial system 
• RNAi - RNA interference 
• ROBO4 - roundabout guidance receptor 4 
• ROS - reactive oxygen species  
• RPMI-1640 - Roswell Park Memorial Institute medium-1640 
• RPN1 - ribophorin I 
• RUNX1 - Runt-related transcription factor 1 
• RUNX1T1 - RUNX1 translocated to 1 
• RXR - retinoid X receptor 
• s.e.m. - standard error of mean 
• SBDS - Schwachman-Bodian-Diamond syndrome  
• SCA1 - spinocerebellar ataxia type 1 protein 
• SCF - stem-cell factor 
• SDS-PAGE - sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
• SERS - surface-enhanced Raman scattering 
• Shh - Sonic hedgeho 
• shRNA - short hairpin RNA 
• siRNA - small interfering RNA 
• SMA - smooth muscle actin  
• SMANCS - poly(styrene co maleic acid) conjugated neocarzinostatin 
• SN - supernatants 
• SNS - sympathetic nervous system  
• SP - side population 
• SR-1 - StemRegenin1 
• SSC - skeletal stem cell 
• ssDNA - single-stranded DNA 
• STR-HSCs - short-term repopulating haematopoietic stem cells 
• TET2 - tet methylcyto¬sine dioxygenase 2 
• TfR - transferrin receptor 
• TFs - transcription factors 
• TGFβ1 -  transforming growth factor β1  
• THPO - thrombopoietin 
• TIE2 - tyrosine kinase with Ig and EGF homology domains 2 
• TLR - Toll-like receptor 
• TNC - total nucleated cells 
• TNF - tumour necrosis factor  
• TNF- β - transforming growth factor-β  
• TNFα- Tumour necrosis factor alpha 
• TPO - thrombopoietin 
• TRITC – Tetramethylrhodamine 
• TRM - treatment related mortality 
• TSP1 - thrombospondin-1 
• UCB - umbilical cord blood 
• UCBT -  umbilical cord blood transplants 
• USPIO - ultra-small paramagnetic iron oxide 
• UV - Ultraviolet light 
• VE-cadherin - vascular endothelial-cadherin 
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• VEGF-A - vascular endothelial growth factor A 
• VEGFR2 - vascular endothelial growth factor receptor-2 
• WBC - white blood cells 
• WHO - Word Health Organization 
• Wnt - wingless-type 
• WT1 - Wilms tumour 1 
• XIAP - X-linked inhibitor of apoptosis protein 
• β-ER - β-estradiol 
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Research aim and thesis outline 
Nanomedicine has gained enormous focus on the last decade with nanoplatforms presenting 
themselves as an attractive strategy to improve old and open new venues of cancer therapy. However, 
most of these advancements have been made only in solid tumours and not in leukaemia and other 
“liquid tumours”. Despite all advances, approximately 25% of APL patients receiving RA will develop 
serious complications, such as “differentiation syndrome”1. Hence, there is a need for more effective 
formulations to deliver RA into leukaemia cells while preventing RA side effects. In addition, leukaemia 
cells resistant to conventional therapies reside in microenvironmental niches in the bone marrow that 
are difficult to access by therapeutic interventions2. New strategies are required to address these 
problems. With this work, we explore the potential of using stem cells as carriers for targeted delivery 
of photo-triggerable NPs not only to modulate the diseased HSC BM niche in AML but also healthy 
HSC BM niches. 
 
This PhD thesis is divided in five chapters: Chapter 1 provides a general overview of the present 
work, providing information about the problem, motivations and contribution to the state of art. Chapter 
2 reviews the state of the art on the bone marrow microenvironment during healthy and malignant 
haematopoiesis along with a description on the latest advances in nanomedicine and targeted drug 
delivery in leukaemia. In Chapter 3 and 4 there is a description of all the results obtained during the 
development of a novel photo-triggerable nanoformulation, the pivotal element in our controlled drug 
delivery system, in which cells are used as carriers of photo-triggerable RA+NPs, allowing precise 
control of timing, duration and magnitude targeted drug delivery system. In Chapter 3, initial work on 
NP formulation and in vitro testing was developed by Dr.Carlos Boto, which I followed and continued 
with in vitro and in vivo experiments. In this chapter, we were able to demonstrate that RA+NPs can 
reduce the clonogenicity of bone marrow tumour cells from patients with acute myeloid leukaemia bone 
marrow and induce the differentiation of RA-low sensitive leukaemia cells expressing the chimeric 
promyelocytic leukaemia zinc finger/RARα fusion protein. RA released from light-activated NPs was 
superior at inducing leukaemia cell differentiation compared to soluble RA and RA released from NPs 
by passive diffusion. Further, we demonstrate the importance of temporal activation of the 
nanoformulation during the intracellular trafficking to maximize RA effect and show in vivo that 
leukemic cells loaded with NPs kept their natural tropism to leukaemic BM niches and that NPs can be 
light-activated to release RA, thereby allowing greater spatio-temporal control of drug delivery. In 
Chapter 4, we continue to explore the applicability of our drug delivery system. In this chapter, we 
show that RA+NPs have a paracrine effect in vivo within the BM leukaemic niche upon NP activation. 
We were able to decrease total disease burden in RA+NPs mice, which could be explained by the 
differentiation of RA+NPs carriers cells in macrophages, confirmed in vitro and in vivo, along with the 
observed activation in pro-inflammatory and anti-tumoral M1 macrophages observed in vitro. We also 
tested NP loading and activation in human CD34+ and the use of a nanoformulation for the transport of 
a transcription factor involved in the HSC self-renewal and expansion. 
Finally, in Chapter 5 we summarize the main findings, general conclusions and future directions opened 
by this work. 
In Chapter 6 we list all the references used in this work. 
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2.1. Haematopoiesis 
Every day, thousands of blood cells and immune cells are produced in our body by a continuous 
hierarchical process called haematopoiesis. On top of this hierarchy are haematopoietic stem cells 
(HSCs). This immature cell type can be functionally defined by the capacity for self-renewal and 
differentiation into multipotent progenitors. These progenitors will in turn become progressively more 
restricted to committed precursors until they give origin to the different types of mature blood cells 
(Figure 2.1).  
The origin of the concept of an immature cell common to all blood lineages goes back to the early 
20th century 3,4, but it was only in the 1960s, with the work of James Till and Ernest McCulloch 5, that 
this concept was first demonstrated. They were able to rescue lethally irradiated mice with a transplant 
of a donor bone marrow (BM), which reconstituted the recipient BM. Later, in 1978, Schofield6 
proposed that HSCs reside in a specialized tissue microenvironment “niche”, where HSCs could be 
protected and regulated. Since then, extensive studies have been made to identify the cellular 
components of this niche, as well as the autocrine, endocrine and paracrine signals and cell-to-cell 
interactions that are essential for the correct regulation of haematopoiesis. 
Most studies on this subject have been carried out using mouse models, which are considered 
comparable to humans in terms of haematopoiesis; despite presenting some differences, mostly in terms 
of location7. After birth, most HSCs are almost exclusively found in the BM. In response to acute stress, 
however, haematopoiesis can take place in extramedullary tissues. Similarly, during development, HSCs 
reside in the foetal liver and spleen 8. 
Due to their high heterogeneity, the classification and isolation of HSC subpopulations has been a 
challenge. Although it is still not clear whether HSCs can be naturally divided into subpopulations or if 
they represent a continuum of states of the same population, the most widely accepted model for 
haematopoiesis categorizes HSCs and progenitor cells based on their self-renewal capacities9,10,life 
span11-13 and differentiation capabilities14.  
Based on transplantation experiments, HSCs can be divided in 3 subpopulations: long-term (LT-
HSC), intermediate-term (IT-HSC), and short-term repopulating HSCs (ST-HSC)15. This division is 
based on distinct capabilities of HSCs to engraft, repopulate, and maintain multilineage haematopoiesis 
in irradiated recipients16. LT-HSCs self-renewal capacity assures the maintenance of a pool of clonal 
haematopoietic progenitor cells and haematopoiesis sustainability throughout an individual’s life-span. 
They are less frequent, mostly found in quiescent state and can be isolated by the CD150 marker 17,18. 
The IT-LSC represents an intermediate population with six to eight months of reconstitution potential 
before their clones become exhausted and can be isolated from both LT and ST-HSC fractions using  
the integrin α2 (CD49b) marker19. By contrast, ST-HSCs have a limited self-renewal capacity (up to 
two months) and are found mostly in the peripheral blood where they contribute to the pool of progenitor 
cells which will reconstitute the myeloid and lymphoid compartments. Common myeloid progenitors 
(CMP) are the source of megakaryocyte/erythroid progenitors (MEPs) and granulocyte-macrophage 
progenitors (GMPs). GMPs give rise to the committed precursors of mast cells, eosinophils, neutrophils, 
and macrophages, whereas common-lymphoid progenitors (CLPs) are the source of committed 
precursors of B and T lymphocytes13. The contribution of HSC to lymphoid and myeloid lineages is still 
not clear and seems to be biased by the diversity of the BM niches they occupy 20-22. This supports the 
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hypothesis that there is not a unique BM niche, but rather a variety of “microniches”, that at the same 
time create and are created by chemotactic gradients and different cell populations. Each of these 
microniches induces different responses in HSCs such as homing, mobilization, quiescence, self-
renewal, or lineage commitment. 
 
Figure 2.1 - Haematopoiesis. The long-term reconstitution potential of the pluripotent long-term haematopoietic 
stem cells (LT-HSCs), can further differentiate toward the multipotent short-term (ST)-HSCs in the BM. 
Subsequent differentiation gives rise to either the common-lymphoid progenitors (CLPs), able to generate the 
complete lymphoid lineage (natural killer [NK] cells as well as B and T lymphocytes) or the common-myeloid 
progenitors (CMPs), which are able to differentiate into the myeloid lineage. Following these committed 
progenitors, both megakaryocyte/erythroid progenitors (MEPs) and granulocyte-macrophage progenitors (GMPs) 
are able to form all mature myeloid lineage cells in the BM. Figure and legend adapted from 23 . 
2.2. Adult BM niche 
In mice, haematopoiesis is supported by all bones, but in humans it is only supported by axial 
skeleton such as the skull, sternum, ribs, spine, sacrum, and pelvis24,25. HSCs, along with other 
haematopoietic cells, blood vessels and neurons form the soft tissue of the bone, which is distributed by 
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the interconnecting bone rods and trabeculae, which in turn is covered by a cellular layer called 
endosteum. Recent extensive studies have uncovered that many cell types in the BM participate in niche 
activities to support HSC function. Although more than one HSC niche has been defined in the bone 
marrow, all have the commonality to maintain the unique features of HSCs over time. The bone marrow 
is a cellularly diverse and dynamic structure that includes HSCs, stromal cells, vascular cells, 
osteolineage cells, neuronal cells, and the extracellular matrix in which these cells reside. HSC niches 
are formed from these elements and function to regulate haematopoiesis and maintain HSC quiescence 
(Figure 2.2) either by direct contact or by the production of niche factors that regulate HSCs and other 
cells populations of the niche (Table 2.1). 
 
 
Figure 2.2 - The adult bone marrow HSC niche. The vasculature has emerged as a key structure for the 
maintenance of HSCs in the bone marrow. Dormant HSCs are found around arterioles where factors such as CXC-
chemokine ligand 12 (CXCL12) and SCF secreted by perivascular, endothelial, Schwann, and sympathetic 
neuronal cells promote their maintenance. Less quiescent or activated HSCs are located near sinusoidal niches 
which are likely diverse in their influence for self-renewal, proliferation, and differentiation. Haematopoietic cells 
such as macrophages or megakaryocytes are examples of HSC-derived progeny that can feed back to the niche to 
influence HSC migration or proliferation. GFAP, glial fibrillary acidic protein; TGF-β1, transforming growth 
factor beta-1. Figure and legend adapted from 26. 
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Table 2.1 - Soluble Factors in the Bone Marrow Niche Affecting Mammalian HSCs.  
Factor Source Receptor 
Responding cell 
type or types 
Effect on niche or 
hematopoiesis 
Angiogenin 27  
Mesenchymal stromal 
cells and hematopoietic 
cells 
Secreted RNase that 
changes RNA processing 
in a cell-type-specific 
manner 
HSCs, LSK cells 
and myeloid 
progenitors 
Promotes quiescence in 
HSCs and the 
proliferation of myeloid 
progenitors 
Angiopoietin 1 
28 
HSCs, KIT+ cells and 
LEPR+ cells 
TIE2 Endothelial cells 
Promotes the 
regeneration of patent 
blood vessels after 
vascular injury 
Angiopoietin-
like protein 3 29  
Sinusoidal endothelial 
cells and liver cells 
Unknown HSCs 
Promotes the 
maintenance of HSCs 
and some types of 
restricted hematopoietic 
progenitor 
BMPs 30-32 
Osteoblasts, 
endothelial cells and 
megakaryocytes 
Complexes of BMP type 
I and type II receptors 
HSCs 
Canonical signaling does 
not affect HSC 
maintenance or 
haematopoiesis; BMP4 is 
required for normal niche 
function 
CXCL 4 33 Megakaryocytes Unknown HSCs 
Inhibits self-renewal and 
induces quiescence 
CXCL 12 34,35 
Osteoblasts, 
endothelial cells, CAR 
cells, MSCs, LepR+ 
perivascular cells 
CXCR4 
HSCs and 
lymphoid 
progenitors 
Positive regulator of self-
renewal, retention and 
function 
FGF1 36,37  Megakaryocytes FGFR1 
HSCs and 
megakaryocytes 
Promotes the 
regeneration of HSCs 
and megakaryocytes 
after myeloablation 
FGF2 38 
Bone marrow stromal 
cells 
Multiple FGFRs are 
present on HSCs 
HSCs 
Promotes the 
proliferation of HSCs 
and stromal cells after 
myeloablation 
G-CSF 39,40 
Monocytes and 
macrophages, bone 
marrow stromal cell 
populations 
G-CSF receptor 
Stromal cells and 
myeloid 
progenitors 
Mobilizes HSCs and 
increases myelopoiesis 
IL-6 41,42 
T cells and 
macrophages 
IL-6 receptor 
HSCs and 
restricted 
progenitors 
Promotes HSC self-
renewal and regulates the 
function of restricted 
progenitors 
IGF143,44 Liver and osteoblasts IGF1R 
HSCs, myeloid 
progenitors and 
pro-B cells 
Reduced plasma IGF1 
levels promote increased 
HSC self-renewal and 
increase the frequency of 
myeloid progenitors 
Leptin 45,46 Adipocytes LEPR 
LEPR+/CAR 
perivascular 
stromal cells 
Causes LEPR+ cells to 
form adipocytes at the 
expense of bone 
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FGFR - FGF receptor; IL-6, interleukin-6; LSK, lineage−SCA1+KIT+; ROBO4, roundabout guidance receptor 4; SCA1, 
spinocerebellar ataxia type 1 protein; TIE2, tyrosine kinase with Ig and EGF homology domains 2. CAR cell, 
CXCL12-abundant reticular cell; EMH, extramedullary haematopoiesis; ERα, oestrogen receptor-α; IGF1, insulin-like growth 
factor 1; IGF1R, IGF1 receptor; MPL, myeloproliferative leukaemia protein; SSC, skeletal stem cell. 
 
Endosteal niche 
The formation and regulation of bone matrix is mediated by the opposing actions of the osteoblasts 
and osteoclasts (cellular components of the endosteum), contributing to the structural foundations for 
the development of the soft tissue. Together, these osteolineage cells create the “endosteal niche”, the 
preferential site for homing of transplanted HSCs 69-72. Furthermore, HSCs isolated from this region tend 
to be more primitive, with higher proliferation rate and long term reconstitution potential73,74. After birth, 
the development of the haematopoietic systems is closely related with bone formation75,76. Osteolineage 
Notch ligands 
47,48 
Bone marrow stromal 
cells, endothelial cells 
and osteoblasts 
Notch receptors, 
particularly Notch 2 
HSCs, progenitors 
and endothelial 
cells 
Notch 2 promotes HSC 
regeneration after 
myeloablation 
Osteopontin 49 Osteoblasts Integrins and CD44 HSCs 
Negatively regulates 
HSC frequency 
Oestrogen 50 Ovary ERα 
HSCs as well as 
other 
hematopoietic 
cells 
Promotes HSC self-
renewal and EMH 
Pleiotrophin 51 
Endothelial cells and 
LEPR+ perivascular 
stromal cells 
Inhibits protein tyrosine 
phosphatase receptor-ζ 
HSCs 
Knockout mice have a 
reduced HSC frequency 
and show impaired 
recovery after irradiation 
SCF52,53 
Osteoblasts, 
endothelial cells, 
MSCs, nestin+ MSCs 
c-KIT receptor (CD117) HSCs 
Induces HSC 
maintenance and self 
renewal 
SLIT ligands 54-
56 
SLIT2 and SLIT3 are 
produced by 
perivascular stromal 
cells 
ROBO4 
HSCs and 
sinusoidal 
endothelial cells 
Has cell-autonomous and 
non-cell-autonomous 
effects on HSC 
engraftment and 
mobilization 
TGFβ 36,57 
Multiple cells 
including 
megakaryocytes; other 
cells such as Schwann 
cells regulate TGFβ 
activation 
Multiple type I and type 
II TGFβ receptors 
HSCs and other 
cell types 
Promotes HSC 
quiescence and self-
renewal 
Thrombopoietin
58-65 
Highest production in 
the liver and kidney, 
but the source of the 
thrombopoietin that 
acts on HSCs is not 
known 
MPL 
HSCs and 
megakaryocytes 
Required for the 
postnatal maintenance of 
HSCs, and for 
megakaryocyte and 
platelet production 
WNT ligands 66-
68 
Bone marrow stromal 
cells and lymphoid 
cells 
Frizzled receptors 
HSCs and 
lymphoid 
progenitors 
Canonical WNT 
signaling through β-
catenin and γ-catenin is 
dispensable for adult 
HSC maintenance and 
for hematopoiesis 
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cells are probably the most studied haematopoietic niche component, with osteoblasts being initially 
identified as key regulators of haematopoiesis by in vitro studies showing they can promote the 
expansion of haematopoietic progenitor cells in culture75-79.  In the beginning of this century, two 
independent studies have shown the first in vivo evidence that osteoblasts regulate the self-renewal and 
expansion of HSCs53,80. The increased osteoblast proliferation achieved either by using an osteolineage-
specific activator of parathyroid hormone (PTH), or conditional deletion of bone morphogenetic protein 
(BMP) receptor type IA was correlated with an increase of HSCs numbers. Osteoblasts are also 
contributing for the pool of cytokines and growth factors involved in the regulation of HSC homing, 
mobilization, and quiescence, such as: CXC-chemokine ligand 12 (CXCL12), which controls HSC 
homing, retention and repopulation81;  stem-cell factor (SCF), a key component in HSCs maintenance, 
although mainly secreted by perivascular cells, is also produced by osteoblasts52; osteopontin (OPN), a 
component of the glycoprotein matrix responsible for the retention, migration, proliferation and 
differentiation of HSCs at the endosteal surface49,82,83; granulocyte colony-stimulating factor (G-CSF), 
important in myelo-differentiation of HSCs75,84; annexin 2 (ANXA2), involved in the control of  HSCs 
homing and engraftment85;  angiopoietin 1 (ANG1) produced by osteoblast, induces HSC quiescence 
and adhesion by interaction with TIE286,87; or thrombopoietin (TPO), involved in the regulation of LT-
HSCs quiescence60.  
Despite these evidences, more recent studies have questioned the importance of osteolineage cells 
in haematopoiesis regulation, mainly in HSCs steady-state maintenance. For example, specific deletion 
of CXCL12, SCF or N-cadherin of osteolineage cells did not seem to influence the HSCs number in the 
BM34,52,88. Also, HSC expansion promoted by osteoblasts through parathyroid hormone (PTH) 
administration is due to increased Jagged-1 expression in osteoblasts and consequent activation of 
Notch-1 signalling pathway in HSCs89-91. However, inhibition or conditional deletion of receptors of 
canonical Notch-1 pathway in HSCs did not affect their maintenance in the BM92. Additionally, imaging 
studies have shown no association between phenotypic HSCs and osteoblasts93,94. Nevertheless, these 
observations are not necessarily contradictory but rather be an evidence of different regulation 
mechanism dependent on the differentiation state of osteolineage cells. Immature osteoblasts are more 
associated with the regulation of primitive HSCs, whereas mature osteoblasts and osteocytes are more 
connected to the regulation and mobilization of haematopoietic progenitor cells. For instances, in 
osteoblast-ablated mice, LT-HSCs show reduced long-term engraftment and self-renewal capacity as 
well as loss of quiescence95. On the other hand, it seems that osteopontin, mainly produced by mature 
osteoblasts and osteocytes, negatively regulates the HSC pool49. Also, a decrease in osteoblast number, 
similar to what happens during haematopoietic aging, promotes myeloid expansion at the expense of 
lymphoid and erythroid expansion and may predispose the BM to the development of acute myeloid 
leukaemia (AML)96.  
Perivascular niche 
The continuous production of blood cells is a metabolic demanding process that depends on a 
distribution system for gas exchange, nutrient supply, waste removal and to facilitate the trafficking of 
haematopoietic cells between the BM and the rest of the organism. This is why the niche is in close 
proximity to blood vessels which are extremely relevant in the maintenance and proliferation of HSCs17 
(Figure 2.2). The blood vessels entry point in the compact BM is made through the bone canal by 
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arteries that branch first into small arterioles and then to venous sinusoids near the endosteum surface. 
Venous sinusoids are composed of ECs, separated by basal lamina from discontinuous pericytes, which 
allow mobilization of mature blood and HSCs97. 
Despite of first experimental evidence that pointed the endosteal area as the main HSC-supporting 
niche69, further studies gave indication that endogenous HSCs were more closely related with 
sinusoids17, with the majority of quiescent HSCs occupying the perivascular niche98-100. Also, 
perivascular cells have a major contribution for the pool of niche factors101,102. Endothelial cells (EC) 
are one of the components of the perivascular niche and regulate HSC by the secretion of angiocrine 
factors such as CXCL12, vascular endothelial growth factor A (VEGF-A), fibroblast growth factor 2 
(FGF2), ANG1 and thrombospondin-1 (TSP1)103-105. EC isolated from the BM have shown to promote 
proliferation and differentiation of human HSC in vitro106 . Neutralization of vascular endothelial growth 
factor receptor-2 (VEGFR2) and vascular endothelial-cadherin (VE-cadherin) reduced the supportive 
function of ECs to LT-HSCs47. Although ECs have reduced expression of CXCL12 and SCF, the 
conditional deletion of these niche factors has shown a reduction in HSC number in the bone marrow52,88. 
Deletion or blockage of E-selectin, an adhesion molecule expressed only by bone marrow ECs, increases 
HSC quiescence and survival107. The activity of HSCs is also regulated by direct cell-to-cell contact 
through Notch signalling47. Besides ECs, the perivascular niche is also composed by stromal cells of 
mesenchymal origin. The best characterized are the CXCL12-abundant reticular (CAR) cells108. These 
cells are mainly found around sinusoids and create a homogeneous tangled network throughout the 
BM35. CAR cells express high levels of Cxcl12 and Scf genes, for example CAR cells express Cxcl12 
levels about 100-fold and 1000-fold higher than ECs and osteoblasts, respectively52. Most of CAR cells 
also express the receptor for leptin (LepR), a hormone secreted by adipocytes46,52,98. Indeed, conditional 
deletion of Cxcll12 from LepR-cre-marked cells promoted the mobilization of HSC from the BM to the 
peripheral blood and spleen but HSC numbers in the BM remained unaltered88.  On the other hand, 
conditional deletion of Scf on these cells, depleted HCSs in the BM, indicating that CXCL12 and SCF 
produced in LepR cells are critical for the mobilization and maintenance, respectively, of HSC in the 
BM52. Other markers have been identified to characterize the perivascular stromal cells, including the 
transcription factor Osx, paired related homeobox-1 (Prx-1)34,88 and neural/glial antigen 2-Cre-marked 
cells (NG2)109, expressed exclusively in cells marked with green fluorescent protein (GFP) under 
regulation of the Nestin promotor (Nes-GFP+). However, these markers are mostly overlapping with 
CAR LepR+ cells in respect to location and Cxcl12 and Scf expression levels93,101. 
More recently it has been proposed that there are two anatomically and functionally distinct 
perivascular niches, the peri-arteriole and peri-sinusoidal. This is supported by the evidence that LT-
HSCs seem to be more closely located to the arterioles rather than venous sinusoids93,97,98,110. Also, some 
heterogeneity can be observed in EC and stromal cells. EC expressing higher levels of CD31 and 
endomucin found in the end terminal arterioles also express higher levels of SCF when compared to EC 
associated with sinusoids97,110,111. Similarly, stromal cells expressing Nes-GFP can be divided in two 
populations regarding the GFP expression. Similarly, stromal cells expressing Nes-GFP can be divided 
in two populations regarding the GFP expression: Nes-GFPdim stromal cells which are closely associated 
with perisinusoidal cells and overlap with LepR+ and CAR cell; and Nes- GFPbright stromal cells found 
close to arterioles52. Furthermore, the lower permeability of arterioles promotes a more hypoxic 
microenvironment, protecting HSC from reactive oxygen species concentration (ROS), preventing their 
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differentiation112. On the contrary, venous sinusoids are covered by fenestrated basal lamina making 
them more permeable and exposed to the blood stream, increasing ROS concentration, promoting HSC 
differentiation. 
 
SNS and glia 
The bone marrow is highly innervated by myelinated and non-myelinated nerve fibres and 
associated Schwann cells113, 114. Although most nerve fibres are found near the arterioles rather than 
sinusoids93,97 and have no direct contact with HSCs98, the sympathetic nervous system (SNS) has an 
important role in the regulation of haematopoiesis. SNS controls the circadian mobilization of HSC to 
the BM by catecholamine signalling, which are delivered to the BM niche through the blood circulation 
or by secretion from the nerve endings acting in a paracrine mode115. Catecholamines acts on the β3 
adrenaline receptor of Nes-GFP+, suppressing their niche function by regulation of CXCL12 
expression116. SNS is also related to HSC mobilization controlled by granulocyte colony-stimulating 
factor (G-CSF)113,117,118. Non-myelinating Schwann cells produce numerous niche factors and promote 
HSC quiescence by activation of transforming growth factor-β (TGF-β)57,119. 
 
Haematopoietic cell components of the niche  
Megakaryocyte 
More recent findings have identified HSC directly adjacent to megakaryocytes (MKs)33, which are 
found in close proximity to sinusoidal endothelium, with extensions of cytoplasmatic protrusions into 
the sinusoids to produce platelets120 . MK regulate haematopoiesis in steady-state haematopoiesis33, 121 
and under stress 36. Under homeostatic conditions MK regulate HSCs quiescence by the production of 
multiple cytokines (e.g., TPO, TGFβ, and CXCL4)119,121,122. Conditional ablation of MKs in vivo led to 
loss of quiescence in HSCs and consequently increased HSC frequency and proliferation36,123. This 
effect could be reverted by the administration of transforming growth factor β1 (TGFβ1, encoded by 
Tgfb1)36 or the chemokine C-X-C motif ligand 4 (CXCL4, also known as platelet factor 4, PF4)123. 
Accordingly, Cxcl4 and Tgfb1 knock-out mice have both shown increased HSC proliferation33,36. Under 
stress conditions, after BM radioablation, endogenous MK are recruited to the endosteum by 
thrombopoietin (TPO) signalling124. There, MKs promote HSCs engraftment and BM reconstitution by 
synthetizing MK-derived mesenchymal growth factors, such as fibroblast growth factor 1 (FGF1)36,37 
and platelet-derived growth factor-β (PDGF-β), which stimulates osteoblast expansion124. 
 
 
Macrophages 
Macrophages have been identified as an important BM niche player. They can be found near the 
endosteal osteoblasts and actively participate in bone mineralization125-127. Moreover, conditional 
deletion of macrophages by using macrophage-Fas-induced apoptosis transgenic (MAFIA) mice or 
administrating clodronate-loaded liposomes in wild-type mice led to HSC mobilization from the BM 
and reduction of endosteal osteoblasts. The same phenotype could be observed in G-CSF-induced HSC 
mobilization, where a reduction of macrophages and bone loss was detected40,128. 
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Macrophages, more specifically CD169+ macrophages, regulate HSC maintenance in the BM 
endosteal niche by promotion of CXCL12 expression in Nes-GFP+ stromal cells129 through secretion of 
oncostatin M130. The ligand for VCAM-1, integrin VLA-4 which is expressed by macrophages, also 
regulates HSC maintenance in the BM and spleen131-133. More specifically, in the spleen, silencing or 
conditional deletion of VCAM-1 in CD169+ macrophages promoted HSCs retention in the spleen134. It 
has also been proposed that macrophages mediate BM HSCs mobilization after phagocytosis of aged 
neutrophils135. A rare subset of macrophages, identified by expression of smooth muscle actin (SMA), 
were found close to HSC of the BM136. They promote HSC expansion after irradiation by 
cyclooxygenase 2 (COX2)-mediated expression of prostaglandin E2, associated with decreased ROS 
levels in HSCs128. Prostaglandin E2 increases CXCL12 expression in Nes-GFP+ stromal cells136 and 
CXCR4 expression on HSCs137. Macrophages also contribute to steady-state and stress-induced 
erythropoiesis. Reduction of BM erythroblasts is observed after specific depletion of CD169+ 
macrophages in mice. This depletion also led to myeloablation, decreased erythropoietic recovery 
followed by acute blood loss, myeloablation138. In contrast, in JAK2(V617F)-driven mouse model of 
polycythemia vera, characterized by elevated erythropoiesis, macrophage depletion normalized the 
erythroid compartment.139. 
Macrophages are also key regulators of the neuroprotective effect of neuropeptide Y, which 
regulates homeostasis in tissue expressing Y receptors140-142. Moreover, neuropeptide Y (NPY) deficient 
mice showed impaired HSC survival and BM regeneration, which could be rescued by pharmacological 
elevation of NPY143. 
 
Neutrophils 
Neutrophils are the most abundant subpopulation of leukocytes, are highly migratory cells and are 
sensitive to tissue damage or infection144. Neutrophil expansion in the BM is induced by G-CSF145 and 
may lead to mesenchymal stem cell (MSC) and osteoblast apoptosis and consequent reduction of several 
cytokines and receptors essential for HSC maintenance in the BM146. In vitro experiments have shown 
that neutrophils synthetize serine proteases, which are capable of cleaving CXCL12147 CXCR4148, 
VCAM-1149, c-Kit150 and SCF151. However, serine proteases might not be essential in vivo, as no 
alteration of G-CSF-induced mobilization was observed in vivo in mice without these proteases152. 
Furthermore, HSC mobilization is not directly proportional to neutrophil numbers in the BM40. Under 
homeostatic conditions, BM neutrophils seem to shadow HSC circulation regulated by the circadian 
rhythm. Aged neutrophils show higher tropism to the BM by low CD62L and high CXCR4 expression 
levels. Clearance of aged neutrophils is done by CD169+ macrophages which inhibit CXCL12 
production by Nes-GFP+ stromal cells, promoting HSC mobilization from the BM135. 
 
2.3. Haematological Malignancies 
Haematopoiesis balance can be deregulated in response to stress, like infection and wounding, by 
induction of HSC. These return to a quiescent state when the stress is over or the injury is healed153. 
However, disruption of homeostasis can lead to haematological malignancies, and ultimately to 
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leukaemia (Figure 2.3), which is sustained by leukaemia stem cells (LSC), which share many biological 
features with HSC154.  
Emerging evidence shows that alterations of the complex and dynamic signalling network regulated 
by cells of the BM niche are critical in the initiation, maintenance and outcome of myeloid and lymphoid 
disorders. These alterations can be driven by genetic mutations in stromal cells of the BM and/or 
promoted by malignant cells, which hijack BM niche supportive function, promoting a leukaemic niche 
at the expense of HSC155-162. Although most research has been done in leukaemic settings, these 
mechanisms can also be observed in multiple myeloma patients163. 
 
 
 
 
Figure 2.3 - Two models of the interaction of leukemic cells and their microenvironment. While 
leukemic cells can induce changes in HSC niche (a), abnormalities in bone marrow microenvironment have 
a potential to initiate hematological malignancies (b). It is of note that these two models are not mutually 
exclusive. They can form a self-reinforcing loop, contributing to the disease 
progression. KO knockout, OE overexpression. Figure and legend adapted from164. 
2.3.1. Initiation 
The first cue for a disease-initiation in the niche was given by the observation of donor-derived 
leukaemia in patients receiving allogeneic stem cell transplantations158. This concept gained support by 
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the experimental observation of myeloproliferative neoplasm phenotype (MPN) induced by genetic 
deletion of retinoblastoma (Rb) or retinoic acid receptor γ (RARγ) in mice. Furthermore, only 
transplantation of healthy HSCs to mutant mice and not transplantation of mutant HSC to wild-type 
mice, lead to MPN-like disease155,156. Development of MPN was also observed in mice with impaired 
Notch signalling in nonhaematopoietic cells165 and more recently in genetically altered Nes+ stromal 
cells160. 
Alterations at the endosteal niche, more specifically, mutations in osteoblastic lineage cells (OBC) 
have been implicated in the development of myelodysplasia (MDS) 162 and AML disease159. Inactivation 
of Dicer1 in OBC promotes aberrant gene expression and led to MDS in mice. For example, a 
downregulation of sbds, the gene mutated in Schwachman-Bodian-Diamond syndrome (SBDS) 162 was 
observed when Dicer1 was inactivated. In a subsequent study, sbds deletion in stromal cells promoted 
an inflammatory response which increased oxidative stress and DNA-damage response in HSC This 
effect was driven by the activation of Toll-like receptor (TLR) signalling in HSC, by stromal secretion 
of endogenous damage-associated molecular pattern (DAMP) molecules S100A8/9. Interestingly, AML 
development risk in MDS patients can be predicted by the expression levels of S100A8/9 166 
Deregulation of Notch pathway was also shown to promote MDS development which rapidly 
evolves to AML. A mutation in mice OBC led to overexpression of Jagged-1, a Notch ligand, followed 
by Notch signalling activation in HSC and β-catenin accumulation. This pathway triggered recurrent 
chromosomal aberrations and somatic mutations promoting clonal expansion91,159. Notably, stromal 
cells isolated from MDS/AML patients have also shown increased Jagged1-expression together with 
downregulation of key molecules in HSC regulation. MSC derived from MDS patients show decreased 
osteogenic differentiation and impaired support of healthy CD34+ in long-term culture-initiating cell 
assays. These observations where correlated with hypermethylation patterns in these MSC161. 
 
2.3.2. Progression and expansion 
The impaired haematopoietic function and decreased HSC numbers observed in patients with 
haematological malignancies suggests that HSCs are being expelled from their niche by LSC. This 
action takes possession of the niche for leukaemogenesis. Alongside with this concept, morphological 
and functional changes in the BM microenvironments were also reported in patients with different 
haematological malignancies, such as primary myelofibrosis (PMF), myelodysplastic syndrome (MDS), 
and different kinds of leukaemia157. Recent advances in murine mouse models of haematopoietic 
malignancies have helped to gain further insight in the mechanism of BM niche remodelling by 
myelodysplastic cells. More specifically, LSCs can remodel osteoblastic, neural, and endothelial BM 
microenvironments, by deregulated production of a variety of signals, including proinflammatory and 
angiogenic chemokines and cytokines, such as CXCL12, VEGF, tumour necrosis factor (TNF)-α, IL-1, 
IL-6, and IL-8166-168. 
 
Aberrant endosteal niche  
Besides all the HSC-intrinsic transformation steps that need to occur in AML there are extrinsic 
niche-specific factors that are fundamental for disease development. The characterization of the impact 
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that the disease has in the niche, and vice-versa, is very important. Clinical reports of osteopenia and 
osteoporosis in MDS and AML patients has been attributed to the observation of reduced numbers of 
osteoblasts in newly diagnosed AML patients. Decreased levels of cell cycle related genes and CXCL12 
was also observed in BM plasma of AML patients, but MSC isolated from the same patients had 
increased levels of Jagged-1 and CXCL12 that favour leukaemogenesis169,170. Furthermore, better 
prognosis after chemotherapy was correlated with an increase in osteoblast activity and bone mass171-
173. Accordingly, in AML and ALL mouse models deletion of OBC led to a reduction of bone mineral 
density accompanied by an increase in bone remodelling osteoclasts. This alteration of the endosteum 
niche seems to favour leukaemia progression and reduce HSC maintenance174-176. 
The role of osteoblast microenvironment in leukaemia was further elucidated by stimulated normal 
haematopoiesis, delayed disease engraftment, reduced tumour burden, and prolonged survival, after 
pharmacological induced maintenance of osteoblast number96. In a more recent study, the establishment 
of a human AML xenotransplant model in Nod-Scid-gamma (NSG) mice allowed to observe that 
patient-derived MSC can grow and differentiate effectively at the NSG-mice BM cavity, recapitulating 
the leukaemic-supportive function and LSC increased engraftment promoted by the formation of 
functional vascularized ossicles177. 
Similar to AML, in pediatric ALL patients, it was also observed a decrease in CXCL12 in the BM 
and peripheral blood plasma when compared with samples of healthy donors178. This observation was 
reinforced using osteoblastic T cell ALL mouse models, where a decrease in OBC numbers was 
accompanied by a reduced CXCL12 expression. This could be reversed by administration of Notch 
inhibitors176, in accordance with the observation of decreased CXCL12 in Notch-induced T cell ALL 
mouse model179. 
Furthermore, with the help of intravital imaging at the calvaria BM, was also possible to observe 
that Nalm-6 ALL transplanted cells can compete with haematopoietic progenitor stem cells for 
perivascular niches and are able to disrupt normal HSC regulation by the upregulation of SCF and 
downregulation of CXCL12 recruitment CD34+ HSC to leukaemic niches and impaired CD34+ 
mobilization in response to G-CSF180. 
An opposite effect at the endosteal niche has been observed in BCR/ABL transgenic chronic 
myeloid leukemia (CML) mice. In this model, transplantation of BCR/ABL mutant cells into wild-type 
mice promoted the expansion of OBCs in the BM. This effect was mediated by direct contact of 
leukaemic cells with MSC and increased secretion of inflammatory cytokines and chemokines, 
including macrophage inflammatory protein-1α (MIP-1α), chemokine ligand 3 (CCL3), TPO, 
interleukin-1α (IL-1α), IL-1β, tumour necrosis factor-α (TNF- α), IL-6, and G-CSF. This 
proinflammatory environment compromised HSC support function of OCB, with loss of LT-HSC at the 
BM and establishment of leukaemia supportive microenvironment181,182. 
 
Perivascular niche 
Malignant cells have also been shown to manipulate the perivascular niche in ALL and AML. 
Increased expression levels of VEGF and basic fibroblast growth factor (bFGF) are found in BM plasma 
of ALL patients. Also, evidence of neoangiogenesis was observed in immunocompromised mice when 
transplanted with cells from primary ALL patients183.  Cells isolated from AML patients were shown to 
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induce EC proliferation when co-cultured with human lung or dermal microvascular ECs, this was 
associated with increased levels of pro-angiogenic CXCL8, and decreased levels of anti-angiogenic 
factors CXCL9, CXCL10, and CXCL11184. In AML models, leukaemia cells can modulate ECs by 
upregulation of c-FOS and senescence-related genes, including interferon signalling and COL3A1185. 
Interestingly, the perivascular niche seems to act as a protective AML niche, as leukaemic cells adjacent 
to vessels become more quiescent and resistant to chemotherapy186. Accordingly, pharmacological 
degradation of EC adhesion molecules, reduced AML chemoresistance187. 
Neuropathy induced by malignant cells alters the BM Niche 
The SNS niche was also shown to be disrupted in a murine MPN model generated by Janus kinase 
2 (JAK2) mutation. In this model, damage of sympathetic nerve fibres and death of Schwann cells was 
induced by IL-1β produced in mutant cells, which lead to a reduction of Nes+MSCs and followed by 
decreased CXCL12 levels. Recovery of Nes+MSCs and reduction of leukaemia burden at the BM could 
be achieved by treatment with β3-adrenergic receptors (Adrβ3) agonist188. Similar results were obtained 
in a MLL-AF9 AML model, where SNS niche disruption led to a decrease of Adrβ3 expression and 
HSC maintenance factors, such as CXCL12, SCF, ANG1, and VCAM1 followed by expansion of MSC 
primed for osteoblastic differentiation. This effect could be mediated by β2 adrenergic receptor (Adrβ2) 
as increased number of LSC were observed at the BM when using Adrβ2 antagonist but not (Adrβ3)175. 
 
Exosomes 
The observation of high numbers of microvesicles in leukaemic areas of ALL, CLL, AML and CLL 
patients, associated with detection of VEGF, bFGF, hepatocyte growth factor (HGF), and TNF-α in the 
plasma and urine of patients,  indicates that exosomes might be instrumental during BM niche 
modulation by haematological malignancies189,190. Moreover, in vitro studies have shown examples of 
leukaemia-secreted exosomes in CML, AML cells lines and primary AML samples 191. These exosomes, 
enriched in unique RNA and microRNA, can be up taken by BM stromal cells, which leads to direct 
and indirect effects on HSC. Exosomes isolated from AML cells induced downregulation of CXCL12 
and SCF in stromal cells as well as downregulation of CXCR4 and c-kit in HSCs191,192. In CML, 
exosomes induce IL-8 production in stromal cells, a CML survival factor and also carried miR126, 
which targets HSC niche factors CXCL12 and VCAM1193,194. ECs and MSCs can be reprogrammed to 
leukaemia supporting cells by CLL-derived exosomes.  Leukaemia cell proliferation and angiogenesis 
was promoted by secretion of cytokines from these cells and was observed ex vivo after CLL-exosome 
uptake195. Exosomes released from BM MSC collected from MDS patients can modulate in vitro CD34+ 
cells expression of MDM2 and TP53 genes by transferring miR-10a and miR-15a, suggesting that 
intercellular communication between malignant BM niche and HSC can also be mediated by 
exosomes196. 
2.3.3. AML 
AML is a malignant blood disorder characterized by rapid abnormal proliferation and differentiation 
of HSCs, resulting in the accumulation of immature myeloid precursors (myeloblasts) in the BM and 
peripheral blood (PB). This uncontrolled expansion of malignant haematopoietic precursor cells at the 
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expense of normal haematopoietic cells results in the exhaustion of the BM. AML it’s the most common 
type of acute leukaemia in adults197, with an incidence of 3 to 5 cases per 100.000 in patients with less 
than 65 years old and in patients older than 65. After an increased incidence observed in the last quarter 
of the 20th century, AML incidence started to stabilize in this century198. To this contributed the 
advancement of diagnostic and treatment procedures, which led to an improvement in the disease 
outcome, mostly in young patients. With a median age at diagnosis of approximately 70 years199, AML 
has the worst prognosis within all types of leukaemia, especially in elder patients200, with a recovery rate 
of 35% to 40% in patients younger than 65 years old and only 5% to 15% in patients older than 65 years 
old, within the first year of the diagnosis198,201-203.  
In most of the cases, AML appears as a de novo malignancy in previously healthy individual or as 
therapy-related AML, as a consequence to previous treatments by exposure to DNA-damaging and 
cytotoxic agents (for example, ionizing radiation, alkylating agents or topoisomerase II inhibitors)204,205. 
Although no strong evidence of familiar predisposition to AML has been reported, except relatives of 
young patients, there is an increased risk for haematological malignancies and solid tumours among 
relatives of AML patients206. Also, there is predisposition of AML development in individuals with 
inherit disorders, such as Down syndrome, Fanconi anemia, Bloom syndrome, ataxia-telangiectasia, 
Diamond–Blackfan anemia, Schwachman–Diamond syndrome and severe congenital neutropenia (also 
called Kostmann syndrome) (for a review see REF 207). 
The clinical diagnosis of acute leukaemia is established by the presence of 20% or more blasts in 
the BM or PB202. Furthermore, AML and its subtypes are distinguished from other leukaemias by 
immunophenotyping, cytogenetic and molecular characterization of the myeloblasts. The cytogenetic 
heterogeneity in AML has been known for more than 30 years, with about half of all AMLs having 
structural cytogenetic changes visible at the karyotype level, with translocations and chromosomal gains 
or losses 208-210. For example, the chromosomal translocations such as t(8:21) in core-binding factor 
AML (CBF-AML) or t(15:17) in acute promyelocytic leukaemia (APL) result in the formation of 
chimeric proteins (RUNX1-RUNX1T1 and PML-RARΑ, respectively), which alter the normal 
maturation process of myeloid precursor cells. 
However, advancements of the past decade have uncovered an enormous molecular heterogeneity 
of the disease. In fact, genetic mutations can be found in more than 97% of the cases, independently of 
the presence of large chromosomal changes211,212.  In 2016 a report from Word Health Organization 
(WHO), classified AML based in genetic criteria along with morphological, immunophenotyping and 
clinical presentation to define five major disease entities(Table 2.2).: AML with recurrent genetic 
abnormalities, AML with myelodysplasia-related features; therapy-related AML; AML not otherwise 
specified; myeloid sarcoma; and myeloid proliferation related to Down syndrome213. The recognition of 
different combinations and accumulations of genetic abnormalities in AML, allowed better prognosis 
definition and adjustment of treatments to the specific AML subtype 211,214  
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Table 2.2 - Who classification AML subtypes 215.  
 
WHO classification of AML subtypes 
AML with recurrent genetic abnormalities 
• AML with t(8;21)(q22;q22); RUNX1–RUNX1T1 
• AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB–MYH11 
• APL with t(15;17)(q22;q12); PML–RARA  
• AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A 
• AML with t(9;11)(p22;q23); MLLT3–MLL 
• AML with t(6;9)(p23;q34); DEK–NUP214 
• AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1–EVI1 
• AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM 
• AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15–MKL1 
• Provisional entity: AML with mutated NPM1 
• Provisional entity: AML with mutated CEBPA  
• Provisional entity: AML with BCR-ABL1 
• Provisional entity: AML with mutated RUNX1 
AML with myelodysplasia-related changes* 
Therapy-related myeloid neoplasms 
AML not otherwise specified 
• AML with minimal differentiation 
• AML without maturation 
• AML with maturation 
• Acute myelomonocytic leukaemia 
• Acute monoblastic and monocytic leukaemia 
• Acute erythroid leukaemia 
• Acute megakaryoblastic leukaemia 
• Acute basophilic leukaemia 
• Acute panmyelosis with myelofibrosis 
Myeloid sarcomas 
Myeloid proliferations related to Down syndrome 
• Transient abnormal myelopoiesis 
• Myeloid leukaemia associated with Down syndrome 
Blastic plasmacytoid dendritic cell neoplasms 
CBFB, core-binding factor-β; CEBPA, CCAAT/ enhancer-binding protein-α; MKL1, megakaryoblastic leukaemia 
(translocation) 1; MLL, myeloid/lymphoid or mixed-lineage leukaemia (also known as KMT2A); MLLT3, MLL translocated 
to 3; MYH11, myosin heavy chain 11 smooth muscle; NPM1, nucleophosmin; NUP214, nucleoporin 214kDa; PML, 
promyelocytic leukaemia; RBM15, RNA-binding motif protein 15; RPN1, ribophorin I; RUNX1, Runt-related transcription 
factor 1; RUNX1T1, RUNX1 translocated to 1. *Includes specific recurrent chromosomal abnormalities. 
 
Classification/Genetics  
Observations in animal models that more than one cooperating mutations is necessary to develop 
AML led to the concept of a two-hit model of leukaemogenesis 216-218. According to this model, these 
mutations can be categorized in three functional groups: Class I, mutations which activates cell 
signalling pathways involved in the regulation of cell proliferation and survival; Class II, mutation in 
genes encoding transcription factors which regulate cell differentiation and self-renewal; and Class III, 
mutations in epigenetic modifiers which regulate the expression of several genes with effect on both 
cellular differentiation and proliferation. Impairment of normal haematopoiesis and consequent 
leukaemia development requires the conjugation of class I mutations with class II and/or III219,220. 
However, data from genome sequencing revealed a large number of functional categories, also including 
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cohesin complex and spliceosome mutation 211 (Table 2.3). The combination of mutations is highly 
variable, but some combinations can be specific, as for example, acquired mutation in GATA-binding 
protein 2 (GATA2) are always paired with mutations in CCAAT/enhancer-binding protein-α (CEBPA) 
suggesting that they are cooperative 221. Other combinations appear to be mutually exclusive, for 
example, the coincidence of the FMS-related tyrosine kinase 3 (FLT3) and RAS or of isocitrate 
dehydrogenase (IDH), tet methylcytosine dioxygenase 2 (TET2) and Wilms tumour 1 (WT1) mutations 
is uncommon, suggesting they are functionally related211. Somatic mutations in genes involved in 
epigenetic regulation, including genes involved in the regulation of DNA methylation and post-
translational histone modifications, such as DNMT3A, TET2, WT1, IDH1 and IDH2. These recurrent 
mutations are found in preleukaemic HSC, which are capable of multilineage differentiation and confer 
these cells a higher resistance to chemotherapy and increased probability of relapse during remission 222-
224. Recent studies show that these kinds of mutations increase with age in clonal haematopoiesis and 
are associated with higher risk of haematological malignancies and death225-227. 
 
Table 2.3 - Proposed Genomic Classification of AML 228 .  
Genomic Subgroup 
 
Frequency in 
the 
Study Cohort 
(N = 1540) 
no. of patients 
(%) 
Most Frequently Mutated Genes* 
gene (%) 
AML with NPM1 mutation 418 (27) 
NPM1 (100), DNMT3A (54), FLT3ITD (39), NRAS 
(19), TET2 (16), PTPN11 (15) 
AML with mutated chromatin, RNA-splicing 
genes, or both† 
275 (18) 
RUNX1 (39), MLLPTD (25), SRSF2 (22), 
DNMT3A (20), ASXL1 (17), STAG2 (16), NRAS 
(16), TET2 (15), FLT3ITD (15) 
AML with TP53 mutations, chromosomal 
aneuploidy, or both‡ 
199 (13) 
Complex karyotype (68), −5/5q (47), −7/7q (44), 
TP53 (44), −17/17p (31), −12/12p (17), +8/8q (16) 
AML with inv(16)(p13.1q22) or 
t(16;16)(p13.1;q22); CBFB–MYH11 
81 (5) 
inv(16) (100), NRAS (53), +8/8q (16), +22 (16), 
KIT (15), FLT3TKD (15) 
AML with biallelic CEBPA mutations 66 (4) 
CEBPAbiallelic (100), NRAS (30), WT1 (21), 
GATA2 (20) 
AML with t(15;17)(q22;q12); PML–RARA 60 (4) t(15;17) (100), FLT3ITD (35), WT1 (17) 
AML with t(8;21) (q22;q22); RUNX1–
RUNX1T1 
60 (4) t(8;21) (100), KIT (38), −Y (33), −9q (18) 
AML with MLL fusion genes; t(x;11)(x;q23)§ 44 (3) t(x;11q23) (100), NRAS (23) 
AML with inv(3)(q21q26.2) or 
t(3;3)(q21;q26.2); GATA2, MECOM(EVI1) 
20 (1) 
inv(3) (100), −7 (85), KRAS (30), NRAS (30), 
PTPN11 (30), ETV6 (15), PHF6 (15), SF3B1 (15) 
AML with IDH2R172 mutations and no 
other class-defining lesions 
18 (1) IDH2R172 (100), DNMT3A (67), +8/8q (17) 
AML with t(6;9)(p23;q34); DEK–NUP214 15 (1) t(6;9) (100), FLT3ITD (80), KRAS (20) 
AML with driver mutations but no detected 
class-defining lesions 
166 (11) FLT3ITD (39), DNMT3A (16) 
AML with no detected driver mutations 
62 (4) 
 
 
AML meeting criteria for ≥2 genomic 
subgroups 
56 (4) 
 
 
 
* Genes with a frequency of 15% or higher are shown in descending order of frequency. Key contributing genes in each 
class are shown in boldface type. 
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† Classification in this subgroup requires one or more driver mutations in RUNX1, ASXL1, BCOR, STAG2, EZH2, SRSF2, 
SF3B1, U2AF1, ZRSR2, or MLLPTD. In the presence of other class-defining lesions — namely, inv(16), t(15;17), t(8;21), 
t(6;9), MLL fusion genes, or complex karyotype or driver mutations in TP53, NPM1, or CEBPAbiallelic — two or more 
chromatin–spliceosome mutations are required. 
‡ Classification in this subgroup requires TP53 mutation, complex karyotype, or in the absence of other class-defining 
lesions, one or more of the following: −7/7q, −5/5q, −4/4q, −9q, −12/12p, −17/−17p, −18/18q, −20/20q, +11/11q, +13, +21, or 
+22. 
§ Multiple fusion partners for MLL were found, with the clinical implications depending on the specific fusion partner. 
2.3.4. Traditional treatments  
If eligible for intensive treatment, according to a modification of the widely used European 
LeukaemiaNet guidelines, newly diagnosed AML patients are divided in four risk groups based on the 
cytogenetic and molecular abnormalities. This classification has prognostic and recommended treatment 
indications, as well as recommendation to use or not allogeneic HSCT after first complete remission 
(CR) (Table 2.4).  
 
Table 2.4 – Therapeutic implication of current stratification of Molecular Genetic and Cytogenetic 
Alterations, according to ELN Recommendations*. Adapted from 215. 
 
* Three changes were made to the original recommendations reported by 229 First, cases of AML with mutated CEBPA 
are now restricted to cases with biallelic CEBPA mutations.4 Second, the molecular designation of inv(3)(q21q26.2) or 
t(3;3)(q21;q26.2) has been changed to GATA2–MECOM (EVI1).3 Finally, for MLL, the official gene symbol KMT2A (lysine 
[K]-specific methyltransferase 2A) has been adopted. 
Risk Profile Subsets 
Induction 
therapy 
Consensus 
regarding 
allogeneic 
HSCT after 
first CR 
Risk of 
relapse 
with or 
without 
HSCT 
Comments 
Favorable 
t(8;21)(q22;q22); RUNX1-RUNX1T1 
inv(16)(p13.1q22) or 
t(16;16)(p13.1;q22); CBFB-MYH11 
Mutated NPM1 without FLT3-ITD 
(normal karyotype) 
Biallelic mutated CEBPA (normal 
karyotype) 
Standard 
induction# 
or FLAG-
Ida+ 
Not 
recommended 
• 40–50% 
without  
• 15–20% 
with 
Consider HSCT if:  
Risk of TRM with 
HSCT is <10% (HCT-
CI:0); 
MRD is present after 
two courses of 
chemotherapy 
Intermediate 
I† 
Mutated NPM1 and FLT3-ITD 
(normal karyotype) 
Wild-type NPM1 and FLT3-ITD 
(normal karyotype) 
Wild-type NPM1 without FLT3-ITD 
(normal karyotype) 
Standard 
induction# 
or FLAG-
Ida+ 
Usually 
recommended 
50–70% 
without 20–
30% with 
Consider no HSCT if 
the risk of TRM with 
HSCT is >30% 
(HCT-CI: >4) 
Intermediate 
II 
t(9;11)(p22;q23); MLLT3-KMT2A 
Cytogenetic abnormalities not 
classified as favorable or adverse‡ 
Standard 
induction# 
or FLAG-
Ida+ 
Strongly 
recommended 
70–80% 
without  
30–40% 
with 
As in intermediate I 
Adverse 
inv(3)(q21q26.2) or 
t(3;3)(q21;q26.2); GATA2–MECOM 
(EVI1) 
t(6;9)(p23;q34); DEK-NUP214 
t(v;11)(v;q23); KMT2A rearranged 
−5 or del(5q); −7; abnl(17p); complex 
karyotype§ 
FLAG-Ida+ 
or clinical 
trial 
Strongly 
recommended 
90–100% 
without 40–
50% with 
CR rate is <50% with 
standard 
Induction and -
5/del5q.-7/del7q or 
complex 7 
Consider no HSCT if 
the risk of TRM is 
>40% (HCT-CI>7) 
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† This category includes all cases of AML with a normal karyotype except for those included in the favourable subgroup; 
most of these cases are associated with a poor prognosis, but they should be reported separately because of the potential different 
response to treatment. 
‡ Adequate numbers of most abnormalities have not been studied to draw firm conclusions regarding their prognostic 
significance. 
§ A complex karyotype is defined as three or more chromosomal abnormalities in the absence of one of the World Health 
Organization–designated recurring translocations or inversions — t(8;21), inv(16) or t(16;16), t(9;11), t(v;11) (v;q23), t(6;9), 
and inv(3)/t(3;3). About two thirds of patients with AML with a complex karyotype have a mutation of TP53, a deletion of 
TP53, or both. TP53 alterations in AML rarely occur outside a complex karyotype. 
 #Standard induction therapy consists of an anthracycline for 3 days combined with cytarabine for 7–10 days.  
+ FLAG-Ida consists of high-dose cytarabine, idarubicin, fludarabine and granulocyte colony-stimulating factor. 
HCT-CI, Haematopoietic Cell Transplantation Co-morbidity Index; ITD, internal tandem duplication; MRD, minimal 
residual disease; NK, normal karyotype  
 
Traditional treatment of AML is normally divided in induction, consolidation and maintenance 
phases. Eligible patients will first undergo induction therapy (cytotoxic chemotherapy) until they 
achieve CR, however, minimal residual disease often persists, and a relapse is highly likely to occur 
after induction phase is completed, so a round of consolidation therapy is usual applied after induction. 
Except for the cases when HSCT is used, consolidation therapy is usually in a similar or slightly lower 
intensity than induction therapy. During maintenance therapy, doses of the cytotoxic agents are normally 
lower than the previous phases. Usually it is applied only: after 3-4 cycles of induction and consolidation 
therapy in patients aged 60 or less, and after 2-3 cycles in older patients202.  The dose intensity of the 
cytotoxic therapy is also defined taking in account the efficacy/adverse effects ratio, which is strongly 
related with patient age. 
The typical induction therapy consists of 7 to 10 days of continuous infusion of cytarabine (also 
known as ARA-C), combined with 3 days of an anthracycline and is generally offered to patients with 
a favorable to intermediate prognosis and a low risk of treatment related mortality (TRM)230. Standard 
induction doses consist of 100-200 mg/m2 of cytarabine daily infusion, although higher doses have 
shown higher efficacy, this came with increased toxicity to the patients, thus only used in refractory 
disease 230-232. In leukaemia treatment, more specifically in AML, daunorubicin (60-90 mg/m2) or 
idarubicin (12 mg/m2) are the commonly used anthracyclines, both with similar CR and survival rates 
230,233,234. Higher doses of daunorubicin can be beneficial in patients with DNMT3A and KMT2A 
mutations, which represents a poor prognostic marker212. Typically, in patients younger than 65 years 
old, induction therapy has a CR rate between 60-80% 235, but 25% to 50% of the patients still present 
persistent cytological evidence of the disease after one cycle of induction therapy and require 
reinduction236. In these cases, treatment options include a second cycle of cytarabine combined with an 
anthracycline, higher doses of cytarabine alone or patients can also be administrated with a combination 
of fludarabine, cytarabine (ARA-C) and G-CSF (FLAG) and in some cases with the addition of 
idarubicin (FLAG-IDA), although it did not increase CR rate, it increased remission duration230,237-239. 
Patients older than 65 are more likely to present more adverse cytogenetic-risk profiles, are less likely 
to respond to chemotherapy (up to 40%-60% CR rates) and often more susceptible to treatment related 
toxicities. Despite the significantly worse prognosis, induction therapy still shows better survival rates 
when compares to supportive care and palliative chemotherapy and should be pursued when possible232. 
Taking in account the low success rate of conventional therapy in older patients, they are usually 
considered good candidates for investigational therapies. 
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Other cytotoxic agents have been studied as an alternative to traditional induction regimes. For 
example, the use of hypomethylating agents, traditionally used in the treatment of myelodysplastic 
syndrome (MDS), as recently arise as a potential candidate for the treatment of older patients as well as 
patients with adverse cytogenetic-risk profile or MDR-AML240. Also, the addition to induction therapy 
of Gemtuzumab ozogamicin, a humanized anti-CD33 monoclonal antibody (present in AML blast) 
combined with the cytotoxic agent calicheamicin, have shown to reduce the risk of relapse and improved 
survival in patients with favorable and intermediate risk profiles241,242. Although Gentumuzab 
ozogamicin is no longer available in USA and Europe, analogues of it are in clinical trials. More 
recently, a large randomized international study suggested that the addition of Midostaurin (a 
multikinase inhibitor) to induction and consolidation therapy and its use as a single agent during 
maintenance improved overall and event-free percentages243. 
While in remission, patients should be offered consolidation therapy to eliminate residual disease 
and reduce the risk of relapse. The standard consolidation therapy includes conventional chemotherapy 
and allogeneic haematopoietic stem cell transplantation (allo-HSCT) alone or most commonly in 
combination. The choice between them is based mainly on the leukaemic genetic risk profile and on the 
risk of death weighed against the likelihood of treatment failure or relapse 202,244-246.  In patients with 
favorable prognosis, chemotherapy is normally the first choice as HSCT shows no benefit in these 
patients when compared with chemotherapy in patients with a favourable cytogenetic-risk profile247,248. 
Consolidation chemotherapy protocols consist of an intermediate dose of cytarabine (2-4 cycles of six 
doses at 2–3 g/m2) which has been shown to be as efficient as high dose cytarabine or multi-agent 
protocols and have cure rates around 60%-70%231,237,249. In patients with intermediate or high-risk 
profile, allo-HSCT remains the most effective long-term therapy for AML. However, several patients 
never become eligible for transplant given co-morbidities, failure to achieve CR or lack of suitable donor 
250-252. Autologous HSCT normally does not improve the outcome, but it can be considered as an 
alternative consolidation therapy for selected patients 253. 
Haematopoietic stem cell transplantation 
The potentially lethal levels of chemotherapy during induction phase may compromise the function 
of normal haematopoiesis. Post-remission allogeneic HSCT provides an important rescue tactic for the 
replenishment of normal haematopoiesis and also to trigger an immunological antileukaemic response, 
the graft-versus-leukaemia effect245,254 (Figure 2.4).  
Before transplantation, immunosuppressive conditioning is necessary to permit the engraftment. 
Chemoradiotherapy is often chosen because of its immunosuppression plus anti-leukaemic effect. 
However, HSCT is not risk-free (e.g. Graft-versus-host disease – GVHD) and the choice of whether to 
perform HSCT or not after remission is dependent on balancing the reduction in relapse rate against the 
procedure related mortality and morbidity, being HSCT normally reserved for intermediate and adverse-
risk AML patients who otherwise are unlikely to achieve an extended complete remission244,246,247,255-259. 
The discovery of Human leukocyte antigen (HLA) system of MHC class I and II receptors, which 
engage T-cell antigen receptors, allowed to find histocompatible matching donors and recipients and 
open the doors to implement HSCT as a therapy260,261. The most common sources of HSC for transplant 
are the BM and mobilized PB. Their use was initially restricted to HLA-matched siblings but since the 
late 1980’s, HLA-matched unrelated donors have been used with similar outcomes. 
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Figure 2.4 - Haematopoietic stem cell transplantation strategies in AML. Allogeneic HSCT refers to the option 
in which a human leukocyte antigen-matched sibling or an unrelated adult donor voluntarily donates either bone 
marrow or peripheral blood stem cells to be infused in a recipient, who received prior conditioning with cytotoxic 
and immunosuppressive therapy to allow engraftment and prevent host-versus-graft and graft-versus-host 
reactions. Autologous HSCT refers to the option in which the stem cells from the patient are harvested and frozen 
to be thawed and re-infused after high-dose cytotoxic therapy to enable haematopoietic recovery. Figure and 
legend adapted from215.  
However, these donors are not identified as often as necessary, especially for patients from minority 
ethnic backgrounds262,263. As an alternative approach for patients lacking an HLA-matching donor, 
conditioning and immunosuppressive regimes have been applied to allow haploidentical HSCT with 
reduced GVHD, but these regimes can increase the probability of opportunistic infections and relapse264.  
Also, closely matched umbilical cord blood (UCB) units have been shown to be a good alternative 
source of HSCs265,266. However, the HSC number in a single UCB unit is insufficient for HSCT in 
adults267. The HSC number is crucial for the time required for engraftment and patient survival267-269. 
Due to lack of sufficient HLA-matched donors and HSC number from common sources, specially 
UCB270, still present serious limitations to HSCT eligibility in cancer or other haematological disorders 
treatment. 
Despite the low HSC numbers in UCB267 and delayed engraftment when compared to BM or PB, 
the ease of collection and banking, plus the possibility to perform UCB transplants (UCBT) in 
mismatched donors271 lead to an increased interest in finding strategies to enable UCBT to more patients. 
To achieve this, most studies have aimed to increase HSC number by ex-vivo expansion using molecular 
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factors. But other efforts have also been made to improve UCBT, such as: HSC harvesting and 
purification methods272,273; HSC survivability274; HSC homing to the BM and engraftment275. 
To be able to achieve HSC expansion, symmetrical self-renewal divisions over unlimited 
differentiation are required. The balance in HSC self-renewal is modulated by cell-intrinsic factors (i.e. 
transcription factors, epigenetic modifiers and cell cycle regulators) or by extrinsic factors produced by 
both local niche and systemic environment.  
 
HSC expansion - Intrinsic Factors, e.g. HOXB4 
One of the first molecules to be described as able to expand HSC was HoxB4, a member of the Antp 
homeobox family, transcription factors with specific DNA-binding domains276. The ectopic expression 
of Hoxb4 led to a 40-1000-fold expansion of HSC in vitro and in vivo277-279. Furthermore, HSC 
expansion could also be achieved by extrinsic delivery of the recombinant fusion protein TAT-HOXB4, 
however the levels of expansion were much lower when compared with the ectopic protein 
expression280. The study of other transcription factors involved in haematopoiesis regulation allowed to 
identified other possible candidates to use in HSC expansion, such as other members of the HoxA and 
HoxB clusters (e.g. HoxA4, HoxA9, HoxB6)281-284 Gata2285 and Gfi1286. Ectopic expression of 
chromatin-associated factors has also shown to improve HSC expansion, specially proteins members of 
the Polycomb group family (PcG), such as Ezh2 and Bmil, which modulate HSC activity either by 
preventing stem cell expansion or by increasing HSC self-renewal287-289. Despite the high levels of HSC 
expansion achieved with ectopic expression, the introduction of genetic material is undesired in clinical 
protocol290 and the use of recombinant proteins is often limited by their stability in culture280. Therefore, 
transient activation of self-renewal by extrinsic factors or molecules that regulate the activity of intrinsic 
factors can be a good alternative. 
 
Extrinsic factors, e.g. cytokines and small molecules 
The first attempts to expand HSCs ex-vivo were made using combinations of haematopoietic 
cytokines identified to be produced in vivo by the HSC microenvironment, such as SCF, TPO, Flt3L, 
IL-6, IL-3, G-CSF291,292. However, the efficiency of these cytokines in HSC expansion remains 
controversial, as they often do not achieve the desired expansion and usually leads to HSC differentiation 
and/or exhaustion277,293-295. Nonetheless, a mix of SCF and Flt3L with IL-11 (mouse) or TPO (human) 
become the core cocktail of cytokines routinely used in vitro for haematopoietic stem and progenitor 
cell culture, supporting their survival, proliferation and maintenance in culture and is often 
complemented with other cytokines and other small molecules (Table 2.5) 291,296,297.  
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Table 2.5 - Successful Protocols for HSC Expansion Ex Vivo.  
 
CB, cord blood; CRU, competitive repopulating unit; Dppa5, developmental pluripotency associated 5; Fbxw7, F-box and WD 
repeat domain containing 7, E3 ubiquitin protein ligase; IGF-2, insulin-like growth factor 2; IL-3, interleukin 3; LT, long-term; 
MPB, mobilized peripheral blood; MS-5, murine MS-5 stromal cell line; SP, side population; SR-1, StemRegenin1; THPO, 
thrombopoietin; TFs, transcription factors. 
 
Further studies were made in developmentally conserved signalling pathways with critical roles 
during ontogeny and fetal haematopoiesis, such as, wingless-type (Wnt)309, Notch (Jagged/Delta)310, 
Sonic hedgehog (Shh)/BMP311, FGF312, IGF and Angptls298,313, pleiotrophin299, and the TGFβ/smad4 
Factors Cells tested Species Supplement 
Culture 
period 
Assay Fold expansion 
Cytokines291 
CB 
CD34+38- 
H 
SCF, Flt3L, 
G-CSF, IL-3, 
IL-6 
4 days 
CFU and CRU (HSC 
frequency) 
15-fold CFU; 
fourfold 
chimera 
Cytokines292 
CB 
CD34+38- 
H 
Flt-3, SCF, IL-
3, 
IL-6, and G-
CSF 
5–8 days 
CFU, LTC-IC, CRU 
(HSC frequency) 
100-fold CFU; 
fourfold 
LTC-IC; twofold 
CRU 
Angiopoietin298 
SP CD45+ 
Sca-1+ 
M 
SCF, THPO, 
FGF-1, IGF-2 
10 days 
CRU (HSC 
frequency) 
24–30-fold 
Pleiotrophin299 
CD34- LSK, 
CB CD34+ 
38- 
M and 
H 
SCF, Flt3L, 
THPO 
 
7 days 
CRU frequency/LT 
engraftment 
Fourfold CRU; 
10-fold chimera 
HOXB4300 CB CD34+ H 
Co-culture on 
MS-5 mouse 
stromal cells 
4–5 
weeks 
LTC-IC assay, 
reconstitution 
analysis 
20-fold LTC-ICs; 
2.5-fold long-
term 
repopulation 
Fbxw7301 LSK M SCF, THPO 10 days 
Competitive 
reconstitution 
analysis 
>Twofold long-
term 
repopulation 
Dppa5302 
CD34-48- 
LSK 
M SCF, THPO 14 days 
Competitive 
reconstitution 
analysis 
6–10-fold 
PDH inhibitor 
(1- 
aminoethylphosphinic 
acid, 1-AA)303 
CD34-Flts- 
LSK 
M 
SF-O3 medium 
1.0% BSA, 
serum-free, 
SCF, THPO 
2–4 
weeks 
 
CFU/competitive 
reconstitution 
analysis 
 
Twofold CFUs; 
fivefold 
LT repopulation 
 
Mitochondrial 
phosphatase Ptpmt1 
inhibitor, alexidine 
dihydrochloride (AD)304 
LSK and in 
vivo 
treatment 
CD34+ 38- 
M 
H 
SCF, THPO, 
Flk-3 
 
7 days 
CFU and LT 
chimera 
34+38_ 
number/CFU 
 
Twofold CFUs; 
3–5-fold 
LT repopulation 
Twofold number; 
twofold CFUs 
GSK-3b inhibitor, 
CHIR99021305,306 
 
LSK and 
CB CD34+ 
LSK Flk- 
 
M and 
H 
M 
With 
rapamycin 
in cytokine-free 
X-VIVO 
medium 
SCF, THPO, 
and insulin 
7 days 
14 days 
 
HSC frequency/LT 
engraftment 
Competitive 
reconstitution 
analysis 
10–20-fold HSC 
number; 2–5-fold 
LT repopulation 
100-fold number; 
2–10-fold LT 
repopulation 
SR-1307 
CD34+ 
MPB 
UBC 
H 
SCF, Flt3L, 
THPO, IL-6 
 
7–21 
days 
Number/CFU/ 
competitive 
reconstitution 
analysis 
65-fold CFUs; 
17-fold enhanced 
chimera 
UM171308 
CD34+ 
MPB 
UBC 
H 
SCF, Flt3L, 
THPO 
7–21 
days 
Number/CFU/ 
competitive 
reconstitution 
analysis 
>100-fold LT-
HSC; 
35-fold enhanced 
chimera 
CHAPTER 2 - State of the Art 
35 
 
signalling pathway. Adult HSCs have been shown to express receptors that can activate all these 
pathways, indicating that these pathways could be used for extrinsically control HSC fate in culture. 
More recently, powered by emergence of computational methods, small molecules have emerged as 
valuable tools for regulation stem cell fate, as they present several advantages such as easier 
manipulation, typically rapid and reversible effects, various and unlimited concentrations and structures, 
and rapid phenotype-based high-throughput screening and many of these factors are currently being 
used in clinical trials for UCB expansion and transplantation (Table 2.6) 295,314-316. 
 
Table 2.6 - Current Approaches to Ex Vivo Manipulation of UCB Stem Cells in Clinical Trials.  
 
Ex Vivo 
Treatment 
Biologic 
Rationale 
Ex Vivo 
Expansion 
Ex Vivo 
Processing 
Median Days 
to Myeloid 
Engraftment 
Long-term 
Engraftment 
by Treated 
UCB 
Immune 
Reconstitution 
Tetraethylene 
pentamine 
(SCF, FLT-3L, 
TPO, IL-6)317 
copper 
chelation 
blocks HSC 
differentiation 
TNC +++, 
CD34 +, 
CFUs ++ 
21 days 
granulocytes: 
30; 
platelets: 48 
 
not evaluated not evaluated 
Notch ligand 
Delta 1 
(fibronectin, 
SCT, 
FLT-3L, TPO, 
IL-6, IL-3)318 
provides HSC 
proliferative 
signal 
TNC +++, 
CD34 +++ 
 
16 days 
granulocytes: 
13; 
platelets: 38 
 
<5% not evaluated 
Mesenchymal 
stromal cells 
(SCF, FLT3L, 
TPO, G-
CSF)319 
 
MSCs provide 
signals 
for HSC 
expansion 
TNC +, 
CD34 ++, 
CFUs ++ 
 
14 days 
granulocytes: 
15; 
platelets: 42 
 
<10% not evaluated 
16,16-dimethyl 
prostaglandin 
E2 320 
 
facilitates HSC 
homing, 
proliferation, 
and self-
renewal 
N/A 2 hr 
granulocytes: 
18; 
platelets: 43 
 
83% delayed 
Nicotinamide 
(SCF, FLT-3L, 
TPO, IL-6) 321 
 
inhibits HSC 
differentiation; 
facilitates HSC 
homing 
TNC +++, 
CD34 ++ 
 
21 days 
granulocytes: 
13; 
platelets: 33 
 
60%–80% not evaluated 
Fucosylation322 
facilitates HSC 
homing 
 N/A 30 min 
granulocytes: 
17; 
platelets: 35 
50% not evaluated 
StemRegenin-1 
(SCF, FLT-3L, 
TPO, IL-6)323 
 
SR-1 
inhibition of 
aryl 
hydrocarbon 
receptor blocks 
HSC 
differentiation 
TNC +++, 
CD34 +++, 
CFUs +++ 
 
15 days 
granulocytes: 
15; 
platelets: 49 
 
65% delayed 
TNC, total nucleated cells; N/A, not applicable. 
2.3.5. Differentiation therapy/APL 
The notion that acute leukaemias arise not only from the uncontrolled proliferation but also halted 
differentiation of haematopoietic stem or progenitor cells has encouraged the pursue of treatments which 
stimulate the terminal differentiation and subsequent proliferation arrest of malignant leukaemic cells. 
A successful example of this is the differentiation therapy applied to patients with APL, a subtype of 
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AML. APL characterized by a balanced reciprocal translocation between chromosomes 15 and 17 
leading to the fusion of promyelocytic (PML) gene with the retinoic receptor α (RARα). This results in 
a PML-RARΑ fusion protein with oncogenic potential, has this protein is responsible for arresting the 
differentiation of myeloid precursors in promyelocytes and is able to induce leukaemia in animal models 
324,325. 
What was once a rapidly onset fatal disease, characterized by a harmful coagulopathy which could 
result in life threatening hemorrhages and more rarely thrombosis, became highly curable disease with 
the introduction of differentiation therapy, which increased the median of survival from 1 week to a 
stable CR (<90% rate) over 5 years 324,326. The first agent used in differentiation therapy was all-trans-
retinoic acid (ATRA) and later arsenic trioxide (ATO). These drugs are able to degrade the PML-RARΑ 
oncoprotein and induce the terminal differentiation of leukaemic promyelocytes in APL327,328. Although 
ATRA was initially used as a single agent in induction therapy with CR rates of up to 80%, the long-
term results were not satisfactory as a high relapse rate was observed, especially in high risk profile 
patients329-331. Currently, ATO plus ATRA without chemotherapy is offered as standard induction and 
consolidation therapy for low risk patients (white blood cells (WBC) count <10,000/µL)332. For patients 
with higher risk profile, although more data is still needed, standard treatment consists of ATO plus 
ATRA with the addition of an anthracycline ( reviewed in 333). 
Despite the success of the differentiation therapy in APL treatment, some complication can still 
occur in the first weeks of ATRA and/or ATO administration. The most common is the differentiation 
syndrome (DS-previously known as “retinoic acid syndrome”), with an incidence of 25-30%, DS is 
characterized by the increased differentiation of WBC and capillary leakage334. Prophylactic steroids 
can be administrated to prevent DS, especially in high-risk patients (WBC count>10,000/µL)335. Hepatic 
toxicity and cardiac arrythmia are also common in protocol where ATO is administered alone or in 
combination with ATRA. In more rare cases (3% incidence), Pseudotumour cerebri (PTC) can be 
observed in patients, mostly in children and adolescents332,336. 
 
2.4. RA in the niche 
The success of differentiation therapy raised the interest on the role of ATRA signalling pathways 
in normal and malignant haematopoiesis and possible use of ATRA in other AML subtypes. In fact, 
preclinical studies have gathered evidence that specific molecular abnormalities can increase ATRA 
sensitivity in non-APL AML patients’ cells. More specifically, in AML with: a FMS-like tyrosine kinase 
3/internal tandem duplication (FLT3-ID) 337; mutant nucleophosmin gene (NPM1)338-340; mutant 
isocitrate dehydrogenase 1 (IDH1)341; overexpression of ecotropic viral integration site 1 (EVI-1)342; 
and in MLL-positive AML343,344. 
ATRA is a member of retinoids, a class of signalling molecules and active metabolites of Vitamin 
A (retinol), which are essential for normal embryonic development in vertebrates and modulation of 
multiple biological processes, such as haematopoiesis, vision, reproduction, immune function and cell 
growth and communication 345-350.  
Dietary vitamin A can be obtained from plant sources (as provitamin A carotenoids, mostly β-
carotene) and animal sources as retinyl esters. Retinols are oxidized in the body first by alcohol 
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dehydrogenases (ADHs) into retinaldehyde (crucial for vision) and then by aldehyde dehydrogenases 
(ALDHs) into ATRA351. After being synthetized, ATRA is transported within the cells by CRABP 
(cytoplasmic retinoic acid binding protein352,353 and CRBP II (cytosolic retinoid binding protein), which 
can signal ATRA for degradation mediated by the bone marrow stroma’s expressed cytochrome P450 
retinoid-inactivating enzyme, CYP26354,355 or transport it to the nucleus. Within the nucleus, ATRA acts 
as a ligand for two families of nuclear hormone receptors, preferentially to the retinoic acid receptors 
(RAR), specific to the retinoid signalling pathway, and retinoid X receptor (RXR), which as higher 
affinity to 9-cis-RA than to ATRA and, can heterodimerize with other members of the nuclear hormone 
receptors356, such as vitamin D and thyroid hormone receptors357.  
Retinoid acid receptors are composed by three subtypes (α, β and γ), each subtype with at least 2 
different isoforms created by alternative splicing358,359. All are structurally similar and differ mainly on 
the tissue and development expression (for example, RARγ is expressed at higher levels in skin and 
RARα in haematopoietic cells)360. RARs can act as transcriptional modulators by forming homodimers 
or, mainly, heterodimers with RXR, which bind to specific retinoic acid response elements (RAREs) 
present in the promoter region of RA signalling target genes356. In the absence of ligands, RAR-RXR 
heterodimers repress transcription by forming complexes with nuclear receptor co-repressors with 
histone deacetylase activity, which promote chromatin condensation and subsequent transcriptional 
repression360-363. When ATRA (or other retinoids) interact with RARs, promotes a conformational 
exchange and silencing of the co-repressor complex and allows for the recruitment of transcriptional co-
activators, including histone acetyltransferases, which leads to transcriptional activation of retinoid 
target genes by chromatin decondensation360,363. 
Despite of the key role of RA signalling during vertebrate’s development and in the early embryonic 
haematopoiesis being well documented346,348,364-366, the role of ATRA in regulation of adult 
haematopoiesis, more specifically in haematopoietic stem and progenitor cell biology remains 
controversial.  
Some studies have reported increased proliferation of human haematopoietic progenitor cells367-369, 
while others report an inhibitory effect on both proliferation and differentiation of human and murine 
haematopoietic progenitor cells, upon ATRA treatment370-374.  Furthermore, murine models have shown 
that HSC expansion can be achieved either by activation of the RA pathway375 or its inhibition via 
retroviral-mediated expression of dominant negative RARα376. These contradictory effects of ATRA 
may be due to combination of the following: cells targeted by ATRA377, differential expression and 
activity of RARs329,378,379 and metabolic state in such cells380, and regulation of intrinsic RA 
concentration by the microenvironment355,381.  
While initial studies were done using either mice fed with a Vitamin A deficient diet382 with a pan-
RAR-antagonist383, the emergence of RAR knockout murine models and specific agonists and antagonist 
for the different RAR subtypes, allowed a better understanding of RA signalling in haematopoiesis. 
Purton et al demonstrated that ATRA as pleiotropic effect on murine haematopoiesis by showing that 
ATRA is a potent inducer of terminal differentiation in normal promyelocytes (linage negative, ckit 
positive, sca-1 negative LKS- cells) but has the opposite effect in more primitive HSC (LSK+) cells377. 
Furthermore, it was observed that expression of RARs is not the same in purified populations of murine 
haematopoietic cells. The more primitive population of HSC (LKS+) express RARα1, RARα2, RARβ2, 
RARγ1, and RARγ2384. Due to this, most studies have focused on the role of RARα and RARγ in RA 
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signalling during haematopoiesis. The strongest evidence for the involvement of RARs in 
haematopoiesis has come from the knowledge gained with APL, demonstrating the importance of RARα 
in myelopoiesis385,386. Activation or overexpression of RARα shows an increase in granulocytes 
expression379,384. Surprisingly, RARα knock-out mice, despite the early lethality, show no defects in 
myelopoiesis387,388. Also, overexpression or activation of RARγ promotes the self-renewal and 
expansion of HSC 379,384. On the other hand, mice deficient for RARγ are anemic389, show reduced HSCs 
numbers with significantly increased granulocyte/macrophage progenitors and develop a 
microenvironment induced myeloproliferative syndrome (MPS) 155,384. Interestingly, transplantation 
studies indicate that this disorder is likely mediated through a defect in the microenvironment that 
supports HSC activity rather than an autonomous defect in the HSCs themselves. Collectively, these 
studies indicate a key role of RARγ signalling in the homeostasis of the haematopoietic in response to 
RA.  
Retinoic acid is also a well-known modulator of the cell cycle, causing an accumulation of cells in 
G0/G1 phase and a decrease in the S phase population390. Accordingly, ATRA treatment in vitro has 
also been shown to promote cell-cycle arrest in G0/G1 phase in HSC371,377. In a more recent study, it 
was shown in vitro and in vivo that ATRA and Vitamin A are responsible to maintain primitive HSC in 
a dormant state and protecting them from entering in cell-cycle under stress conditions. This reduced 
metabolic state of HSCs promoted their maintenance in long-term self-renewal and low proliferation 
and was associated with decreased Cdk6 levels, expression of transcription factors essential for HSC 
maintenance, such as Hoxb4, reduced ROS generation and low c-myc levels380  
 
2.5. Novel therapies 
The deeper understanding of the molecular, epigenetic and metabolic abnormalities responsible for 
the development of haematopoietic malignancies and their resistance to conventional therapy, allied 
with the development of new molecular and nanotechnology tools, allowed the development of new 
strategies to treat leukaemia. More recent studies try to target directly LSC, by: using antibody based 
therapy specific for LSC cell surface markers; engineering chimeric antigenic receptor(CAR) T/NK 
cells; using nanoplataforms for accurate delivery of anti-leukaemic compounds; or more recently, direct 
genetic correction of molecular abnormalities, made possible with the discovery of CRISP-CAS9 
molecular tool. Targeting of LSC can be indirect, by disrupting the metabolic environment that favours 
LSC expansion and resistance (e.g. hypoxia); or epigenetic manipulation of the malignant niche  
 
2.6. Nanomedicine 
Since 1980s, with the first FDA of a nanoparticle (NP) formulation, for cancer treatment391, 
nanotechnologies gained increased interest from the scientific and medical community. 
Nanomedicine is defined as the use of nanotechnology, materials with size ranging from 1 to 100 
nm in health and medicine, although of nano-sized materials with several hundred nanometres 
can be considered as long they have a relevant biological effect392. These nanocarriers have unique 
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characteristics that allows its use for the improvement of drug delivery, diagnosis and imaging, 
synthetic vaccine development and miniature medical devices393-398. Current problems in cancer 
treatment399 (e.g. low specificity, rapid drug clearance, biodegradation and limited targeting) 
could be potentially addressed by the use of NP platforms. Their nanoscale size, high surface-to-
volume ratios, favourable drug release profiles, and targeting modifications, can allow them to 
better reach target tumour tissue and release drugs in a stable, controlled manner392. Furthermore, 
NPs are able to incorporate multiple features allowing to have diagnostic, tracking, targeting and 
drug delivery all combined in a single nanoformulation. Currently, a wide variety of NP platforms 
(e.g. lipo-based, polymer-based, inorganic, viral and drug conjugates) are being investigated for 
cancer diagnosis and treatment, with several of them already approved for clinical use (Table 
2.7). 
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Table 2.7 - Examples of clinical-stage nanomedicines for cancer therapy.   
Therapy 
modality 
Generic name 
and/or proprietary 
name 
Nanotechnolog
y 
platform 
Active 
pharmaceutical 
ingredients 
Cancer type Status 
Chemotherapy: 
non-targeted 
delivery 
Liposomal doxorubicin 
(Doxil)400 
Pegylated 
liposome 
Doxorubicin 
HIV-related Kaposi sarcoma, ovarian cancer, 
and multiple myeloma 
Approved by 
FDA (1995) 
EMA (1996) 
Liposomal daunorubicin 
(DaunoXome) 400 
Liposome (non-
PEGylated) 
Daunorubicin HIV-related Kaposi sarcoma 
Approved by 
FDA (1996) 
Liposomal vincristine 
(Marqibo) 400 
Liposome(non-
PEGylated) 
Vincristine sulfate 
Philadelphia chromosome negative acute 
lymphoblastic leukaemia 
Approved by 
FDA (2012) 
Liposomal irinotecan 
(Onivyde or MM-398)401-
404 
Pegylated 
liposome 
Irinotecan 
Post-gemcitabine metastatic pancreatic cancer 
(2nd line) 
Small cell lung cancer, metastatic pancreatic 
adenocarcinoma, pediatric solid tumors 
Approved by 
FDA (2015) 
Phase I, II, 
III (2017) 
Liposomal doxorubicin 
(Myocet) 400 
Liposome Doxorubicin Metastatic breast cancer 
Approved in 
Europe 
EMA (2000) 
and Canada 
Mifamurtide (Mepact) 400 
Liposome (non-
PEGylated) 
Muramyl tripeptide phosphatidyl-
ethanolamine 
Nonmetastatic, resectable osteosarcoma 
Approved in 
Europe 
EMA (2009) 
Nab-paclitaxel 
(Abraxane) 400,405 
Albumin NP Paclitaxel 
Metastatic Breast, advanced non-small-cell 
lung and metastatic pancreatic cancer 
Approved by 
FDA(2005) 
and by EMA 
(2008) 
SMANCS400 
Polymer protein 
conjugate 
Styrene maleic anhydride 
Neocarzinostatin (SMANCS) 
Liver and renal cancer 
Approved in 
Japan (1994) 
Polymeric micelle 
paclitaxel (Genexol-PM) 
400,406-408 
PEG-PLA 
Polymeric 
micelle 
Paclitaxel 
Breast cancer and NSCLC  Lung cancer, 
Ovarian cancer 
Gynecologic cancer, hepatocellular 
carcinoma, advanced breast cancer, non-small 
cell lung cancer 
Approved in 
South Korea 
(2007) 
Phase I/II 
2016* 
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Liposomal cisplatin 
(Lipoplatin) 409 
Pegylated 
liposome 
Cisplatin NSCLC Phase III 
NK-105410 
Polymeric 
micelle 
Paclitaxel Metastatic or recurrent breast cancer Phase III 
Liposomal paclitaxel 
(EndoTAG-1)411-414 
Liposome Paclitaxel 
Pancreatic cancer, liver metastases and HER2 
negative and triple-negative breast cancer 
Phase II 
Nab-rapamycin (ABI-
009) 415,416 
Albumin NP Rapamycin 
Advanced malignant PEComa and advanced 
cancer with mTOR mutations 
Phase II 
CRLX 101417-419 Polymeric NP Camptothecin 
NSCLC, metastatic renal cell carcinoma and 
recurrent ovarian, tubal or peritoneal cancer 
rectal, fallopian tube, lung (small cell and non-
small cell) primary peritoneal, stomach, 
gastroesophageal, and esophageal cancers 
Phase  I/II 
(2016) 
Chemotherapy: 
targeted 
delivery 
MM-302 420 
HER2 targeting 
liposome 
Doxorubicin HER2-positive breast cancer Phase II/III 
BIND-014421,422 
PSMA-targeting 
polymeric NP 
Docetaxel NSCLC and mCRPC Phase II 
MBP-426 423 
TfR targeting 
liposome 
Oxaliplatin 
Gastric, oesophageal and gastro-oesophageal 
adenocarcinoma 
Phase I/II 
Anti EGFR 
immunoliposomes loaded 
with doxorubicin 424,425 
EGFR targeting 
liposome 
Doxorubicin Solid tumours,  Breast cancer 
Phase I/ II 
(2016) 
Chemotherapy: 
stimuli-
responsive 
delivery 
ThermoDox 426 Liposome Doxorubicin Hepatocellular carcinoma Phase III 
Chemotherapy: 
combinatorial 
delivery 
Liposomal cytarabine–
daunorubicin (CPX-351 
or Vyxeos) 427 
Liposome Cytarabine and daunorubicin (5:1) High-risk acute myeloid leukaemia 
Phase  I 
(2014) 
 Phase III 
CPX-1 428 Liposome Irinotecan and floxuridine (1:1) Advanced colorectal cancer Phase II 
Hyperthermia 
NanoTherm400 Iron oxide NP NA Thermal ablation glioblastoma 
Approved in 
Europe 
EMA (2010) 
AuroLase 429,430 
Silica core with 
a gold nanoshell 
NA 
Prostate, head and neck cancer, and primary 
and metastatic lung tumours 
Pilot study 
Phase I 2016 
Radiotherapy NBTXR3431 
Hafnium oxide 
NP 
NA Adult soft tissue sarcoma Phase II/III 
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Gene or RNAi 
therapy 
SGT53 432,433 
TfR targeting 
liposome 
Plasmid encoding normal human 
wild-type p53 DNA 
Recurrent glioblastoma and metastatic 
pancreatic cancer 
Phase II 
PNT2258434 Liposome 
DNA oligonucleotide against BCL-
2 
Relapsed or refractory non-Hodgkin 
lymphoma and diffuse large B-cell lymphoma 
Phase II 
SNS01-T 435 
Polyethylenimin
e NP 
siRNA against eIF5A and plasmid 
expressing eIF5A K50R 
Relapsed or refractory B cell malignancies Phase I/II 
Atu027436 Liposome siRNA against protein kinase N3 Advanced or metastatic pancreatic cancer Phase I/II 
TKM-080301437 Lipid NP siRNA against PLK1 
Neuroendocrine tumours, adrenocortical 
carcinoma and advanced hepatocellular 
carcinoma 
Phase I/II 
DCR MYC 438 Lipid NP 
Dicer-substrate siRNA against 
MYC 
Hepatocellular carcinoma Phase I/II 
MRX34439 Liposome miR 34 mimic 
Primary liver cancer, solid tumours and 
haematological malignancies 
Phase I 
CALAA-01440 
TfR targeting 
polymeric NP 
siRNA against ribonucleotide 
reductase M2 
Solid tumours Phase I 
ALN-VSP02441,442 Lipid NP siRNAs against KSP and VEGFA Solid tumours Phase I 
siRNA EPHA2 DOPC443 Liposome siRNA against EPHA2 Advanced cancers Phase I 
pbi shRNA STMN1 LP 
444 
Lipid NP shRNA against stathmin 1 Advanced and/or metastatic cancer Phase I 
Immunotherapy 
Tecemotide445 Liposome MUC1 antigen NSCLC Phase III 
dHER2 + AS15446 Liposome 
Recombinant HER2 (dHER2) 
antigen and AS15 adjuvant 
Metastatic breast cancer Phase I/II 
DPX-0907447 Liposome Multi-tumour associated antigens 
HLA-A2-positive advanced stage ovarian, 
breast and prostate cancer 
Phase I 
Lipovaxin-MM448 Liposome Melanoma antigens Malignant melanoma Phase I 
JVRS 100449 Lipid NP Plasmid DNA Relapsed or refractory leukaemia Phase I 
CYT 6091450 
Colloidal gold 
NP 
TNF Advanced solid tumours Phase I 
 
EGFR, epidermal growth factor receptor; eIF5A, eukaryotic initiation factor 5A; EPHA2, ephrin type A receptor 2; FDA, US Food and Drug Administration; KSP, kinesin spindle protein (also 
known as KIF11); mCRPC, metastatic castration resistant prostate cancer; miR, microRNA; mTOR, mammalian target of rapamycin; MUC1, membrane bound mucin 1; NA, not applicable; nab, 
nanoparticle albumin bound; NSCLC, non small cell lung cancer; PEComa, perivascular epithelioid cell tumours; PEG, poly(ethylene glycol); PLK1, polo like kinase 1; PSMA, prostate specific 
membrane antigen; RNAi, RNA interference; shRNA, short hairpin RNA; SMANCS, poly(styrene co maleic acid) conjugated neocarzinostatin; TfR, transferrin receptor 
 
.
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2.6.1. Proprieties 
Depending on their material composition, size, shape, surface charge and chemistry, NPs offer a 
wide variety of physico-chemical and biological proprieties which can be tailor made to treat specific 
tumours. Size is important for travel the bloodstream and to bypass biological barriers (e.g. blood brain 
barrier) to reach the desired location and cellular uptake. While smaller particles are more easily 
internalized by cells and able to accumulate more easily in the leaky blood vessels of tumours, known 
as the enhanced permeability and retention (EPR) effect, they can also extravasate to normal tissue. On 
the other hand, bigger NPs are less likely to accumulate in normal tissue, but their bloodstream 
distribution is highly variable. Thus, optimization of particle size can be important to improve specific 
uptake in tumour tissue451. The shape of NPs can influence fluid dynamics and cellular uptake, with 
spherical nanocarriers being the most common used shape, as their synthesis and testing is less 
challenging than non-spherical varieties452. The charge of NPs is also important for their stability, 
distribution and cellular uptake. Positively charged particles were shown to target tumour vessels more 
efficiently453. Also, positively charged NPs are more likely to interact with the negatively charged lipids 
of cellular membranes and, when inside of endosomes, to disrupt them by activating the proton pumps 
and increase the osmotic pressure inside the endosome, culminating in the swelling/bursting of the 
endosome, thus avoiding lysosomal degradations of the drug, also called the “proton-sponge effect”454. 
 
2.6.2. Composition 
Both organic and inorganic materials have been used in the synthesis of NPs (Figure 2.5), both with 
pros and cons. In general, organic NPs have better drug loading capacity and biocompatibility and have 
been the most explored nanocarriers for cancer treatment, including: dendrimers, which are highly 
branched, allowing the delivery of cargo and produced by controlled polymerization with a maximum 
of 10 nm of size; lipid-based NPs, such as liposomes and micelles that may carry a hydrophobic cargo 
and typically have 50–100 nm of size; polymeric NPs, produced in a size range from 10 to 400 nm from 
synthetic, natural, hydrolytically, or enzymatically degradable polymers onto which a cytotoxic drug 
can be covalently attached, dissolved, encapsulated, or entrapped; and more recently, natural NPs, such 
as exosomes, have also been used455-458 On the other hand, inorganic NPs offer advantages in terms of 
chemical proprieties (e.g. conjugation) and in vivo quantification.  These nanomaterials include carbon-
based NPs (e.g. carbon nanotubes, graphene) which feature unique electrical proprieties, quantum dots 
(QDs), which have been mainly explored for optical imaging since they show narrow and tuneable 
emission spectra, and metal NPs (e.g. gold, silver and iron oxide), which are easy to synthetize and 
functionalize. Gold NPs (AuNPs) have been used for drug and gene delivery, thermal ablation, 
radiotherapy augmentation and also diagnostics, due to their high sensitivity. Iron oxide NPs, beside the 
possibility for surface functionalization, they feature unique magnetic proprieties, which can be used as 
contrast agent for magnetic resonance imaging (MRI), hyperthermia and drug delivery. 
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Figure 2.5 - Examples of organic and inorganic nanoparticles used in nanomedicine. Figure adapted from459   
2.6.3. Drug delivery 
The use of nanocarriers for drug delivery offers several advantages to conventional drug 
administration routes, such as increased drug stability and bioavailability, increased specificity and 
decrease of possible side effects. In turn, these advantages can translate to an increased success of the 
clinical application of many molecules, such as small molecules, proteins and nucleic acids used in gene 
therapy (e.g. siRNA, miRNA, lncRNA; CRISP-CAS9 system). 
The first generation of NP was mostly aimed to increase the stability of hydrophobic drugs, which 
can be rapidly eliminated from the bloodstream. The use of hydrophilic NPs to encapsulate hydrophobic 
drugs may improve they solubility, increasing their bioavailability in vivo and thus a more effective 
delivery can be achieved using NP, without the need to increase the concentrations of the drug 
administrated and consequent increased toxicity392,399,451,460. Furthermore, many biomolecules have 
negative charge (e.g. nucleic acids) at physiological pH, which may represent a limitation in their use 
for intracellular delivery, as negatively charged molecules are less likely to be internalized by cells461. 
Coating NPs with poly(ethylene glycol) (PEG), a hydrophilic and non-ionic polymer, was shown to 
increase NP solubility and stability451 without disrupting the function of charged molecules462. Masking 
hydrophobicity of NPs and carried molecules, prolongs their circulation in the blood and subsequently 
the likelihood of reaching their target, as it decreases the activity of the reticulo-endothelial system 
(RES), also known as the mononuclear phagocyte system (MPS)463. MPS recognizes hydrophobic 
materials as foreign and initiate a local inflammation response, increasing NP clearance from the blood 
stream464. 
Most nanocarriers are administered systemically, so its important make sure NPs reach their 
target efficiently without accumulating in other tissues and only release their cargo when they reach the 
tumour microenvironment. Therefore, efforts have been made by researchers to increase the control of 
NP targeting and drug release beyond the more simplistic passive targeting and drug release (Figure 
2.6). Drug delivery systems can rely on intrinsic and biological proprieties (e.g. pH, enzymes, redox 
gradient or EPR) to passively reach and release the cargo to target environment465. However, passive 
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targeting does not eliminate the potential for accumulation of NPs in tissues with fenestrated blood 
vessels, such as the liver and spleen392. Furthermore, the environment of the disease site can be highly 
heterogeneous, differing between patients, which makes difficult to control and predict the NP 
pharmokinetics466-469. Modifications of the NP surface with ligands allows a more precise, active 
targeting. These ligands have high specificity to receptors and other specific ligands expressed at the 
surface of tumour cells470. Such ligands include transferrin, folic acid, enzymes, engineered antibodies, 
and macromolecules like proteins and carbohydrates392,451. However, these systems still lack control of 
the dose of drug release. 
 
 
 
Figure 2.6 - Types of targeting for NP delivery to tumour tissue. (A) Passive targeting relies on the leaky 
vasculature that is exhibited by tumours, allowing NPs to travel through the fenestrations and reach tumours. (B) 
Active targeting can be used when NPs have ligands on their surface that can recognize and bind receptors that are 
overexpressed on tumour cells. (C) Triggered release allows NPs to congregate if exposed to an external stimulus 
such as a magnetic field or light. Figure and legend adapted from 471. 
Triggerable nanoformulation 
Actively triggered systems are probably the most useful regarding the improvement of the 
therapeutic effect of drug delivery nanotechnology, as it allows a more precise control of targeting 
without the need of specific ligands (i.e. application of stimulus at desired area/tissue), time of drug 
release (spatio-temporal control) and/or dose. Triggered drug delivery events can be achieved with 
several external stimuli such as: ultrasound, magnetic, thermic, chemical, electric or light (Table 2.8).  
Light can penetrate the human body ~1mm with 440nm wavelength, up to more than 4mm with 
wavelengths above 650nm472,473, and offers some advantages relatively to other stimuli, such as: 
possibility of activating multiple drug systems using specific wavelengths; step-wise drug release from 
a single nanoformulation, using ligands responsive to different wavelengths; more precise targeting drug 
release at specific areas with a resolution determined by laser spot; and a light-trigger is user friendly, 
since the operator can easily change parameters such as intensity and wavelength of light474,475.  
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Table 2.8 - Triggerable NPs examples.  
 
DEACM, (7-diethylaminocoumarin-4-yl)methyl; MNPs, magnetic nanoparticles; PdPc(OBu)8, 1,4,8,11,15,18,22,25-
octabutoxyphthalocyaninato-palladium-(II); PLGA, poly(lactic acid-co-glycolic acid); PNIPAM, poly(N-
isopropylacrylamide); ssDNA, single-stranded DNA. 
 
Stimulus 
Mechanism (effector molecule or material, 
if applicable) 
Drug delivery systems (main parameter 
or trigger in parentheses) 
Light 
Photocleavage reactions (molecules with 
photolabile groups, such as o-nitrobenzyl or 
coumarin-4-yl-methyl groups)  
Coumarin-functionalized nanoparticles 
(420 or 800 nm light) 476 
Photoisomerization (azobenzenes and 
spiropyrans)  
Spiropyran-functionalized nanoparticles 
(365 nm light) 477 
Upconversion (for example, photosensitizers 
and annihilators for triplet–triplet 
annihilation)  
DEACM-caged micelles (530 nm light) 478 
Photodynamic reaction (photosensitizers, for 
example, PdPc(OBu)8)  
Photosensitizer-loaded liposomes (730 nm 
light) 479 
Photothermal effect (plasmonic nanoparticles, 
such as gold nanoparticles)  
Gold nanorods attached to liposomes (808 
nm light) 480 
Gold nanocages (790 nm light) 481 
Magnetic 
field 
Heating (magnetic nanoparticles, such as 
nanoparticles of magnetite, maghemite and 
ferrites) 
PNIPAM-based nanogels (alternating 
magnetic field of 220–260 kHz) 482  
Hydrogels composed of MNPs and 
thermoresponsive microgels (200 kHz 
magnetic field) 483 
Mechanical deformation (MNPs) 
Liposomes attached to chains of MNPs (10 
kHz magnetic field) 484 
Magnetic guidance (MNPs) 
PLGA-based nanoparticles loaded with 
paclitaxel and superparamagnetic iron 
oxides (static magnetic field) 485 
Ultrasound 
Cavitation 
Microbubble–liposome complexes (pulsed 
ultrasound with an amplitude of 1.9 MPa) 
486 
Liposomes (continuous-wave ultrasound 
with intensity >100 mW cm−2) 487 
Phase transition 
Phase-transition droplets (high-intensity 
focused ultrasound with an amplitude of 11 
MPa) 488 
Heating 
Liposomes (pulsed high-intensity (1,300 W 
cm−2) focused ultrasound) 489 
Electric 
field 
Electrokinetic flow 
Polyelectrolyte hydrogels (constant 1.0 
mA current for 1–10 min) 490 
Redox reaction 
Conductive polymers (3 V potential for 
150 s) 491 
Redox reaction and electrokinetic flow 
Conductive polymer nanoparticles 
embedded in hydrogel (−1.5 V and 0.5 V 
potentials) 492 
Chemical 
Binding interaction 
Hydrogel containing ssDNA 493 
Aptamer-functionalized hydrogels 
(complementary nucleic acid sequences) 
494 
Hydrogels containing antibiotic-binding 
units (novobiocin) 495 
Chemical ligation Antibody–drug conjugates (tetrazine) 496 
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Light-triggered drug delivery systems  
Absorbed light can induce chemical changes in administered or endogenous compounds such as: 
photochemical reactions (i.e. photocleavage or photoswitching, or by generation of reactive oxygen 
species in photodynamic therapy); emission of light (e.g. fluorescence); or the transfer of energy  to 
other forms (e.g. heat or acoustic waves)497. Most common wavelengths of light used in light triggered 
systems are within the ultraviolet (UV) and near infrared regions (NIR) of the light spectrum. NIR 
radiation can penetrate deeper in the body498,499 and has been used in the clinic for more than 30 years. 
Therefore, NIR exposure safe limits have already been established500,501. Despite being a safer type of 
irradiation, NIR low-energy radiation has reduced capacity to break chemical bonds (e.g. between a drug 
and its carrier)498, limiting its application as a trigger in light-sensitive nanoformulations. On the other 
hand, UV light is a high-radiation energy, able to break chemical bonds but it has a lower penetration 
capacity in biological tissues473 and prolonged exposure of cells and tissues to UV light may induce 
deleterious effects (e.g. DNA damage and ROS production)502,503. Nevertheless, short exposure to UV 
light has been used in the clinic to treat various diseases (e.g. skin disorders and ocular conditions)504 
and its limited body penetration can be circumvented through the use of optical fibre and endoscopic 
apparatus498,505,506. Also, it should be considered that in cancer therapy, more harmful forms of radiation 
are used (i.e. radiotherapy). 
The wavelength of the light determines its uses in photo-triggered nanoformulations. Higher energy 
lights (e.g. UV) have sufficient energy to cleave chemical compounds (i.e. photolabile or photocaging 
groups) such as o-nitrobenzyl, coumarin-4-yl-methyl, p-hydroxyphenacyl and 7-nitroindoline 
derivatives507. Photocleavage can be used to drive destabilization of hydrophobic/hydrophilic balance 
of NPs and consequent release of its cargo508, release drugs by cleaving the link between drug and NP509 
or by removing protective moieties from ligands at NP surface, allowing their binding to cells510. UV 
light can also be used to induce reversible photoisomerization of photochromic groups such as 
azobenzenes and spiropyrans. When a photochromic group is embedded in a nanoformulation, 
photoisomeration can induce changes in the geometry, polarity or hydrophobicity of the groups can lead 
to reorganization or disassembly of the NPs, followed by drug release477,511. 
NIR-triggered nanoformulations rely on photochemical reactions such as upconversion and 
plasmonic effect. Upconversion has been explored to take advantage of the deep tissue penetration of 
NIR with the high energy of UV, by combining the energy of multiple NIR photons to achieve a higher 
energy state or to create a single UV photon. This can be achieved by a two-photon absorption process, 
in which chemical groups that are normally sensitive to UV light, such as o-nitrobenzyl and coumarin 
derivatives, simultaneously absorb two photons of NIR light to achieve a chemical reaction507. Another 
way to achieve upconversion is by using higher energy states rather than higher photon energy. For 
example, polymeric micellar nanoparticles were designed with a photosensitizer in their cores that, when 
irradiated with green light, transfers its energy to annihilator molecules, which then undergo triplet–
triplet annihilation upconversion. The upconverted energy can then be transferred by Förster resonant 
energy transfer (FRET) to cleave and release a hydrophobic photocleavable group, reactivating the 
activity of a cell-binding peptide478,512. 
Nobel metal NPs (e.g. AuNPs) can respond to NIR by producing heat (i.e. photothermal effect). 
Under NIR irradiation, the free electrons in metal NPs collectively oscillate in phase with the electric 
field of the incident radiation, a phenomenon known as surface plasmon resonance (SPR). The SPR 
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spectrum is dependent on the geometry of the nanostructures, as explained by the Mie-Gans theory513,514 
and allows plasmonic NPs to efficiently convert photon energy to heat, increasing the temperature in 
their immediate vicinity, leading to drug release events515. For example, the heat produced can induce 
the release of oligonucleotides from the NP by dehybridization516, by triggering drug-release from 
nanoformulation composed of thermally responsive polymers, such as Poly(N-isopropylacrylamide) 
(PNIPAM)517,518, or by using the heat produced by gold nanorods to destabilize the liposomal lipid 
bilayers present in lipidic NPs (LNPs), with a consequent phase transition and drug release480,519.  
 
2.6.4. Targeting the BM  
When drug administration is systemic, drug availability is often quite low at the BM, due to rapid 
metabolization and clearance. Most injected drugs are either cleared by the body’s metabolic and 
excretory system or accumulate in other highly perfused organs before reaching the BM. Thus, drugs 
are always administered in high doses and/or frequency to achieve the therapeutic effect at the BM, 
which can lead to unwanted systemic side effects520. Although the combination of leaky vasculature 
with poor lymphatic drainage has shown to promote accumulation of NPs due to EPR, little is known 
about EPR at the BM compartment521. Moreover, the existence of fenestrae (size between 85 nm and 
150 nm) at the endothelium of BM vascular sinusoids can represent a limitation to NPs sized over 150 
nm522. However, several studies have demonstrated that the BM is the main organ for the specific uptake 
of bioparticles (i.e. senescent cells, lipoproteins and nuclei from erythroid precursor cells) by the MPS523-
526, suggesting that phagocytic activity in the bone marrow can be potentially used for NP drug delivery. 
In fact, early formulation studies using liposome-based drug delivery systems have demonstrated that 
negatively charged LNPs accumulate more in the BM, with increased BM macrophage uptake527-531. 
Selective uptake of LNPs by macrophages seems to occur through the scavenger receptor on BM’s 
macrophages, as polyanions such as dextran sulphate and polyinosinic acid have been reported as 
ligands for this receptor532,533. 
To overcome the problem of low accumulation at the BM, some nanotechnologies have been 
developed for leukaemia treatment and BM targeting534, with some of them already in clinical trials 
(Table 2.9). 
In this case, NPs have been conjugated with specific ligands (e.g. CD45, CD20, CD19, E-E-
selectin)535,536, or have been activated by intrinsic or extrinsic cues at the BM leukaemic niche537-540. 
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Table 2.9 - Rationales and applications of bone marrow-targeted delivery systems.  
 
Carrier type Targeting Drug Application 
liposome541,542 
anionic low-
cholesterol 
liposome 
promotes 
accumulation 
in BM 
cytarabine: daunorubicin 
increase drug 
accumulation in 
leukemia cells inside 
BM and enhance 
efficacy in AML mice 
liposome543 
folate binds to 
FR-β 
doxorubicin 
folate-modified 
liposomes increase 
median survival 
times of AML mice 
SLN 544  n.a. ATRA 
In vitro acute 
leukemia (HL60, 
Jurkat and THP1 cell 
lines) 
LNP 545 n.a. Mcl1 siRNA 
In vitro mantle cell 
lymphoma [JeKo-1 
(normal) and 
MAVER-1 
(aggressive) cell 
lines] 
LNP 546 
CD45.2 
antibody 
AntagomiR-126 
In vitro/in vivo AML 
(human primary 
cells; murine model) 
lipid nanocapsule 546 
Healthy 
primary T-cells 
(live vector) 
Topoisomerase I poison 
SN-38 
In vivo lymphoma 
(murine model) 
micellar NPs protected by 
porous silicon (pSi) coating 536 
E-selectin 
thioaptamer 
(ESTA) (bone 
marrow-
directed 
aptamer) 
Parthenolide (PTL) 
In vivo AML (patient-
derived murine 
xenografts) 
Nanopolymer 535 CD19 antibody DOX 
In vitro/in vivo ALL 
(REH and RS4; 11 
cell lines: human-
derived murine 
xenografts) 
MSN (pH-controlled delivery) 
547 
Rituximab 
(CD20 
antibody) 
DOX and rituximab 
In vitro/in vivo B-cell 
lymphoma (Raji and 
Daudi cell lines; 
murine model) 
PEG-PLGA nanoparticle548 
alendronate-
HA binding in 
bone matrix 
bortezomib 
pretreatment 
inhibits myeloma 
growth better than 
free drug in 
myeloma mice 
model 
PEG-PLA micelle549 
alendronate-
HA binding in 
bone matrix 
ponatinib, SAR302503 
extend survival time 
of BaF3/T315I cells 
inoculated CML 
mice 
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porous silicon particle550 
E-selectin 
specific 
thioaptamer 
parthenolide 
impairment of LSCs 
in AML secondary 
transplantation mice 
nanostructured lipid carrier551 
dual targeting 
via 
alendronate-
HA and folate-
FR-β bindings 
mitoxantrone 
deliver drugs to LSCs 
in bone marrow for 
refractory leukemia 
therapy 
QD-CdTe 552 n.a. Wogonin 
In vitro/in vivo 
multidrug-resistant 
leukemia (K562-A02 
cell line; leukemia-
bearing mice) 
MNP-Fe3O4 553 n.a. Wogonin 
In vitro multidrug-
resistant leukemia 
(K562-A02 cell line) 
MNP-Fe3O4 554 n.a. Cytarabine 
In vitro acute 
leukemia (HL60 and 
KG1 cell lines) 
Burkitt’s lymphoma 
(Raji cell line) 
AuNP or AuNP 
controlled drug release via 
presence of BIRC5 mRNA) 555 
BIRC5 dsDNA 
oligonucleotide 
Dasatinib 
In vitro/in vivo CML 
(K562 cell line; 
K562-derived 
murine xenografts) 
AuNP556,557 n.a. 
Lestaurtinibmidostaurin 
sorafenib quizartinib (FLT3 
inhibitors) 
In vitro AML (THP1 
and OCI-AML3 cell 
lines) 
AuNP 539 Folic acid Fludarabine phosphate 
In vitro AML (KG1 
cell line) 
AuNP 558 n.a. 
BCR-ABL1 ssDNA 
oligonucleotide (e14a2) 
In vitro CML (K562 
cell line) 
AgNP 559 
Rituximab 
(detection of 
CD20) 
Rituximab 
In vitro Burkitt’s 
lymphoma (Daudi 
and Raji cell lines) 
DNPs 560 
Idiotype-
peptide 
specific BCR 
BCL2 siRNA 
In vitro lymphoma 
(murine A20 cell 
line) 
NP-albumin-bound PTX 561 
Rituximab 
(CD20 
antibody) 
PTX and rituximab 
In vitro/in vivo B-cell 
lymphoma (Daudi 
cells; human B-cell 
lymphoma murine 
model) 
  
HA, hydroxyapatite; FR-β, folate receptor-β; AuNP, gold nanoparticle; CLL, chronic lymphocytic leukemia; PTK7, 
protein tyrosine kinase 7; FRET, fluorescence energy transfer; QD, quantum dot; SERS, surface-enhanced Raman scattering; 
ISH, in situ hybridization; FFPE, formalin-fixed paraffin embedded tissues; XIAP, X-linked inhibitor of apoptosis protein; 
CTC, circulation tumor cell; AF750, alexafluor 750; CML, chronic myeloid leukemia; DOX, doxorubicin; polyArg, peptide 
sequence with nine arginines; PTX, paclitaxel; BCR, B-cell receptor; LNP, lipid NP; MSN, mesoporous silica NP; ABX, 
ambraxane. 
 
2.6.5. Cells as carriers 
Despite the huge advances in the development of nanoformulations, their therapeutic efficiency is 
restricted by inefficient avoidance of MPS or targeting. As an alternative strategy, cell-mediated drug 
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delivery strategies have been explored. This concept emerged from a pioneering study in the 1970s that 
successfully encapsulated β-glucosidase and β-galactosidase into red blood cells (RBCs) for the 
treatment of Gaucher’s disease562. Since then, RBCs, leukocytes and stem cells (Table 2.10), have been 
studied in cell-mediated drug delivery due to their long circulation, specific tropism to diseased tissue 
and ability to cross biological barriers, such as blood brain barrier563. In fact, leukocytes and stem cells 
are already used for tumour immunotherapy and tissue regeneration in clinical trials564-567. 
 
Table 2.10 - Stem cells as a vehicle to transport nanoparticles (NPs): physical–chemical properties of 
NPs.  
 
Formulation 
Drug 
(conc.) 
NP 
size 
(nm) 
NP 
zeta 
(mV) 
Intracellular 
retention of 
NPs (days) 
NP 
degradation 
Response 
to 
remote 
trigger 
Stem cells 
as 
transporter 
Phototriggerable 
polyplex NPs 400 
Retinoic 
acid (150 
g per mg 
of NPs) 
160 +22 Up to 6 days Yes Yes LSCs 
Poly(lactic acid) 
(PLA) NPs and 
lipid nanocapsules 
(LNCs) 568 
Coumarin 
136 
(PLA) 
88 
(LNC) 
−2.1 
(PLA) 
−3.7 
(LNC) 
Up to 7 days Yes No MSCs 
Assembly of 
superparamagnetic 
NPs with 
biodegradable 
polymers 569 
Paclitaxel 110 - - - Yes ADSCs 
Porous hollow 
silica NPs 570 
Purpurin18 
150– 
200 
- Up to 5 days - Yes MSCs 
Mesoporous silica 
NPs571 
Doxorubicin 190 +23.3 Up to 5 days – No MSCs 
pH-sensitive NPs 
572 
Docetaxel 100 – 
Conjugation 
to the cell 
membrane 
(up to 7 
days) 
- - NSCs 
Ultrasound-
responsive 
copolymer 
covalently grafted 
to mesoporous 
silica NPs573 
Doxorubicin 150 +23 Up to 6 days - Yes MSCs 
Poly(lactic-
coglycolic acid) 
NPs574 
Doxorubicin 150 −37 Up to 1 day – No MSCs 
Gold nanorods 
conjugated with 
CXCR4 
antibody575 
No 50:10 – Up to 3 days No Yes iPSCs 
NSCs, neural stem cells; HSCs, hematopoietic stem cells; MSCs, mesenchymal stem cells. 
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Red Blood Cells 
RBC are natural carriers of oxygen and nutrients to all parts of the body and are the most readily 
available and abundant cells. Besides their high number, they also possess other attractive characteristics 
to increase the efficiently of drug delivery such as long-life span and widespread circulation; they protect 
encapsulated drugs, thus can be used as drug reservoir for a sustained drug release in the blood; and they 
are completely biodegradable, non-toxic and show very low to no immunogenic response576. RBCs can 
be loaded with NPs by hypotonic dialysis, an encapsulation process involving reversible hypotonic 
swelling of the RBCs, which transiently opens pores in the membrane allowing drugs or NPs to diffuse 
into the cells and when changed back to a isotonic medium, pores are sealed and the cargo 
entrapped577,578. However, this process can induce structural and chemical changes on RBCs, affecting 
their normal function and can be recognized by MPS579,580. More recently, a novel encapsulation process 
was developed to overcome these obstacles. By conjugating the drug with a cell penetrating peptide via 
disulphide linkage, RBCs could be loaded without affecting their natural structure and functionality. 
Once inside RBCs, the cell penetrating peptide is detached from the drug by degradation of the 
disulphide bond, due to the presence of high levels of cytoplasmatic glutathione found in RBCs581. This 
technique was successfully applied to target acute lymphoblastic leukaemia (ALL) and increase L-
asparginase half-life in mouse models582. 
 
Leukocytes 
Leukocytes are a more attractive cell type than RBCs to be used as NP carriers. They can be used 
as drug depots for a sustained and prolonged drug release, with the added advantage of their natural 
ability to home into inflammation tissues563,583,584. The process of inflammation triggers the mobilization 
of leukocytes from the BM or its vicinity into blood circulation, with a specific migration to diseased 
sites. This migration is mediated by the overexpression of cell adhesion molecules on the surface of the 
EC layer, which facilitates the initial process of leukocyte rolling, attachment to endothelial layer and 
transmigration to the inflammation site585,586. This process was first explored by producing microspheres 
with leukocyte adhesion ligands attached to their surface. The microspheres successfully mimicked the 
leukocyte migration behaviour into inflammation sites587-589. Later, leukocytes were directly used as 
carriers in Parkinson’s disease model. Bone marrow derived macrophages were able to carry and cross 
blood brain barriers to deliver catalase NPs, with increased accumulation in the brain563. 
The inflammatory response has been shown to play an important role in all stages of tumour 
development583,590, with evidence showing that tumour cells produce high levels of chemoattractants, 
which can recruit a large number of leukocytes, mainly T-cells and macrophages591,592. In one study, 
drug loaded NPs were attached to the surface of T-cells and promoted tumour reduction and prolonged 
survival of mice when compared with free NP administration593. In another study, monocytes were used 
as NP carriers for co-delivery of echogenic polymer/C5F12 bubbles and doxorubicin-loaded polymer 
vesicles towards hypoxia regions of malignant tumours594. 
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Stem cells  
Over the last decade, stem cells have emerged as a promising therapeutic option for a wide range of 
diseases. As leukocytes, stem cells exhibit an intrinsic tropism to injury, inflammation and tumour 
sites595-598, with other additional advantages comparing to other cell types, as stem cells can secret 
trophic factors promote the recovery of the damaged tissue and potentially differentiate to a wide variety 
of functional cells and consequently help in the repopulation of their target site. Moreover, MSCs and 
HSCs have high bioavailability and can be harvested readily from bone marrow of healthy unaffected 
individuals or isolated from UCB units599-604. MSCs have been used as NP carriers to target brain 
tumours568,605 and in regenerative medicine, for example in the treatment of ischemic hindlimbs, where 
MSC loaded with NPs conjugated with VEGF were able to promote vascularization and tissue 
regeneration606, MSCs have also been used as carriers for anti-cancer therapy. In one study, MSC 
transfected with liposomes containing a constructed vector, were able to inhibit tumour growth by way 
of lymphoma cell apoptosis induction through the bystander effect when co-cultured with Raju cells 
604,607. 
HSCs are also good candidates to target NPs to the HSC niche at the bone marrow in regenerative 
medicine and to treat haematological malignancies. NPs can modulate HSC paracrine activity and their 
engraftment in the BM. For example, protamine-sulfate coated PLGA NPs encapsulating an MRI agent 
have the capacity to downregulate the immune response of HSCs, by decreased expression of 
proinflammatory cytokines (e.g. interferon (IFN)-γ, IL-8, macrophage inflammatory protein (MIP)-1 
and TNF-α)608. In another study, HSCs were chemically decorated with NPs containing Wnt activator, 
enabling continuous pseudo autocrine stimulation of the transplanted HSCs, which translated into a 6-
fold increase in HSC engraftment, without affecting their multilineage differentiation potential593. NPs 
can also be used to target HSCs into the BM niche or to recruit other cells to the niche. For example, 
PLGA NPs were surface modified with bisphosphonate to provide them with a bone-binding capacity548. 
The bisphosphonates are calcium-ion-chelating molecules that, after systemic administration, deposit in 
bone tissue, particularly at the sites of high bone remodelling. In another study, CXCL12 loaded chitosan 
NPs were able to induce BM MSCs migration in vitro609. 
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3.1. Abstract 
Leukaemia cells that are resistant to conventional therapies are thought to reside in protective niches. 
Here, we describe light-inducible polymeric retinoic acid (RA)-containing nanoparticles (NPs) with the 
capacity to accumulate in the cytoplasm of leukaemia cells for several days and release their RA 
payloads within a few minutes upon exposure to blue/UV light. Compared to NPs that are not activated 
by light exposure, these NPs more efficiently reduce the clonogenicity of bone marrow cancer cells from 
patients with AML and induce the differentiation of RA-low sensitive leukaemia cells. Importantly, we 
show that leukaemia cells transfected with light-inducible NPs containing RA can engraft into bone 
marrow in vivo in the proximity of other leukaemic cells, differentiate upon exposure to blue light and 
release paracrine factors that modulate nearby cells. The NPs described here offer a promising strategy 
for controlling distant cell populations and remotely modulating leukaemic niche. 
3.2. Introduction 
The differentiation of leukaemia cells is a therapeutic strategy often used in the clinic to eradicate 
blood cancers. The concentration of the agent used for inducing leukaemia cell differentiation and the 
spatio-temporal control of its application are important variables for the success of this therapeutic 
approach610. Induction of leukaemia cell differentiation by RA is a therapeutic strategy that has been 
used with great success in the treatment of APL611,612. RA activates nuclear RA receptors (RARs) that 
induce cell growth arrest and differentiation613. Despite its clear therapeutic efficacy, approximately 
25% of patients receiving RA will develop serious complications, such as “differentiation syndrome”1. 
Hence, there is a need for more effective formulations to deliver RA into leukaemia cells while 
preventing RA side effects. In addition, leukaemia cells resistant to conventional therapies reside in 
microenvironmental niches in the bone marrow that are difficult to access by therapeutic interventions2. 
New strategies are required to address these problems.   
NPs that disassemble in response to light614-616 offer a promising approach for reducing the side 
effects of conventional therapies and increasing access of therapeutic agents to the target cells. Recently, 
light-inducible NPs have been reported to target solid tumours due to their specific accumulation in 
tumour vasculature after intravenous injection617. However, such an approach is not applicable to 
leukaemia. The hypotheses of the present work are: (i) light-inducible NPs containing RA may be a 
more effective strategy for differentiating leukaemia cells because they release high and more effective 
concentrations of RA in a short period of time (within minutes) after NP disassembly, and (ii) light-
inducible NPs containing RA accumulated in the cytoplasm of leukaemia cells may offer a unique 
opportunity to remotely differentiate these cells in leukaemic niches in the bone marrow, which in turn 
may interfere with the differentiation profile of leukaemia cells in a paracrine manner.  
Here, we describe light-inducible polymeric NPs containing RA that effectively disassemble within 
cells after light activation. These NPs accumulate in the cytoplasm of leukaemia cells for more than 6 
days. They are internalized primarily through a clathrin-mediated mechanism and at minor extent by 
macropinocytosis. They escape in few hours the endolysosomal compartment and accumulate in cell 
cytoplasm. We show that these NPs are more efficient and quicker at inducing transcription from the 
RARE-luciferase locus than RA in solution. We further show that these NPs can be activated to release 
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RA in vivo in a highly controlled manner. Finally, we demonstrate that leukaemia cells transfected with 
these cells can home in the bone marrow in the same niche as other leukaemia cells, differentiate after 
blue laser activation and modulate the activity/phenotype of the resident leukaemia cells. 
3.3. Results and discussion 
3.3.1 Nanoparticle preparations and in vitro photo-disassembly 
To prepare light-inducible polymeric NPs, poly(ethyleneimine) (PEI) was initially derivatized with 
4,5-dimethoxy-2-nitrobenzyl chloroformate (DMNC), a light-sensitive photochrome (Figure 3.A). PEI 
was selected as the initial NP block because it facilitates the cellular internalization of NPs and their 
subsequent escape from endosomes618,619, while DMNC was selected because it responds rapidly to light 
(Figure 3.B) and its degradation products are relatively non-cytotoxic620. PEI-DMNC was then added 
to dextran sulphate (DS) to form NPs by electrostatic (PEI:DS) and hydrophobic (DMNC:DMNC) 
interactions. To stabilize the NP formulation, zinc sulfate was added619,621. NPs with an average diameter 
of 108.1  9.9 nm and a zeta potential of 27.4  1.6 mV were obtained (Figure 3.2 A and B). To 
demonstrate that the NP formulation could be photo-disassembled, a suspension of NPs was exposed to 
UV light for up to 10 min. The number of NPs (as assessed by Kcps) decreased to below half of the 
initial number after 1 min of UV exposure, confirming NP disassembly (Figure 3.2B). The disassembly 
was likely due to a change in the NP’s hydrophilic/hydrophobic balance after DMNC photo-cleavage. 
Importantly, a conventional blue laser (405 nm, 80 mW) (Figure 3.2D) or a blue confocal laser (405 
nm, 30 mW) (Figure 3.2E) can replace the UV light to induce the photo-disassembly of NPs. The 
response of the NPs to a blue laser was mediated by DMNC coupled to PEI, as NPs without DMNC did 
not respond to the laser (Figure 3.2B). 
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Figure 3.1 - Characterization of PEI derivatized with DMNC. (A) Schematic representation for the photo-
disassembly of RA+NPs. (B) Effect of UV light (365nm, 100Watts) in the absorbance properties of PEI-DMNC 
(1mg/mL in DMSO), PEI (1mg/mL in DMSO) and DMNC (250 µg/mL in DMSO). The experimental degree of 
substitution of PEI-DMNC was 10% as determined by spectrophotometry, using a calibration curve of DMNC and 
by (C) 1H NMR spectra in DMSO-D6 of (a) PEI-DMNC conjugate, (b) DMNC and (c) PEI. For DMNC, the 
absorption maximum at 355nm reverted back to baseline levels after 10 min of UV exposure, indicating the photo-
cleavage of DMNC and a new absorption peak was observed at 320nm, due to the formation of 4,5-dimethoxy-2-
nitrobenzyl alcohol. For PEI-DMNC, there was a decrease in intensity of the 355nm peak and a concomitant 
increase in the 320nm peak; however, our results suggest that not all the attached DMNC molecules were photo-
cleaved. 
We further evaluated the feasibility of triggering intracellular NP disassembly. For that purpose, 
human vein umbilical endothelial cells (HUVECs) were transfected with quantum dots 525-labelled 
NPs for 4 h (Figure 3.2E and F), and a small region of the cell housing NPs was excited by a blue laser 
(405 nm) under a confocal microscope. Under these conditions, NP fluorescence increases compared to 
a reference region not excited with UV light. This increase is due to NP disassembly and a resultant 
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decrease in the quenching of the quantum dots immobilized in the NPs. Overall, our results show that 
we can disassemble NPs by light, either in vitro or within cells.  
 
 
Figure 3.2 - Properties and disassembly of light-triggerable NPs. (A) TEM of the light-triggerable NPs. Bar 
represents 100 nm. (B, C, D) Size, zeta potential and number of NPs (Kcps) of an aqueous suspension of NPs. (B) 
UV light (365nm, 100W) activation of NPs exposed up to 10 min. (C, D) Blue laser (405 nm, 80 mW) activation 
of NPs with (D) and without (C) DMNC photochrom, exposed up to 20 min. A suspension of NPs (100 μL, 100 
μg, in water) was exposed to a UV (up to 10 min) or a blue laser (up to 20 min). Then, the NP suspension was 
diluted up to 50 μg/mL in water and the size, zeta potential and number of NPs (Kcps) in the suspension was 
evaluated by dynamic light scattering. Results are expressed as mean±s.e.m (n = 5). (E and F) Confocal images 
showing light-disassembly of quantum dots 525 (Qdot525)-labeled NPs. (E) A section of a NP aggregate (area 
delimited in the figure) was bleached continuously by a laser at 405 nm as confocal images were collected every 
20 s. The images show the disassembly of the bleached area of the NP aggregate. Fluorescence intensity of the 
area bleached by the laser and reference area (i.e. not activated by the laser) overtime. Our results show that 
fluorescence intensity increases after light exposure due to the disassembly of the NP and the decrease in the 
quenching of Qdot fluorescence after NP disassembly. (F) Confocal imaging of HUVECs after exposure for 4 h 
to QDot525-labelled NPs. A small section of the cell (region 1, created by a mask) was then exposed to blue light 
laser cycles (405 nm) in a Zeiss confocal microscope and the intensity of fluorescence at 525 nm monitored. In 
parallel, the fluorescence of another section of the cell (region 2) not excited with the laser was monitored as a 
control. Our results show that the fluorescence intensity in region 2 maintains overtime while in region 1 the 
intensity increases. Blue dots and line presents the blue light laser-exposed area of Qdot525-labelled NPs; orange 
dots and line presents the control unexposed area of Qdot525-labelled NPs. Dashed areas show cell membrane and 
nucleus. 
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3.3.2. Loading and controlled release of Retinoic acid. 
To evaluate the light-inducible polymeric NPs as a method for the controlled release of RA, a 
solution of RA with PEI-DMNC was assembled with DS in aqueous solution to form NPs (RA+NPs). 
Under these conditions, the carboxyl groups of RA tend to form electrostatic interactions with the amine 
groups of PEI14. The resultant NP formulation contained approximately 150 µg of RA per mg of NP, an 
average diameter of 160 nm and a zeta potential of 22 mV. The release profile of the NP formulation 
containing [3H]RA was monitored by scintillation after NP exposure to UV light or a blue laser for up 
to 10 min (Figure 3.3A). Up to 50 ng of RA was released per µg of NP after 10 min of activation. In 
the absence of light, up to 10 ng of RA was released per µg of NP after 8 days (Figure 3.3B).   
 
 
Figure 3.3 - Release of RA from Light-triggerable RA+NPs. (A) Release of [3H]-RA from an aqueous 
suspension of RA+NPs after exposure to UV or a blue laser. (B) Passive release of RA from RA+NPs without 
light activation. In (A) the NPs were prepared using [3H]-RA, diluted to 10 µg/mL NP suspension and then 
exposed to UV or blue laser up to 10 min. The released RA was measured in the supernatant by scintillations 
counts, after centrifugation (14000g, 3 min) of the of RA+NPs. In (B) RA+NPs (2.5 mg) were placed in PBS (0.5 
mL) and incubated under mild agitation at 37 °C. At specific intervals of time, the nanoparticle suspension was 
centrifuged (at 14.000 g for 3min) and 0.4 mL of the release medium removed and replaced by a new one. The 
reserved supernatant was stored at 4°C until the RA content in release samples was assessed by spectrophotometry 
at 350 nm. Concentrations of RA were determined by comparison to a standard curve. Results are expressed as 
mean±s.e.m (n=3). 
 
3.3.3. Cytotoxicity of nanoparticles and light activation in leukaemic and non-
leukaemic human cells 
Next, we asked whether leukaemia cells could uptake light-inducible NPs. According to our 
dynamic light scattering studies, RA+NPs are positively charged when resuspended in different culture 
media and relatively stable for at least 24 h (Figure 3.4).  
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Figure 3.4 - Stability of RA+NPs suspended in water or cell culture media. (A) Zeta potential of RA+NPs 
suspended in water, serum-free RPMI (medium used for leukaemia cells) or EBM medium (medium used for 
HUVECs). It should be noted that the transfection of the cells with RA+NPs was always performed in serum-free 
media. Diameter (nm) and counts (Kcps) of RA+NPs suspended in water (B), RPMI medium (C) or EBM medium 
(D). A suspension of RA+NPs (2 mL, 25 μg/mL) was prepared and diameter, counts and zeta potential determined 
by dynamic light scattering method (DLS) using a Zeta Plus Analyzer (Brookhaven). Results are expressed as 
mean±s.e.m (n = 3). 
RA+NPs had no substantial effect on cell metabolism, as evaluated by an ATP assay for 
concentrations up to 20 µg/mL in human leukaemic cell lines (Figure 3.5A) and in case of non-
leukaemic cells no cytotoxicity was observed for NP concentrations up to 10 µg/mL (Figure 3.5B), also 
confirmed by AnnexinV/PI assay (Figure 3.5C). For ATP and AnnexinV/PI assays Human bone 
marrow APL NB4 cells, human myelomonoblastic U937 cells (expressing a chimeric PLZF/RARα 
fusion protein622,623 and showing impaired sensitivity to RA624,625, HUVECs and human dermal 
fibroblasts were exposed to NPs for 4 h, washed to remove excess NPs not taken up by the cells, either 
exposed or not to UV light for 10 min, and finally cultured for an additional 20 h. Because the activation 
of RA+NPs by UV or blue light can induce double-stranded DNA breaks, we used HUVECs to evaluated 
the effect of this radiation on the phosphorylation of histone H2A (γH2AX), an early biomarker of DNA 
damage626. Our results indicate that neither UV nor blue light exposure for 10 min had a significant 
impact on DNA damage (Figure 3.5D and E).  
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Figure 3.5 - Cytotoxicity of RA+NPs and light activation. (A) Cytotoxicity of RA+NPs against human 
leukaemic cell lines NB4 and U937 cells. Cells were cultured in medium supplemented with light-sensitive 
RA+NPs for 4 h, washed, exposed or not to a UV light for 10 min, and then cultured for 20 h. Cell cytotoxicity 
was evaluated by an ATP kit. (B, C) Cytotoxicity of RA+NPs against HUVECs or human dermal fibroblasts. Cells 
were cultured in medium supplemented with light-sensitive RA+NPs for 4 h, washed, exposed or not to a UV light 
for 5 min, and then cultured for 20 h. Cell cytotoxicity was evaluated by an ATP kit (B) or Annexin V/PI staining 
(C) followed by flow cytometry analyses. In this case, the concentration of RA+NPs was 10 μg/mL. Live cells 
were negative for Annexin V and PI staining. In A, B and C results are expressed as mean±s.e.m (n = 3). (D) 
HUVECs were exposure to 10 min or 60 min of UV light (left panel) or blue light (right panel) and allowed to 
recover for 6 h. Cells were then fixed and stained to identify γH2AX-containing foci, as biomarker for nuclear 
sites of DNA damage in affected cells. Bar corresponds to 10 μM. (E) Time-dependent increase of γH2AX after 
UV light (365 nm, 100 W) or blue light (405 nm, 80 mW) irradiation. Quantitative analysis of foci intensity were 
quantified using ImageJ software and normalized to the control condition. Results are expressed as Mean ± SEM. 
The calculations were performed in 5 different images for a total of ca. 250 cells (ca. 50 cells per image). 
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3.3.4. Characterization of the internalization kinetics and pathways of RA+NPs 
The intracellular accumulation of RA+NPs was monitored by flow cytometry and inductively 
coupled plasma mass spectrometry (ICP-MS) (Figure 3.6). Our results show that NP internalization 
peaked at 6 h (Figure 3.6A and B) and the intracellular concentration was dependent on the initial NP 
loading (Figure 3.6C). No significant differences were observed in the internalization profiles between 
cells. Importantly, 60-100% of the leukaemia cells retained NPs in culture for at least six days, as 
confirmed by flow cytometry (Figure 3.6D and E). This corresponded to the retention of 25-50% of 
the initial mass of the NPs during 8-10 cell doublings, as obtained by ICP-MS analyses (Figure 3.6F). 
Altogether, NPs were efficiently internalized by human leukaemia cells and accumulated intracellularly 
for several days.  
 
Figure 3.6 - Cellular uptake and dilution of RA+NPs in human leukaemic cells. (A) Uptake of TRITC-labeled 
RA+NPs (10 μg/mL) in leukaemia cell lines (NB4 and U937) as determined by FACS. Cells were cultured in 
medium supplemented with NPs for the time defined in the graph, washed and characterized by flow cytometry. 
The results are expressed as mean±s.e.m (n = 3). (B-C) Quantification of RA+NP internalization in leukaemia cell 
lines as determined by ICP-MS analysis (Zn quantification). Cells were incubated with 10 μg/mL NPs (B and C) 
or 100 μg/mL NPs (C) up to 24 h. After each incubation period, the cells were extensively washed with PBS 
followed by the addition of an aqueous solution of nitric acid (1 mL, 69% (v/v)). The concentration of intracellular 
levels of Zn was quantified by ICP-MS. The concentration was normalized per cell. The estimation of NPs was 
done based on standard solutions. The results are expressed as mean±s.e.m (n=3). (D, E) Dilution of TRITC 
labeled RA+NPs with cell culture. NB4 (D) and THP-1 (E), were transfected with RA+NPs in serum-free media 
for 4h, washed with PBS to remove non-internalized RA+NPs and cultured in complete media for additional 4h, 
3 days and 6 days. After each incubation time cells were washed, counted (to monitor cell doublings) and NP 
dilution evaluated by flow cytometry (D, E) and by ICP-MS (F). The results are expressed as mean±s.e.m (n=3). 
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To identify the pathways of RA+NP internalization, U937 cells were incubated in the presence of 
endocytosis chemical inhibitors at non-cytotoxic concentrations. Fluorescent-labelled RA+NPs were 
then added, and the internalization monitored by flow cytometry. Whenever possible, molecules that 
enter by a specific internalization pathway were used as positive controls to show the efficacy of our 
inhibitors (Figure 3.7A). Dynasore treatment (clathrin-mediated endocytosis (CME) inhibitor) reduced 
the uptake of RA+NPs by 90% compared to control cells (Figure 3.7B). To further confirm the 
endocytosis mechanisms involved in RA+NP internalization, U937 cells were transfected with siRNAs 
to downregulate key components of different endocytosis pathways (Figure 3.7C). We observed a 
~60% and ~70% reduction in NP uptake upon downregulation of clathrin heavy chain (CLTC), and low-
density lipoprotein receptor (LDLR), respectively, confirming a role for CME. The knockdown of 
macropinocytosis regulators Rac1 and CTBP1 led to a ~40% and ~50% decrease in RA+NPs uptake, 
respectively, suggesting that macropinocytosis was also involved in RA+NP internalization (Figure 
3.7C).  
 
 
 
Figure 3.7 - Internalization mechanisms of RA+NPs in Zn-induced U937 cells. (A) Transport of FITC-labeled 
transferrin (1 μg/mL) known to selectively enter cells via clathrin-mediated endocytosis. Dynasor at concentration 
of 80 μM inhibits the internalization of transferrin in U937 cells. Cells were exposed to culture medium with and 
without dynasor for 30min, exposed to FITC-labeled transferrin for 3 min, at 4 ºC, and finally characterized by 
FACS. Results are expressed as mean±s.e.m (n = 3). Statistical analyses were performed by an unpaired t-test. **** 
Denotes statistical significance (P<0.0001). (B) Uptake of TRITC-labeled RA+NPs by U937 cells in the presence 
of several endocytosis inhibitors. Filipin III inhibits cholesterol dependent internalization mechanisms, 
ethylisopropylamiloride (EIPA) inhibits macropinocytosis, nocodazole inhibits microtubule dependent pathways, 
cytochalasin D inhibits all pathways dependent on actin (including macropinocytosis), dansylcadaverine and 
dynasor inhibits clathrin-mediated endocytosis and polyinosinic acid inhibits scavenger receptors. Results are 
expressed as mean±s.e.m (n = 3). (C) Uptake of TRITC-labelled RA+NPs after silencing of key regulators on 
endocytosis by transfection of siRNAs in U937 cells. Results are expressed as mean±s.e.m (n = 3). Statistical 
analyses were performed between control and the remain experimental groups using one-way ANOVA followed 
by a Newman-Keuls post-test. *P<0.05, ***P<0.001, ****P<0.0001.      
3.3.5. Intracellular trafficking and endolysosomal escape of NPs 
To elucidate the intracellular trafficking of our NPs, we used adherent cells (HUVECs) to allow for 
this characterization by confocal microscopy. The intracellular trafficking of our NPs was assessed first 
by performing a LysoTracker staining to see the general distribution of FITC-labelled RA+NPs in the 
endolysosomal system. During the first few hours, there was an increase in the intracellular signal of 
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FITC-labelled RA+NPs and a clear drop in the intensity of LysoTracker, suggesting an increase in the 
pH of the endolysosomal vesicles by the presence of intracellular PEI (a strong base), as well as possible 
vesicle disruption, as the FITC-labelled NP signal was increased in the cytoplasm (Figure 3.8A). At 
later time points (12 h) of incubation with FITC-labelled NPs, the intensity of LysoTracker reached 
control levels, suggesting that the endolysosomal system regained its normal characteristics. Our results 
further show that most of the NPs (~80% of NP fluorescence) escape endolysosomes within a few hours 
(Figure 3.8B). At 6 h, most of the FITC-labelled NPs were distributed throughout the cytoplasm (~80% 
of the fluorescence) (Figure 3.8B), and those that accumulated in the endolysosomal compartment were 
located in vesicles positive for Rab5 (early/late endosomes) and Rab7 (endosome/lysosomes) (Figure 
3.8C and D). This is consistent with a rapid escape of the NPs from endosomes after uptake by the cell, 
likely due to their buffering capacity which gives rise to osmotic swelling and endosome rupture619.  
 
 
 
Figure 3.8 - Intracellular trafficking of FITC-labelled RA+NPs. (A) HUVECs were incubated with FITC-
labeled RA+NPs (1μg/mL) for 4h, washed extensively, cultured in EGM-2 cultured in normal conditions for 1, 2 
or 8 additional hour/s, respectively, and stained with LysoTracker DND-99 before cell fixation to monitor the NPs 
trafficking through the endolysosomal compartment overtime. (B) Fluorescence of NPs in the cytoplasm measured 
by confocal microscopy. Scale bar represents 10μm. Results are expressed as mean±s.e.m (n = 5). (C, D) Early 
endosome were stained with EEA1 antibody, early/late endosomes were stained with Rab5 antibody and late 
endosome/lysosomes were stained with Rab7 antibody. (C) Quantification of FITC-labelled RA+NPs co-localized 
with EEA1, Rab5 and Rab7. Results are expressed as mean±s.e.m (n = 70-100 cells). At 5 h, there is a clear 
accumulation of FITC-labeled NPs within vesicles that are mostly Rab5 and/or Rab7 positive with very low EEA1 
co-localization. The high co-localization with Rab5 and the size of the vesicles containing NPs (see D) suggests 
that macropinocytosis is also an entrance route for these NPs. (D) Representative images of the intracellular 
distribution of FITC-labelled RA+NPs at time 5 h in relation to early/late endosomes stained with Rab5 antibodies 
(left image), and late endosome/lysosome stained with Rab7 antibody (right image). 
CHAPTER 3 - Prolonged intracellular accumulation of light-inducible nanoparticles in leukaemia cells allows 
their remote activation 
67 
 
Next, we asked whether RA+NPs would be effluxed by leukaemia cells overtime. It is known that 
tumour cells express high levels of P-glycoprotein (P-gp), a membrane transporter that is responsible 
for the efflux of drugs627 and NPs628. Therefore, we used flow cytometry to study the effects of the P-gp 
antagonist, verapamil628, on the intracellular accumulation of RA+NPs in Zn-induced U937-B412 cells 
expressing P-gp (Figure 3.9A). Our results show that the intracellular accumulation of RA+NPs in U937 
slightly decreases from 4 h to 12 h (Figure 3.9B), in contrast to the control, ultra-small paramagnetic 
iron oxide (USPIO). The intracellular accumulation of USPIO was highly dependent on the inhibition 
of P-gp (Figure 3.9C). Overall, our results indicate that RA+NP endocytosis takes place primarily 
through a clathrin-mediated mechanism and at minor extent by macropinocytosis. It is likely that both 
endocytic pathways are interconnected, as has been demonstrated recently for lipid NPs21, 22. Our results 
further show that the internalization of RA+NPs occurs quickly, and within the first 2 h, a significant 
percentage of NPs tend to escape the endolysosomal compartment, while the ones that do not escape 
accumulate in early/late endosomes. 
 
 
 
Figure 3.9 - Effect of inhibition of P-gp in the accumulation of NPs. Expression of P-gp in Zn-induced U937 
cells as evaluated by flow cytometry. (A) Representative flow cytometry gating strategy of TRITC positive cells. 
Percentage of positive cells was calculated based in the isotype control. (B) TRITC-labeled RA+NPs (10 μg/mL) 
or (C) TRITC-labeled USPIO NPs (100 μg/mL) intracellular accumulation in Zn-induced U937 cells in the 
presence of the P-gp antagonist verapamil. Cells were exposed to culture medium with verapamil, TRITC-labeled 
NPs for 4 h, cultured for additional 8 h and finally characterized by flow cytometry. In A, B and C, results are 
expressed as Mean ± SEM, n=3. Statistical analyses were performed using a One-Way Anova followed by a 
Newman-Keuls posttest. *P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. 
3.3.6. Differentiation of leukaemic cells by photo-release of RA from NPs  
Previously, liposomes629 and block copolymer NPs630 have been used for the release of RA in 
myeloid leukaemia cell lines. However, no significant differences were observed between liposome/NP 
formulations and soluble RA in their capacity to induce leukaemia cell differentiation. Therefore, we 
evaluated the capacity of light-inducible RA+NPs to prompt the differentiation of human CD34+ primary 
leukaemia cells isolated from the bone marrow aspirates of AML patients, taken at diagnosis. We 
evaluated their clonogenic potentials in short term (blast colony-forming units, CFU) and long term 
(long-term culture-initiating cell, LTC-IC) assays following treatment with RA or RA+NPs (Figure 
3.10A). Our results indicate that light-inducible RA+NPs were more effective than soluble RA at 
decreasing the number of CFUs (Figure 3.10B). Our results further indicate that RA+NPs activated by 
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light are more effective in decreasing the number of CFUs (Figure 3.10C) and LTC-ICs (Figure 3.10D) 
than non-activated RA+NPs. We extended the previous studies to different leukaemia cell lines, 
including U937, NB4 and THP-1 (Figure 3.10E, G and K).  
The differentiation process was monitored by the expression of myeloid maturation marker CD11b, 
a protein involved in the regulation of leukocyte adhesion and migration. For equivalent concentrations 
of RA, U937 (Figure 3.10E) or NB4 (Figure 3.10G) cells treated with RA+NPs more readily 
differentiated into myeloid cells than cells treated with soluble RA, likely due to the higher efficiency 
of the NPs to deliver RA intracellularly (Figure 3.10J). The differences in the intracellular accumulation 
of RA are likely explained by the differences in RA uptake mechanism. The RA is a hydrophobic small 
molecule with limited water solubility (63 mg/L 631) and thus in vivo, it is transported by proteins called 
cellular retinoic acid-binding proteins (CRABP) both in extracellular and intracellular compartments632. 
The expression of CRABP is relatively low in undifferentiated leukaemic cells633 and thus the transport 
of soluble RA to inside of the cell might be limited. In contrast, the transport of RA+NPs occurs by 
endocytosis which might facilitate the intracellular accumulation of RA. 
U937 (Figure 3.10F), NB4 (Figure 3.10H) or THP-1 (Figure 3.10K) cells treated with light-
activated RA+NPs showed a higher capacity for myelocytic differentiation than cells treated with non-
activated RA+NPs. In the case of NB4 cells, RA released from light-inducible RA+NPs promoted a 
higher percentage of cells expressing CD13highCD11b+ and CD13lowCD11b+ (Figure 3.11A and B) than 
soluble RA. 
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Figure 3.10 - Effect of RA+NPs on human leukaemia cells. Effect of RA+ NPs on human leukaemia cells. 
(A) Schematic representation of the methodology used. (B) Differentiation of CD34+ AML cells isolated from the 
bone marrow aspirates of patients with AML cultured with light-activated RA+NPs or soluble RA. (C, D) 
Differentiation of CD34+ AML cells with RA+NPs (10 μg/mL) or blank (RA-NPs) NPs (10 μg/mL, exposed or 
not to UV light, by a CFU (C) or LTC-IC (D) assays. Results are expressed as a mean percentage of control plates 
containing only AML cells. (E, F) Myelocytic differentiation of human Zn-induced U937-B412 cells cultured with 
light-activated NPs or soluble RA at day 3 (E) or cultured with RA+NPs with or without light activation (F). (G, 
H) Myelocytic differentiation of human NB4 cells cultured with light-activated NPs or soluble RA at day 3 (G) or 
cultured with RA+NPs with or without light activation for 1 or 3 days (H). (I) Intracellular release of RA as 
evaluated by a RARE luciferase cell line. NB4-RARE cells were cultured with soluble RA (3 μg of RA per ml) 
for the entire duration of the experiment, or light-activatable RA+NPs (5 μg/mL; 0.6 μg of RA per mL). Cells were 
exposed to NPs for 1 h, washed with PBS and resuspended in cell media. Some samples were exposed to UV light 
for 5 min. The cells were then cultured for 24 h before luciferase luminescence reading. (J) [3H]-RA uptake by 
NB4 cells. NB4 cells were cultured with soluble [3H]-RA (0.3 and 3 μg/mL) for the entire duration of the 
experiment, or light-activatable [3H]-RA+NPs (1 and 10 μg/mL) for 4 h and then the cells were washed and 
cultured in cell medium for additional 20/68 h before scintillation counting. (K) Myelocytic differentiation of 
human THP-1 cells. THP-1 cells were cultured with soluble RA (3 μg of RA per mL) in culture medium for the 
entire duration of the experiment, or light-activatable RA+NPs (10 μg of NPs/mL, i.e., 1.2 μg of RA per mL), or 
light-activatable NPs without RA (10 μg of NPs/mL). From B to K, results are expressed as mean±s.e.m. (n=3). 
In C, D, F, H,K, statistical analyses were performed by an unpaired t-test while in i were performed by one-way 
ANOVA followed by a Newman–Keuls post-test. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. 
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NB4 cells differentiated by light-inducible RA+NPs have a different morphology from 
undifferentiated cells, showing polylobular nuclei, decreased nuclear:cytoplasmic ratios and decreased 
cytoplasm staining, as characterized by a May-Grunwald Giemsa staining (Figure 3.11C). 
 
 
 
Figure 3.11- Differentiation profile of NB4 cells after treatment with soluble RA or RA+NPs. NB4 cells were 
incubated in serum-free RPMI-1640 with RA+NPs (1 or 10 μg/mL; RA+NPs_1 and RA+NPs_10, respectively) 
for 4 h. Then, cells were washed three times with PBS to remove NPs not internalized, activated by UV light 
(365nm, 100W) during 5 min, and cultured in complete medium for additional 3 days. Alternatively, NB4 cells 
were cultured in complete medium for 3 days having soluble RA (0.3 or 3 μg/mL; RA_0.3 and RA_3, respectively). 
(A) Flow cytometry analysis of differentiated NB4 cells cultured for 3 days. Cells were initially gated in an 
FSC/SSC plot (in red; attached to the scatter plot) and then gated for the expression of CD45 (in red; attached to 
the scatter plot). Percentages of positive cells were calculated based in the isotype controls and are shown in each 
scatter plot. Results are expressed as mean±s.e.m. (n=3). (B) Percentages of CD13highCD11b- CD13highCD11b+, 
CD13lowCD11b- and CD13lowCD11b+ in NB4 cells differentiated for 72 h. Results are expressed as mean±s.e.m. 
(n=3). (C) Representative May-Grunwald Giemsa stains of NB4 cells cultured for 72 h after exposure to RA+NPs 
(10 μg/mL; therefore 1.2 μg/mL of RA) or soluble RA (3 μg/mL). Bar corresponds to 20 μ m. 
The efficiency of the RA+NPs in delivering RA inside NB4 cells and inducing a RA-dependent 
signalling pathway was also confirmed using a NB4-RARE reporter cell line. The RA-dependent 
induction of a RARE element driving the transcription of the firefly luciferase gene was used to evaluate 
the kinetics of RA-induction using RA+NPs or RA in solution. Our results showed that RA+NPs were 
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able to induce high levels of luciferase activity shortly after light activation (Figure 3.10J). RA+NPs 
were more efficient and quicker at inducing transcription from the RARE-luciferase locus than RA in 
solution. 
 
3.3.7. Transcriptional regulation of retinoic acid during differentiation 
Next, we monitored the effects of soluble RA and RA released from RA+NPs in the transcriptional 
regulation of 96 genes involved in the differentiation program of NB4 and U937 cells634,635 (Figure 3.12 
and Figure 3.13). In the case of NB4 cells, CD52, CDKN1A (also known as the p21 gene) and TNFα 
are recognized as direct targets of RA 634; CD52 and CDKN1A are upregulated and TNFα is 
downregulated in response to RA. Our results show that the upregulation of CDKN1A and CD52 mRNA 
transcripts was significantly higher in cells treated with RA+NPs compared to those treated with soluble 
RA for 8 h and 24-48 h, respectively (Figure 3.14). 
 
 
Figure 3.12 - Heat map of the differentiation pattern of NB4 cells after exposure to soluble RA or light-
activatable RA+NPs. Cells were treated with RA+NPs (1 or 10 μg/mL) for 4 h, washed, activated with UV light 
(365 nm, 100 W) for 5 min, and then cultured for up to 48 h. In case of cells treated with soluble RA (0.3 or 3 
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μg/mL), cells were cultured in media containing soluble RA for the entire period of culture. Cells were then lysed 
and gene expression profile monitored by qRT-PCR using a Fluidigm equipment. A red-blue color scale was used 
to reflect standardized gene expression, with red indicating higher expression and blue indicating lower expression. 
Surprisingly, our clustering analysis indicate that NB4 treated with RA+NPs for the first 24 h were more related 
to the non-treated cells than soluble RA. Yet this effect is inverted for 48 h. Therefore, our data suggests that the 
most significant alterations in NB4 cells after treatment with RA+NPs occurs between 24 and 48 h. 
 
 
Figure 3.13 - Heat map of the differentiation pattern of Zn-induced U937 cells after exposure to soluble RA 
or light-activatable RA+NPs. Cells were treated with RA+NPs (1 or 10 μg/mL) for 4 h, washed, activated with 
UV light (365 nm, 100Watts) for 5 min, and then cultured for up to 48 h. In case of cells treated with soluble RA 
(0.3 or 3 μg/mL), cells were cultured in media containing soluble RA for the entire period of culture. Cells were 
then lysed and gene expression profile monitored by qRT-PCR using a Fluidigm equipment. A redblue color scale 
was used to reflect standardized gene expression, with red indicating higher expression and blue indicating lower 
expression. Our clustering analysis indicate that Zn-induced U937 cells treated with 10 μg/mL, but not 1 μg/mL, 
of RA+NPs were more distant to the non-treated cells than soluble RA. This effect was observed for all the times 
investigated. Therefore, in contrast to NB4 cells, our clustering analyses indicate that Zn-induced U937 cells were 
more sensitive to RA released from RA+NPs at least at high concentrations (10 μg/mL). 
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On the other hand, the downregulation of TNFα occurred more slowly in cells treated with RA+NPs 
than in those treated with soluble RA. Other RA-responsive genes were also evaluated by qRT-
PCR634,636. The number of mRNA transcripts for IL-8 and Ly6E genes was higher in cells treated with 
RA+NPs than in those treated with soluble RA for 8-24 h and 24-48 h, respectively. In addition, the 
number of mRNA transcripts for CCR2 and CEBPα genes were lower in cells treated with RA+NPs than 
in those treated with soluble RA for 8-48 h and 8 h, respectively. Importantly, no significant variation 
in mRNA transcripts for RARα, RARβ and RARγ (Figure 3.12 and Figure 3.14) was found between 
all experimental groups. Therefore, our results suggest that the differentiation profile induced by 
RA+NPs is similar to that observed for soluble RA; however, the magnitude of the effect in the initial 
stages (up to 24 h) is higher in cells treated with RA+NPs. 
 
 
 
Figure 3.14 - Genes modulated by RA during differentiation of NB4 cells as assessed by qRT-PCR analyses. 
Results are expressed as mean±s.e.m (n=3). In each run, the expression of each gene was normalized by GAPDH 
gene. Gene expression in each experimental group was normalized by the corresponding gene expression observed 
in nontreated NB4 cells. 
 
3.3.8. Effect of time and irradiation rounds on RA+NPs induced differentiation 
Recent studies report that lipid-based NPs are able to release siRNA cargo in the cytosol only during 
a limited window of time, when the NPs reside in a specific compartment that shares early and late 
endosomal characteristics637,638. Therefore, we evaluated the impact of temporal activation of RA+NPs 
on the differentiation of NB4 and U937 cells. The effect of the intracellular release of RA was evaluated 
in terms of cell differentiation into the myeloid lineage (expression of CD11b at day 3) (Figure 3.15A).  
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Figure 3.15 - Effect of time in the activation of RA+NPs within the cells. (A) Zn-induced U937-B412, NB4 or 
NB4-RARE-luciferase reporter cells were cultured with RA+NPs (1 μg/mL) for variable period of times (1 up to 
24 h), washed with PBS, resuspended in cell culture media, exposed to UV light (365 nm, 100 Watts) for 5 min, 
and cultured for 12 h (luciferase measurements) or 72 h (flow cytometry analyses). Results are expressed as 
mean±s.e.m (n = 3). (B) Zn-induced U937-B412, NB4 or NB4-RARE-luciferase reporter cells were cultured with 
RA+NPs (1 μg/mL) for 4 h, washed with PBS, resuspended in cell culture media, exposed to UV light for 5 min 
at variable periods of time (0 up to 44 h), and cultured for 12 h (luciferase measurements) or 72 h (flow cytometry 
analyses). Results are expressed as mean±s.e.m (n = 3). In NB4-RARE, the activation of RA-dependent signalling 
pathway was measured by luminescence while in U937 B412 and NB4, cell differentiation was evaluated by the 
expression of CD11b by flow cytometry. 
Cells that were incubated with RA+NPs for 4 to 8 h and subsequently activated by light showed the 
highest differentiation into the myeloid lineage. Interestingly, cells incubated with RA+NPs for 1 h 
showed an already high level of differentiation, indicating that NP uptake is rapid, and their endosomal 
escape is efficient. Then, we asked whether cells exposed for the same time (4 h) to NPs but activated 
at different times (up to 44 h) during the intracellular trafficking of RA+NPs would have differences in 
their differentiation pattern (Figure 3.15B). Our results show that even after 44 h following NP 
internalization, the NPs can be activated and the resultant delivery of RA in the cytosol can be relatively 
efficient. Similar results were obtained when the effect of temporal intracellular RA release was 
CHAPTER 3 - Prolonged intracellular accumulation of light-inducible nanoparticles in leukaemia cells allows 
their remote activation 
75 
 
evaluated by the induction of the NB4-RARE reporter cell line (Figure 3.15B). Overall, these results 
show that the NPs can be accumulated in the intracellular environment and activated after a few days, 
without losing their capacity to promote cell differentiation. Importantly, a single activation procedure 
seems to be sufficient to activate RA release from the NPs because no significant increase in efficiency 
was observed when multiple rounds of light activation were performed (Figure 3.16). 
 
 
 
Figure 3.16 - Effect of multiple light activation in the differentiation of Zn-induced U937-B412 cells. (A) 
Schematic representation of the methodology. Cells were cultured with RA+NPs (10 μg/mL) for 4 h, washed with 
PBS, resuspended in cell culture media, exposed to multiple 5 min-cycles of UV light (365 nm, 100 Watts) during 
the 72 h of culture. (B) Myelocytic differentiation at 72 h, as assessed by the expression of CD11b (by flow 
cytometry), of human leukaemia Zn-induced U923-B412 cells. Results are expressed as mean±s.e.m (n = 3). 
Statistical analyses were performed using a One-Way Anova followed by a Newman-Keuls post-test. *P<0.05 and 
**P<0.01. 
 
3.3.9. In vivo differentiation of NB4 cells transfected with RA+NPs 
 Next, we evaluated if RA+ NPs can function in vivo. We investigated whether leukaemic cells 
loaded with RA+NPs could be activated in vivo after subcutaneous transplantation. We selected a 
Matrigel plug subcutaneous model because we know what the attenuation of the blue laser through the 
murine skin is (Figure 3.17A) and we could easily remove the cells from the Matrigel plug and evaluate 
their differentiation by flow cytometry. Initially we evaluated whether the in vivo environment could 
interfere with the differentiation program of leukaemic cells after ex vivo activation.  
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Figure 3.17 - Blue laser (405 nm) attenuation through murine skin or calvaria. NOD/SCID mice were 
euthanized followed by hair shaving and removal of dorsal and ventral skin as well as calvaria bone. Both tissues 
were kept in cold PBS until further analyses. For the laser attenuation studies, 2 cm x 2 cm skin or 0.5 cm x 0.5 
cm calvaria were placed in a plastic petri dish on top of a thermal power sensor (Thorlabs, s310c). Both tissues 
were then irradiated with a 405 nm laser at 80 mW during 1 min. Laser attenuation values were calculated by 
normalizing against laser power values obtained with the empty petri dish. The thickness of the skin and bone was 
measured by a caliper. (A) Blue laser attenuation as a function of skin thickness. Results are expressed as 
mean±s.e.m (n = 2-6 per each thickness interval). (B) Blue laser attenuation in calvaria bone (≈ 260 μM). Laser 
attenuation in calvaria bone is lower than the skin likely due to the high transparency of the bone. Results are 
expressed as mean±s.e.m (n = 4). 
 
Human NB4 cells were cultured with RA+NPs for 4 h, washed and activated ex vivo by exposure to 
a 405 nm blue laser (80 mW) for 5 min, embedded in Matrigel and then injected into a cylindrical 
poly(dimethylsiloxane) (PDMS) construct that was previously implanted subcutaneously in NOD/SCID 
recipients (Figure 3.18A). The PDMS cylinder was used to restrict cell position inside the animal. After 
five days, human cells were isolated from the implants and CD11b expression measured by flow 
cytometry (Figure 3.18B).  
Consistent with our in vitro data, CD11b expression was statistically higher in NB4 cells treated ex 
vivo with light-activated RA+ NPs than in cells treated with RA+ NPs without light activation (Figure 
3.18B). The experiment was repeated with in vivo activation. One day after implantation, the recipients 
were exposed to a 405 nm blue optical fibre for 5 min at the implant site (Figure 3.18C). After three 
days, the recipients were sacrificed, the human cells were isolated and CD11b expression was assessed. 
CD11b expression was higher in NB4 cells from mice that had been exposed to the blue laser, 
demonstrating that internalized RA+ NPs can be activated to release RA in vivo in a highly controlled 
manner (Figure 3.18C).  
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Figure 3.18 - In vivo differentiation of NB4 cells exposed to light-activatable RA+NPs. (A) Schematic 
representation of the in vivo experimental set up. Cells were treated with blank or RA+NPs (both at 10 μg/mL) for 
4 h, washed and then activated or not with a blue optical fibre (405 nm, 80mW) for 5 min. Cells were then 
resuspended in a 1:1 (v/v) Matrigel solution and subcutaneously injected in a PDMS cylinder construct implanted 
in the dorsal region of mice. After 5 days, cells were removed from the construct and characterized by flow 
cytometry, for CD11b expression. (B) Representative flow cytometry plots for mice recipient cells (left), human 
leukaemia NB4 cells (middle) and a mixture of mice recipient cells with human leukaemia NB4 cells (right) and 
percentage of CD11b+ cells in human leukaemia NB4 cells collected 5 days after subcutaneous injection. (C) 
Schematic representation of the in vivo experimental set up. Cells were treated with RA+NPs (10 μg/mL) for 4 h, 
washed and then encapsulated in a 1:1 (v/v) Matrigel solution and subcutaneously injected in a PDMS cylinder 
construct implanted in the dorsal region of mice. After 24 h, some experimental groups were activated in vivo with 
a blue optical fibre for 5 min. Plot shows the percentage of CD11b+ cells in human leukaemia NB4 cells collected 
3 days after the in vivo activation. In B, C, results are expressed as mean±s.e.m. (n=3–4). Statistical analyses were 
performed by one-way Anova followed by a Newman–Keuls post-test. **P<0.01, ***P<0.001, ****P<0.0001. 
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3.3.10. Bone marrow homing and engraftment of THP1 treated with RA+NPs 
  
Leukaemia cells that resist therapy reside in microenvironmental niches in the bone marrow that are 
difficult to reach by conventional therapy2. Therefore, we investigated whether leukaemia cells 
transfected with RA+NPs could engraft into the bone marrow and localize at nearby resident leukaemia 
cells. For this purpose, we transplanted leukaemia cells into immunodeficient CB17-Prkdcscid/J 
(NOD/SCID) mice treated with anti-CD122 to deplete innate immune cells (NS122). Green fluorescent 
protein (GFP)-labelled THP-1 cells, a human APL cell line (NB4 cells were unable to engraft), were 
injected into sub-lethally irradiated mice in the tail vein, followed by the injection of THP-1 cells 
transfected with RA+NPs after 24 h (Figure 3.19A). After 1-2 days, animals were sacrificed and the 
cells in the animal’s calvaria (cranium) were characterized by ex vivo imaging (Figure 3.19B). Both 
cells (GFP-labelled and NP-labelled THP-1 cells) could engraft in the bone marrow of the animals and 
were detected after one or two days. Therefore, NP-labelled THP-1 cells (delivery cells) could enter the 
same niche as the GFP-labelled cells (target cells).   
 
Figure 3.19 - Leukaemia cells transfected with RA+NPs can home at leukaemia niches. (A) Schematic 
representation of the protocol. Human GFP-labelled THP-1 cells were employed as the target cells and human 
THP-1 cells without GFP label were employed as delivery cells. On day 0, the target cells were injected into the 
NOD/SCID mice by intravenous injection through the tail vein. On day 1, the delivery cells loaded with RA+NPs 
were injected intravenously through the tail vein. After 24 (n=3) or 48 h (n=3) of the delivery cell injection, the 
mice were euthanized, the craniums collected and examined with a confocal microscope. (B) Both target and 
delivery cells were observed in mice craniums at 24 and 48 h. Bar scale means 100 µm. (C) Delivery cells close 
(<100 µm) or distant (>100 µm) to target cells were quantified. According to our results, the delivery cells can 
enter into the same niche as the target cells. Results are expressed as mean±s.e.m. (n=3). 
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3.3.11. Modulation of cell differentiation at the bone marrow niche 
Next, we investigated whether we could differentiate the NP-labelled human THP-1 cells (delivery 
cells) at the bone marrow niche (more specifically at the calvaria), and whether they could modulate 
nearby cells (Figure 3.20A).  
 
Figure 3.20 - In vivo activation of leukaemic THP-1 differentiation program by light at the bone marrow. 
(A) Schematic representation for the activation of human THP-1 cells transfected with RA+NPs in the bone marrow 
niche leading to the modulation of leukaemia cells. (B) Percentage of human CD45+ cells in the long bones as 
evaluated by flow cytometry. NOD/SCID mice were injected intravenously with THP-1 cells transfected with 
RA+NPs through the tail vein. After 6 days, animals (n=6) were either irradiated by a blue laser (5 min, 405 nm, 
80mW) or not in the calvaria (n=6). Three days after irradiation, mice were killed and the long bones were 
collected. Cells in the long bones were characterized by flow cytometry for the expression of human CD45 epitope. 
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The engraftment of THP-1 cells was slightly higher in the non-treated than light-activated animals, but not 
statistically different. Percentages of positive cells were calculated based in the isotype controls and are shown in 
each scatter plot. Results are mean±s.e.m. (n=3). (C-E) Differentiation of human CD45+ cells into CD11b+ cells, 
as evaluated by immunofluorescence, in the calvaria of animals irradiated or not with a blue laser. B, bone; BM, 
bone marrow. In D, results are mean±s.e.m. (n=3). ***P<0.001. (F) Expression of CRABP2 in cells of calvaria of 
animals irradiated or not with a blue laser. Scale in, C, E, F means 200, 50 and 100 µm. 
Blue laser attenuation studies in the calvaria bone using a photometer showed an attenuation of  
75% (Figure 3.17B). Human THP-1 cells transfected with RA+NPs were injected intravenously into 
CB17-Prkdcscid/J (NOD/SCID) mice, and six days after injection, the cranium was exposed to a blue 
laser for 5 min. Seventy-two hours after blue laser irradiation, the engraftment of human CD45+ cells in 
the long bones of non-irradiated and blue laser-irradiated mice was 47.7  13.0 and 39.8  3.5%, 
respectively (Figure 3.20B). No statistical difference was found for the engraftment in both groups. Ex 
vivo staining of mice calvaria showed that human CD45+ cells in the non-irradiated mice did not express 
CD11b, while ~80% of the human CD45+ cells in blue-irradiated mice expressed CD11b (Figure 3.20C-
E). In addition, cells surrounding CD45+CD11b+ cells in irradiated mice expressed CRABP, a RA 
protein transporter, while negligible levels of CRABP were found in non-irradiated mice (Figure 
3.20F). Therefore, THP-1 cells differentiated by a blue laser had the capacity to modulate the cells in 
the vicinity. This is likely due to RA secreted (including exosomes containing RA) by the THP-1 cells, 
as observed in vitro using the NB4 cell line (Figure 3.21). Overall, our results show that leukaemia cells 
transfected with RA+NPs could (i) engraft into the bone marrow and localize near to resident leukaemia 
cells, (ii) differentiate after blue laser activation and (iii) modulate the activity/phenotype of the resident 
leukaemia cells. It is possible that the cells that reach the bone marrow are the ones that are less affected 
by the passive diffusion of RA (i.e., RA release without light activation) within the cells. Therefore, the 
cells that engraft are likely the ones that have less leaky RA+NPs and thus are undifferentiated leukaemic 
cells (CD11bnegative phenotype). 
 
 
Figure 3.21 - Paracrine effect of cells treated with RA+NPs. (A) Schematic representation of the assay. NB4 
cells (3,000,000/mL) were grown in RPMI supplemented with 10% (v/v) FBS, penicillin and streptomycin. Cells 
were treated with RA+NPs (10 μg/mL) for 4 h, washed with PBS to remove the NPs that were not internalized, 
activated by a blue laser for 5min, and then cultured for 18 h under hypoxia conditions (0.5% O2) in exosome-
depleted medium. A separate group of cells was treated with RA (3 μg/mL) for 22 h in hypoxia conditions (0.5% 
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O2) in exosome-depleted medium. Then, in both groups, cells were centrifuged at 10.000g (4ºC; 30 min) and part 
of the supernatant (named in the plot as "Sup") added to NB4 RARE cells (100,000/mL; 1 mL of the Sup). 
Alternatively, in both groups, cells were centrifuged in multiple steps (please see methods) to remove exosomes 
(named in the plot as "exo") and added to NB4 RARE cells (100,000/mL; 5 μg/mL de exosomes per mL of media) 
plated in a 24 well plate. After 24 h, the luciferase assay was performed according to instructions of the luciferase 
kit (britelite™). (B) Activation of NB4 RARE reporter cell line with the factors secreted by the NB4 cells for 22 
h cultured with soluble RA or RA+NPs. Results are expressed as mean±s.e.m (n = 3). Statistical analyses were 
performed using a One-Way Anova followed by a Newman-Keuls post-test. * P<0.05, ** P<0.01, *** P<0.001 and 
****P<0.0001. 
3.4. Conclusions 
In conclusion, we have developed a light-inducible polymeric NP for the spatio-temporal release of 
RA within leukaemia cells. We showed the efficiency of RA release both in vitro and in vivo. The 
efficiency is due to a combination of several factors, including (i) high concentration of intracellular 
RA, (ii) high endolysosomal escape (80% of the NPs escape the endolysosomal compartment in the first 
5 h), (iii) prolonged intracellular accumulation of the NPs (more than six days in leukaemia cells) and 
(iv) rapid disassembly of the NPs once activated by UV or blue light (within minutes). We further 
showed that cells transfected with light-inducible NPs can be activated after six days while maintaining 
the same inductive properties. This gives an opportunity to use cells for activation at specific sites in the 
human body and differentiate cells in their proximity. Although the present study uses a RA delivery 
system as a proof of concept, a similar approach could be implemented for other drugs relevant to 
therapeutic or regenerative medicine.  
The present research reports a blue laser/UV-inducible NP. The platform was designed for initial 
proof of concept regarding the modulation of leukaemic cell niches in the bone marrow. Recent studies 
have explored UV/blue laser approaches to trigger in vivo the presentation of bioligands with spatial 
temporal control to regulate cell adhesion, inflammation, and vascularization of biomaterials639 and to 
detect protease activity at sites of disease640. However, the in vivo applications of this light trigger are 
limited, as the optical properties of biological tissue cause attenuation and scattering of light rays, 
reducing their penetration depth. The recent advances in developing NPs activated by near-infrared 
light641 may provide a better option for enhancing light penetration in tissues. For example, up-
conversion nanocrystals that convert near infrared light into visible light (blue light) may be an 
interesting possibility for the photo-cleavage of linkers to which RA is chemically bound642. 
We have used leukaemic cells as a programmable delivery system that recognizes the leukaemic 
niches and modulate them after light activation. The aim of the study was to show the feasibility in 
remotely induce the differentiation of leukaemic cells in the bone marrow and not to demonstrate the 
exhaustion of cancer cells, as this will be difficult using the blue laser activation process. The concept 
here is different from previous studies that have used therapeutic NPs coated with aptamers to direct 
them to the bone marrow550. Although the results achieved are interesting, the side effects of the systemic 
administration of the NPs containing a powerful anti-leukaemic agent remain to be determined. In the 
present study we have used cancer biology to fight cancer. We have used leukaemia cells loaded with a 
clinical-approved AML differentiating agent able to home to leukaemic niches in the bone marrow. 
Although not explored in the current study, normal haematopoietic stem cells may also be used as a 
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nanoparticle carrier as they are able to home to leukaemic niches180, which we explore in the next 
chapter. 
 
 
3.5. Materials and Methods 
Preparation and characterization of PEI conjugated with DMNC. DMNC (48.5 mg, Sigma) 
was slowly added to a solution of PEI in DMSO (2 mL containing 50 mg/mL PEI, Sigma) containing 
triethylamine (24.5 L, Sigma), and the reaction flask cooled to 0 ºC by immersion on ice. Then, the 
reaction was allowed to proceed for 24 h at 25 ºC with stirring. At the end, the PEI-DMNC conjugate 
was purified by dialysis (Spectra/Por® 1 Regenerated Cellulose dialysis membrane, MWCO 6000-8000 
Da, Spectrum) against DMSO overnight at room temperature. Reaction yields above 54 % were 
obtained. For NMR characterization, PEI-DMNC (in DMSO) was precipitated in water, washed, freeze-
dried, and then dissolved (10 mg/mL) in DMSO-d6 and 1H NMR spectra were acquired using a Bruker 
Avance III 400 MHz spectrometer. 
 
Preparation of NPs. Non-activatable NPs were prepared by the electrostatic interaction of PEI 
(polycation) with dextran sulfate (DS, polyanion) in water, at room temperature, as previously described 
by us619. Briefly, an aqueous DS solution (1 mL, 10 mg/mL) was added drop-by-drop to an aqueous 
solution of PEI (5 mL, 10 mg/mL) and stirred for 5 min. Then, an aqueous solution of ZnSO4 (0.6 mL; 
1 M) was added and stirred for 30 min. The NP suspension was then dialyzed (Spectra/Por® 1 
regenerated cellulose dialysis membrane, MWCO 6000-8000 Da, Spectrum) for 24 h, in the dark, 
against an aqueous solution of mannitol (5 %, w/v), lyophilized for 1 day and stored at 4 ºC before use. 
Light-activatable NPs were prepared by adding a PEI-DMNC solution (66.7 L, 150 mg/mL, in 
DMSO) to an aqueous solution of DS (5 mL, 0.4 mg/mL) and stirred for 5 min. Then, an aqueous 
solution of ZnSO4 (120 L, 1 M) was added and stirred for 30 min. The NP suspension was then dialyzed 
(Spectra/Por® 1 Regenerated Cellulose dialysis membrane, MWCO 6000-8000 Da, Spectrum) for 24 h, 
in the dark, against an aqueous solution of mannitol (5 %, w/v), lyophilized for 1 day and stored at 4 ºC 
before use. In some cases, PEI-DMNC was labelled with Qdot525. For that purpose, an aqueous solution 
of 1-ethyl-3-(3-dimethyllaminopropyl)carbodiimide hydrochloride (EDC; 500 L of EDC (10 mg/mL, 
aqueous solution at pH 6.0)) was added to a suspension of Qdots525 (0.16 mmoles, in 310 L of PBS). 
After 5 min, PEI-DMNC solution (200 L, 25 mg/mL in DMSO) was added to the previous solution 
and allowed to react for 1 h, in the absence of light, at room temperature.  
For the preparation of RA-containing NPs (RA+NPs), a RA solution (24 L, 50 mg/mL, in DMSO) 
was added to a solution of PEI-DMNC (66.7 L, 150 mg/mL in DMSO) and maintained at room 
temperature for 30 min, under stirring. The solution was then carefully added to an aqueous solution of 
DS (5 mL, 0.4 mg/mL) and stirred for 5 min. The NPs in suspension were treated with an aqueous 
solution of ZnSO4 (120 L; 1 M) for 30 min. RA that was not encapsulated in the NPs was removed by 
centrifugation (12,000 g for 3 min). The NP suspension was then dialyzed (Spectra/Por® 1 Regenerated 
Cellulose dialysis membrane, MWCO 6000-8000 Da, Spectrum) for 24 h, in the dark, against an 
aqueous solution of mannitol (5%, w/v), lyophilized for 1 day and stored at 4 ºC before use.  
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For the preparation of fluorescently labelled NPs, NPs (2 mg) were resuspended in 0.1 M 
carbonate/bicarbonate buffer (1 mL, pH 8.3) followed by the addition of FITC or TRITC (5 µL in 
DMSO, 3-fold molar excess). The NP suspension was stirred for 1 h in the absence of light and then 
dialyzed (Spectra/Por® 1 regenerated cellulose dialysis membrane, MWCO 6000-8000 Da, Spectrum) 
for 24 h against an aqueous solution of mannitol (5 %, w/v), lyophilized, and stored at 4 ºC before use. 
 
Characterization of the NPs. The diameter of the NPs was measured by photon correlation 
spectroscopy (PCS) using quasi-elastic light scattering equipment (Zeta-Pals™ Zeta Potential Analyzer, 
Brookhaven Instruments Corp., Holtsville, NY) and ZetaPlus™ Particle Sizing Software (version 4.03). 
To measure NP diameter, the NP suspension (2 mL, 50 g/mL in water for molecular biology) was 
added to a cuvette and allowed to stabilize for 10 min. The sample was then vortexed for 5 s and 
subjected to NP size analysis in the ZetaPlusTM for 3 min (3 times; all data were recorded at 90º). After 
each reading the cuvette was again vortexed for 5 s and exposed to UV light (365 nm) or blue light (405 
nm) for a certain period of time (see above). The values of NP diameter and NP counts were recorded. 
The average diameters described in this work are number-weighted average diameters. The zeta 
potential of NPs was determined in a 1 mM KCl pH 6 solution, at 25 °C (2 mL, 50 g/mL). All data 
were recorded with at least 5 runs (in triplicate) with a relative residual value (measure of data fit quality) 
of 0.03. The diameter of NPs was also confirmed on a FEI-Tecnai G2 Spirit Bio Twin at 100 kV. NP 
suspensions (in H2O) were placed on a 200-mesh copper grid coated with a carbon support film (Taab 
Labs Ltd.) and dried overnight.  
 
Release of RA from RA+NPs. [3H]RA solution in DMSO was used for the preparation of NPs, 
using a 1:20 ratio of labelled to unlabelled RA (1 nCi/g RA). The initial RA cargo in the NPs was 
quantified using 2/3 of the original NP suspension (1 mg/ml). To quantify the controlled release of the 
RA, a suspension of [3H]RA-NPs (10 g/mL) was prepared and irradiated with UV light (365 nm) or 
blue light (405 nm). For each time point (0s, 30s, 60s, 180s, 300s, 600s) the NP suspension was 
centrifuged at 14.000g for 3 min, the supernatant collected and mixed with liquid scintillation fluid (1 
mL; Packard Ultima Gold) and the scintillations counted in a TriCarb 2900 TR Scintillation analyser 
(Perkin Elmer).  
 
Cell culture. HUVECs (Lonza) were cultured in EGM-2 medium (Lonza) in a CO2 incubator at 37 
ºC, 5% CO2 in a humidified atmosphere, with media changes performed every other day. Cells were 
passaged every 2-5 days and used for experiments between passage 4 and 6. Human bone marrow acute 
promyelocytic leukaemia NB4 cells, kindly provided by Dr. Arthur Zelent (Institute of Cancer Research, 
Royal Cancer Hospital), were cultured in RPMI-1640 (Gibco) supplemented with 10 % fetal bovine 
serum (Gibco) and 100 U/mL PenStrep (Lonza). Human myelomonoblastic cell lines U937-MT and 
U937-B412, kindly provided by Dr. Estelle Duprez (Centre de Recherche en Cancérologie de Marseille, 
France), were maintained at exponential growth in RPMI-1640 medium supplemented with 10% fetal 
bovine serum and 100 U/mL of PenStrep. For PLZF/RARA induction cells were stimulated with 0.1 
mM ZnSO4 for at least 24 h. Human acute monocytic leukaemia cell line THP-1 (DSMZ no. ACC16) 
was cultured in RPM1-1640 media supplemented with HEPES (10 mM), sodium pyruvate (1.0 mM) 
and 2-mercaptoethanol (0.05 mM).   
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NP cytotoxicity studies. NPs were suspended in a solution of milli-Q water with PenStrep (5 
L/mL of 10000 U/mL stock solution, Lonza) and Fungizone (2.5 g/mL, Sigma-Aldrich) for 30 min, 
centrifuged (14,000 g for 10 min), and finally resuspended in serum free cell culture medium. K562, 
NB4 and U937 cells (0.1  106 cells/condition) were incubated in serum free RPMI-1640 for 4 h in a 
96-well plate containing variable amounts of PEI-DMNC:DS NPs. Once the incubations were 
terminated the cells were washed gently with medium to remove NP excess, and half of the samples 
were exposed to UV light (365 nm, 100 Watts) for 10 min. The cells were then cultured for 20 h in 100 
L of complete medium (RPMI-1640 medium supplemented with 10 % fetal bovine serum and 100 
U/mL PenStrep). A CellTiter-Glo® luminescent cell viability assay (ATP, Promega, USA) was 
performed according to the recommendations of the vendor. 
 
Assessment of histone γH2AX phosphorylation (DNA damage) induced by UV light or blue 
light irradiation. HUVEC cells (passage 4) were cultured on 1% gelatin-coated slides until 
subconfluency in EGM-2, followed by exposure to UV light (365 nm, 100 Watts) or blue light (405 nm, 
80 mW) up to 60 min. Control conditions did not receive any light radiation. Following treatment, the 
medium was replaced by fresh medium and the cells were incubated for additional 6 h on normal culture 
conditions. The cells were then fixed with 4% paraformaldehyde (Electron Microscopy Sciences) for 10 
min at room temperature and then washed with PBS. The cells were then permeabilized with 1 % (v/v) 
Triton-X, blocked with PBS + 2 % BSA and stained for 1 h with anti-human primary γH2AX antibody 
(clone: N1-431, BD Biosciences). Detection was done with secondary antibody anti-mouse Cy3 
conjugate (Jackson ImmunoResearch). Cell nuclei were stained with 4’,6-diamidino-2-phenylindole 
(DAPI) (Sigma), and the slides were mounted with mounting medium (Dako) and examined with a Zeiss 
inverted fluorescence microscope. Quantitative analysis of foci intensity were quantified using ImageJ 
software and normalized to the control condition. The calculations were performed in 5 different images 
for a total of ca. 250 cells (ca. 50 cells per image). 
 
NP internalization studies. NP internalization was monitored by inductive coupled plasma mass 
spectrometry (ICP-MS). In this case, the intracellular levels of Zn were measured before and after cell 
exposure to NPs. NB4 and U937 cells (0.1  106 cells/well) were plated in 24 well plates and incubated 
in serum free RPMI-1640 from 1 to 24 h with variable amounts of PEI-DMNC:DS NPs. After 
incubations, NPs that were not internalized by the cells were washed (three times with PBS) and the 
cells were centrifuged; followed by the addition of an aqueous solution of nitric acid (1 mL, 69 % (v/v)). 
The samples were analysed by ICP-MS for the concentration of intracellular levels of Zn. The 
concentration of Zn was normalized per cell. The estimation of NPs was done based on controlled 
standard solutions. 
 
Mechanism of NP uptake. U937 cells were cultured on 24 well plates (1  105 cells/well) and 
inhibited by one of the following chemicals during 30 min before adding a suspension of TRITC-
labelled NPs (5 μg/mL): EIPA (50 μM), dynasor (80 μM), dansylcadaverine (100 μM), cytochalasin D 
(10 μM), nocodazole (50 uM), filipin III (100 μM) and polyinosinic acid (100 μg/mL). The inhibitor 
concentrations were based in values reported in literature and further validated by us to have no cytotoxic 
effect over the period of the assay (6 h), as confirmed by ATP assay. The incubation of the cells with 
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NPs for different times was performed in the presence of the inhibitor. As controls, we used cells without 
NPs and cells incubated with NPs without inhibitor. At the end of each time point, cells were centrifuged 
at 1300 rpm, 20 ºC for 5 min with PBS, washed one time with cold trypan blue solution (200 L; 600 
g/mL), re-washed 3 times with cold PBS and then resuspended in PBS containing 2.5 % FBS (500 L) 
for flow cytometry analysis. A total of 10,000 events were obtained per measurement. To validate the 
inhibitory activity of dynasor we performed uptake studies of FITC-labelled transferrin, known to 
selectively enter cells via clathrin-mediated endocytosis. Briefly, U937 cells were cultured on 24 well 
plates (1  105 cells/well) and treated or not with dynasor (80 μM, 30 min pre-incubation), followed by 
addition of 1 g/mL FITC-labelled transferrin (Life Technologies). The transferrin was allowed to bind 
for 3 min at 4 ºC. Cells were then evaluated as before.  
The NP uptake mechanism was also studied on U937 cells by silencing specific proteins of clathrin-
mediated endocytosis (CLTC and LDLR), caveolin-mediated endocytosis (CAV1), GEEC-CCLIC 
pathways (CDC42) and macropinocytosis (RAC1 and CTBP1) by siRNA (Thermo Fisher). Transfection 
was performed in a 24 well plate with 0.5  105 cells in antibiotic-free complete medium with 100 nM 
siRNA and 1.5 μL of Lipofectamine RNAiMAX (Life Technologies) transfection reagent for 24 h. After 
this initial period, the transfection medium was replaced by complete medium and the cells incubated 
for another 48 h. Then, cells were cultured with TRITC-labelled NPs (5 g/mL) for 6 h. Once the 
incubations were terminated, the cells were centrifuged at 1300 rpm, 20 ºC for 5 min, with PBS, washed 
one time with cold trypan blue solution (200 L; 600 g/mL), re-washed 3 times with cold PBS and 
then resuspended in PBS containing 2.5 % FBS (500 L) for flow cytometry analysis. Non-transfected 
cells or cells transfected with lipofectamine but without siRNAs (MOCK) were used as controls. In all 
flow cytometry analysis, a total of 10,000 events were recorded per run. All conditions were performed 
in triplicate. 
 
Intracellular trafficking analyses of NPs. HUVEC cells (passage 4) were cultured on 1 % gelatin-
coated slides until subconfluency in EGM-2. The cells were then incubated with FITC-labelled NPs (1 
μg/mL) for 1 or 4 h, washed extensively, exposed or not to UV light (365 nm, 100 Watts) and cultured 
in normal conditions for up to 12 h. For LysoTracker staining, at time points 2, 6 and 12 h, the cells 
were incubated with LysoTracker Red DND-99 (50 nM, Invitrogen). After 30 min of incubation, the 
coverslips were washed extensively with PBS, followed by cell fixation with paraformaldehyde (4%, 
Electron Microscopy Sciences) for 10 min at room temperature and then washed with PBS. Cell nuclei 
were stained with 4’,6-diamidino-2-phenylindole (DAPI) (Sigma), and the slides were mounted with 
mounting medium (Dako) and examined with a Zeiss LSM 50 confocal microscope. 
Co-localization analysis was performed by culturing HUVEC cells (passage 4) on 1 % gelatin-
coated slides until subconfluency in EGM-2. Cells were treated with 1 μg/mL FITC-labelled NPs for 1 
or 4 hours, washed extensively and cultured in normal conditions for 1 or 1/8 additional hour/s, 
respectively. Then the cells were fixed with 4 % paraformaldehyde (Electron Microscopy Sciences) for 
10 min at room temperature, blocked with 2 % (w/v) BSA, and when necessary, permeabilized with 0.5 
% (v/v) Triton-X. Cells were then stained for 1 h with anti-human primary antibodies against EEA1 
(clone: C45B10, Cell Signalling), rabankyrin-5 (Rab 5, ANKFY1 (D-15), Santa Cruz Biotechnology), 
or rabankyrin-7 (Rab 7, clone: D95F2, Cell Signalling). In each immunofluorescence experiment, an 
isotype-matched IgG control was used. Binding of primary antibodies to specific cells was detected with 
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anti-rabbit or anti-goat IgG Cy3 conjugate (Jackson ImmunoResearch). Cell nuclei were stained with 
4’,6-diamidino-2-phenylindole (DAPI) (Sigma), and the slides were mounted with mounting medium 
(Dako) and examined with a Zeiss LSM 50 confocal microscope. Co-localization analysis was done in 
ImageJ through assessment of the percentage of overlapping objects. Two objects are considered to be 
co-localizing when their intensity profile is overlaping more than 40 %. For this analysis the number 
(percentage of FITC-labeled NPs foci that are positive for EEA-1/Rab-5/Rab-7) and the intensity 
volume (percentage of FITC-labeled NPs in the EEA-1/Rab-5/Rab-7-positive compartments) were used. 
This approach was found to be more adequate than classical co-localization tools in ImajeJ or other 
softwares that measure pixel co-occurrence and correlation analyses, because it allowed us to (i) 
discriminate between background and vesicle/NP-foci fluorescence and (ii) interpret the results in terms 
of percentage of NP-foci that are localized to vesicles in another channel of interest. 
 
NP dilution during cell proliferation. NP dilution with cell growth was monitored over 6 days by 
inductive coupled plasma mass spectrometry (ICP-MS) by the quantification of intracellular levels of 
Zn. NB4 and THP-1 cells (0.5 × 106 cells/mL) were plated in 6 well plates and incubated in serum free 
RPMI-1640 with 20 µg/mL of RA+NPs. After 4 h incubation, NPs that were not internalized by the cells 
were washed three times with PBS and the cells were left to grow at 0.2 × 106 cells/mL in complete 
medium for additional 4 h, 3 days and 6 days, maintaining always an exponential growth. After each 
incubation, cells were counted, collected by centrifugation and resuspended in nitric acid (1 mL, 69 % 
(v/v) for ICP analysis. The concentration of Zn was normalized per cell. The estimation of NPs was 
done based on Zn quantification in 20 µg of NPs. In some experiments, cells were transfected with 
RA+NPs labelled with TRITC, and their fluorescence monitored by flow cytometry overtime, to evaluate 
NPs distribution within the cells. 
 
Exocytosis analyses of NPs. To determine exocytose of NPs, NP uptake assays were performed in 
the presence of P-gp antagonist verapamil or the endosome disruption agent chloroquine. U937 cells 
were cultured on 24 well plates (1  105 cells/well) and chloroquine (100 μM, no pre-incubation) and 
verapamil (100 μM, 60 min pre-incubation) conditions were tested. The chemical agents concentrations 
were based on values reported in the literature and further validated by us to have no cytotoxic effect 
over the period of the assay (12 h). After the pre-incubation with the chemical agents, TRITC-labelled 
PEI-DMNC:DS NPs (10 μg/mL) or TRITC-labelled poly-L-lysine USPIO NPs (100 μg/mL) were added 
to the cells, maintaining the chemical agents concentration. As controls we used cells incubated without 
NPs and cells incubated with NPs without chemical agents. At the end of each experiment, the cells 
were centrifuged at 1300 rpm, 20 ºC for 5 min with PBS, washed one time with cold trypan blue solution 
(200 L; 600 g/mL), re-washed 3 times with cold PBS and then resuspended in PBS containing 2.5 % 
FBS (500 L) for flow cytometry analysis. A total of 10,000 events were recorded per measurement, 
and all conditions were performed in triplicate. 
 
[3H]RA internalization studies. [11, 12-3H(N)]-Retinoic acid, 50.4 Ci/mmol, was purchased from 
Perkin Elmer. [3H]RA solution for cell culture assays was prepared on the day of experiments by 
dissolving [3H]RA in DMSO with unlabelled RA in a 1:1000 ratio to a final concentration of 10 M of 
RA. [3H]RA solution in DMSO for the preparation of NPs was prepared on the day of experiments using 
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a 1:4000 ratio of labelled to unlabelled RA. Experiments were initiated by the adding the [3H]RA 
solution (1 M and 10 M; representing less than 1% in volume of the total cell culture medium) or 
[3H]RA-NP suspension (1 g/mL and 10 g/mL) to cultures (60,000 cells/condition, 24-well plate, 1 
mL) of NB4 or U937 cells. In case of soluble RA, cells (NB4 or U937; 60,000 cells/condition, 24-well 
plate) were cultured with medium containing [3H]RA (1 M and 10 M; 1 mL of medium) for 24 or 72 
h, washed with PBS (2 times), harvested, lysed with lysis buffer (100 L) and kept on ice until 
scintillation counting procedure. In case of RA-containing NPs, cells (same conditions as for soluble 
RA) were cultured with [3H]RA-NPs (1 g/mL and 10 g/mL) for 4 h, washed with PBS and cultured 
for additional 20 or 68 h in the respective culture medium. Cells were then collected to eppendorfs, 
washed with PBS, centrifuged (1500 rpm, 5 min), lysed with lysis buffer (see above) and kept on ice 
until scintillation counting procedure. The lysed samples (100 L) were mixed with liquid scintillation 
fluid (1 mL; Packard Ultima Gold) and the scintillations counted in a TriCarb 2900 TR Scintillation 
analyser (Perkin Elmer).  
 
Time-activation of NPs within cells. NB4 and Zn-induced U937-B412 cells (6.0  104 
cells/condition) were plated in 24-well plates and transfected with RA+ NPs (1 g/mL) for different time 
periods (1, 2, 4, 6, 8, 12 and 24 h). The cells were then washed by centrifugation (1300 rpm, 5 min) to 
remove non-internalized NPs, and immediately exposed to UV light (365 nm, 100 Watts, 5 min). In a 
second experimental setup, NB4 and Zn-induced U937-B412 cells (6.0  104 cells/condition) were 
plated in 24-well plates and transfected with RA+ NPs (1 g/mL) for 4 h. The cells were then washed 
by centrifugation (1300 rpm, 5 min) to remove non-internalized NPs, cultured in normal conditions and 
exposed to UV light (365 nm, 100 Watts, 5 min) at different time points (0, 4, 8, 20 and 44 h). The effect 
of the intracellular release of RA was evaluated in terms of differentiation of the cells into the myeloid 
lineage (as assessed by the expression of CD11b) at day 3, as assessed by flow cytometry. All conditions 
were performed in triplicate.  
NB4-RARE cells (2.5  104 cells/condition) were plated in v-shaped 96-well plates and transfected 
with RA+ NPs (1 g/mL) for different time points (1, 2, 4, 6, 8, 12 and 24 h). The cells were then washed 
by centrifugation (1300 rpm, 5 min) to remove non-internalized NPs, and immediately exposed to UV 
light (365 nm, 100 Watts, 5 min). For the second experimental setup, NB4-RARE cells (2.5  104 
cells/condition) were plated in v-shaped 96-well plates and transfected with RA+ NPs (1 g/mL) for 4 
h. The cells were then washed by centrifugation (1300 rpm, 5 min) to remove non-internalized NPs, 
cultured in normal conditions and exposed to UV light (365 nm, 100 Watts, 5 min) at different time 
points (0, 4, 8, 20 and 44 h). The cells were then cultured for 12 hours after each condition light 
activation in RPMI-1640 medium supplemented with 10 % fetal bovine serum and 100 U/mL PenStrep. 
After these procedures luciferase luminescence was quantified as described above for the luciferase 
assays. All conditions were performed in triplicate. 
 
Multiple activation of NPs within cells.  Myelocytic differentiation of Zn-induced U937 cells was 
assessed by the quantification of CD11b expression by flow cytometry. U937-B412 cells (6.0  104 
cells/condition) were cultured with ZnSO4 (0.1 mM) in culture medium up to 24 h prior to experiment 
to induce the expression of promyelocytic leukaemia zinc finger/RARα (PLZF/RARα). Then cells were 
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transfected with RA+ NPs (1 g/mL) for 4 h, washed, placed in normal culture medium and then different 
activated by UV light (365 nm, 100 Watts, 5 min). Cells without light activation were used as control. 
The following conditions were tested: i) single light activation at 4 h; ii) light activations at 4 h and 6 h; 
iii) light activations at 4 h, 6 h and 8 h and iv) light activations at 4 h, 6 h, 8 h and 10 h. After 3 days, 
expression of CD11b on U937 cell surface was measured by staining with a fluorescent (PE)-conjugated 
anti-CD11b mAb (BD Biosciences) using flow cytometry. All conditions were performed in triplicate. 
 
NB4 differentiation assay. Myelocytic differentiation of NB4 cells was assessed by quantifying 
CD11b+, CD11b+CD45+CD13high or CD11b+CD45+CD13low populations using flow cytometry. NB4 
cells (between 6.0  104 and 10  104 cells/condition) were plated in 24-well plates and cultured with 
soluble RA (3 µg/mL) or light-activatable RA+ NPs (10 µg/mL) for 3 days. The NPs were suspended in 
serum free medium and added to cells for 4 h. The cells were then washed by centrifugation (1300 rpm, 
5 min) to remove non-internalized NPs, and half of the samples were exposed to UV light (365 nm, 100 
Watts, 5 min). The cells were then cultured up to 3 days in RPMI-1640 medium supplemented with 10 
% fetal bovine serum and 100 U/mL PenStrep with half medium changes every 3 days.  
 
NB4 RARE cell line generation. The cignal lenti RARE reporter kit (CLS-016L SABiosciences) 
was used for the establishment of a RA reporter NB4 cell line. For that purpose, rectronectin solution 
(15 g/cm2, 30 g, 500 L on PBS, Takara) was plated in a 24-well plate 2 hours prior to cell seeding. 
The plate was kept at room temperature and was washed one time, immediately before seeding, with 
PBS. NB4 cells (1  105) were plated in 175 L of RPMI-1640 medium (Gibco) supplemented with 0.5 
% FBS and 100 U/mL PenStrep and to this condition 125 L of cignal lentiviral particles were added to 
a total experimental volume of 300 L. After a gentle swirl of the plate the cells were incubated 20 hours 
at 37 ºC in a humidified incubator with 5 % CO2 atmosphere. In the following day, cells were washed 
and allowed to recover in the incubator for 24 hours cultured in 500 L of fresh RPMI-1640 medium 
supplemented with 10 % FBS and 100 U/mL PenStrep. After that, 2 g/mL of puromycin (Invitrogen) 
was added to the culture medium for selection of transduced cells. Evaluation of selection efficiency in 
puromycin-containing medium was performed every 3 days for a period of 5 weeks. 
 
NB4 RARE luciferase assay. To assess the biological effect of RA in RAR-regulated signalling 
pathway activity, luciferase reporter assay was performed. NB4-RARE cells (2.5  104 cells/condition) 
were plated in v-shaped 96-well plates and cultured with soluble RA (10 M) or light-activatable RA+ 
NPs (5 g/mL). The NPs were suspended in serum free medium and added to cells for 1 h. The cells 
were then washed by centrifugation (1300 rpm, 5 min) to remove non-internalized NPs, and half of the 
samples were exposed to blue light (405 nm, 80 mW, 5 min). The cells were then cultured for 12/24 
hours in RPMI-1640 medium supplemented with 10 % fetal bovine serum and 100 U/mL PenStrep. 
After these incubation times, the conditions were centrifuged (1500 rpm, 3 min), excess medium 
carefully aspirated and the cells washed with 100 L of PBS. After a new centrifugation and removal 
of PBS, 60 L of cell lysis buffer (8 mM of magnesium chloride; 1 mM DL-Dithiothreitol; 1 mM 
Ethylenediaminetetraacetic acid; 25 mM of 1 M Trizma Base with 1 M Sodium phosphate monobasic; 
15 % Glycerol; and 1 % Triton X-100), was added to each condition. The plate was kept on ice, under 
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agitation for 15 min to allow complete lysis and then the plate was placed on -80 ºC for the amount of 
time necessary for the samples to freeze. After these steps, the plate was removed from the -80 ºC, put 
on ice and allowed to defrost at slow rate.  
For the preparation of the luminescence reading, 40 L of ATP (100 M, Sigma) was added to 
1960 L of reading buffer solution (8 mM of magnesium chloride; 1 mM DL-Dithiothreitol; 1 mM 
Ethylenediaminetetraacetic acid; 25 mM of 1 M Trizma Base with 1 M Sodium phosphate monobasic; 
and 15 % Glycerol) to a final concentration of 2 M ATP. On a second tube, 2 mL of D-Luciferin 
working solution (167 M, Sigma) was prepared protected from light. The injection system of the 
luminometer was primed until ready. Following that step, the luminometer software was programmed 
to set the temperature to 37 ºC, and under stirring for the duration of the experiment accept 50 L of 
sample per condition in a 96-white plate, inject 100 L of ATP working solution 3 seconds after reading 
cycle begins; inject 100 L of D-Luciferin working solution 4 seconds after reading cycle begins and 
read the luminescence 5 seconds after reading cycle begins. The luciferase luminescence was quantified 
in a microplate luminometer reader LumiStar Galaxy (BMG Labtech). All conditions were performed 
in triplicate. 
 
NB4 RARE differentiation by cell conditioned medium obtained from NB4 cells exposed to 
RA or RA+NPs. NB4 cells (3106/mL) were grown in RPMI supplemented with 10% (v/v) FBS, 
penicillin and streptomycin. Cells were treated with RA+NPs (10 g/mL) for 4 h, washed with PBS to 
remove the NPs that were not internalized, activated by a blue laser for 5 min, and then cultured for 18 
h under hypoxia conditions (0.5% O2) in exosome-depleted medium. A separate group of cells was 
treated with RA (3 g/mL) for 22 h in hypoxia conditions (0.5% O2) in exosome-depleted medium. 
Then, in both groups, cells were centrifuged at 10.000 g (4ºC; 30 min) and part of the supernatant (named 
in the plot as "Sup") added to NB4 RARE cells (100,000/mL; 1 mL of the Sup). Alternatively, in both 
groups, cells were centrifuged in multiple steps643 to remove exosomes (named in the plot as "exo") and 
added to NB4 RARE cells (100,000/mL; 5 μg/mL de exosomes per mL of media) plated in a 24 well 
plate. After 24 h, the luciferase assay was performed according to instructions of the luciferase kit 
(britelite™).  
 
U937 differentiation assay. Myelocytic differentiation of U937 cells was assessed by the 
quantification of CD11b expression by flow cytometry. U937-B412 cells (6.0  104 cells/condition) 
were cultured either with or without ZnSO4 (0.1 mM). To induce the expression of promyelocytic 
leukaemia zinc finger/RAR (PLZF/RAR) in U937-B412 cells they were treated for 24 h with ZnSO4 
(0.1 mM). Then cells were treated with soluble RA or light-activatable RA+ NPs (transfection for 4 h 
followed by light activation for 5 min) for 3 days. After 1 and 3 days, expression of CD11b on U937 
cell surface was measured by staining with a fluorescent (PE)-conjugated anti-CD11b mAb (BD 
Biosciences) using flow cytometry. All conditions were performed in triplicate. 
 
AML differentiation assay.  AML bone marrow mononuclear cells isolated by Ficoll-Histopaque 
(GE Healthcare) gradient centrifugation, enriched using the MACS CD34 isolation kit (Miltenyi Biotec) 
and cryopreserved were kindly provided by Dr. Rajeev Gupta (Department of Haematology, UCL 
Cancer Institute). The AML cells were isolated from an 85 years old man patient with AML 
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34+117+33+13+DR+ 35% blasts and a 70 years old woman with RAEB2/evolving AML 34+117+33+ 
12% blasts. Both samples had formal karyotyping/extended FISH panels. Briefly, neither patients were 
PML-RARA: one was standard risk (normal karyotype with a small trisomy 8 subclone), and the other 
was high risk with complex karyotype. The isolated CD34+ AML cells were maintained in StemSpan 
SFEM medium (Stemcell Technologies) supplemented with a human cytokine cocktail containing SCF 
(50 ng/mL, Stemcell Technologies), TPO (15 ng/mL) and Flt-3L (50 ng/mL, PeproTech) plus PenStrep 
(10,000 U/mL, Lonza) and Fungizone (25 mg/mL, Sigma) up to 3 days. Prior to the colony-forming cell 
(CFC) and long-term culture-initiating cell (LTC-IC) assays, AML cells were incubated for 4 h in Ex-
Vivo (Lonza) serum free medium, with and without blank NPs or RA+ NPs in a 24 well plate. After that 
time, the cells were washed to remove loosely bound NPs. For CFC assays (2.0 x 105 cells/condition) 
AML cells were plated in triplicate in MethoCult H4230 medium (3 mL, StemCell Technologies) 
supplemented with SCF [50 ng/mL], IL-3 [10 ng/mL], and Flt-3L [50 ng/mL], all human, plus PenStrep 
(10,000 U/mL, Lonza) and Fungizone (25 mg/mL, Sigma) in 6-well plate. In some conditions, RA+ NPs 
accumulated within the cells were activated by a UV light (365 nm, 100 W, 5 min). Cultures were scored 
after 14 days for the presence of clusters and colonies containing >20 cells using an inverted microscope. 
LTC-IC assays were performed in triplicate in a 6-well plate gelatinized for 2 h prior to adding the 
feeders. The feeder layer was composed of a 1:1 mixture of irradiated (80 Gy) SL/SL (1.5  104 
cells/condition) and M210B4 mouse fibroblasts (1.5  104 cells/condition), kindly provided by Dr. 
Rajeev Gupta (Department of Haematology, UCL Cancer Institute). AML cells (1  106 cells/condition) 
were plated in Myelocult H5100 medium (StemCell Technologies), supplemented with Flt-3L [50 
ng/mL], hydrocortisone [10-6 M] (StemCell Technologies) and PenStrep (10,000 U/mL, Lonza) and 
fungizone (25 mg/mL, Sigma). For some conditions UV light (365 nm, 100 Watts, 5 min) was used to 
trigger RA release. After the cells were inoculated, weekly half medium changes were performed (with 
Flt-3L [100 ng/mL]) for the duration of the culture. After 5 weeks, all cells were harvested and placed 
into methylcellulose based assay for the detection of AML-CFC as described above. 
 
High-throughput gene expression assay. Gene expression was evaluated by real time PCR in 
NB4 cells and U937-B412 cells previously stimulated with ZnSO4 (0.1 M), using a 96.96 microfluidic 
chip (Fluidigm Corporation). Cells were exposed to either soluble RA (1 and 10 µM) or light-activatable 
RA+NPs (0.1, 1 and 10 µg/mL) for 8 h, 24 h or 48 h. From each sample (n=3) a maximum of 0.45 × 106 
cells were collected for RNA extraction using RNeasy Micro Kit. Afterwards, samples were processed 
using Fluidigm standard protocols. Briefly, cDNA was obtained from 50 ng of RNA using Reverse 
Transcription Master Mix (Fluidigm Corporation). Then samples were pre-amplified for 12 cycles, to 
increase the number of copies of target DNA, with Fluidigm PreAmp Master Mix (Fluidigm 
Corporation) and a pool of all the primers tested in the chip. Prior to qPCR reactions the pre-
amplification reaction was treated with Exonuclease I to eliminate the carryover of unincorporated 
primers. Finally, samples and genes pre-mix are prepared separately accordingly to manufactures 
instructions using SsoFast EvaGreen Supermix with Low ROX (Bio-Rad Laboratories) and loaded into 
the chip. A pneumatically operated desktop instrument (IFC Controller HX) was used to mix samples 
and genes pre-mix in the qPCR chamber reaction of the chip. After this procedure, the chip was analysed 
using Biomark HD (Fluidigm Corporation) for the thermal cycling and real time fluorescent readings. 
A melting curve was performed after 30 cycles, for quality control. DeltaCt was calculated using Real 
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Time PCR Analysis Software 4.1.3 (Fluidigm Corporation) and data was further analysed with Cluster 
3.0 and Java Trew View to produced gene expression heatmaps and hierarchical clustering. 
 
Generation of a THP-1- GFP cell line. Viral particles for GFP-expression were produced in 293T 
cells using a standard protocol. Briefly, 293T cells were transfected with GFP DNA construct (30 µg) 
and pCL-Eco (DNA:pCL-Eco; 15 µg) both solubilised in a DNA-CaCl2 mixture (1 mL). Transfection 
efficiency was evaluated by fluorescence microscopy. After 72 hours viral particles were collected and 
THP-1 cells were infected (2 x 105 cells/ml in a 6-well plate with 4μg/ml polybrene). 
 
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis. Total 
RNA was extracted and purified using RNeasy Micro Kit (Qiagen) and immediately stored at -
80ºC. Total RNA was quantified in a NanoDrop ND-1000 Spectrophotometer (NanoDrop 
Technologies, Inc., USA) by spectrophotometry at 260 nm. The cDNA was reverse transcribed 
from 0,5 μg of total RNA, using TaqMan Reverse Transcription Reagents kit (Invitrogen) according 
to the manufacturer’s instructions. The cDNA obtained was stored at -20ºC until further analysis 
by qRT-PCR using SYBR Green technology and qRT-PCR analyses were performed using the ABI 
PRISM 7500 Fast System (Applied Byosystems). Quantification of target genes was performed 
relative to GAPDH gene according to the equation: 2[–(Ct sample –Ct GADPH)]. The mean minimal cycle 
threshold values (Ct) were calculated from quadruplicate reactions. The list of the primers can be 
found in  
 
In vivo study: subcutaneous implantation. The animal work has been conducted according to 
relevant national and international guidelines and approved by the Bioethics Committee of University 
of Salamanca. On the day before injecting the cells, PDMS cylindrical constructs (internal = 1.0 cm; 
external = 1.5 cm) were implanted subcutaneously on NOD/SCID mice (Jackson Laboratory) 
maintained in pathogen-free conditions with irradiated chow. For the ex-vivo activation studies in the 
day of the experiment, NB4 cells were suspended in serum free medium with (i) no NPs, (ii) with empty 
NPs (10 g/mL) or RA+ NPs (10 g/mL) for 4 h. At the end, cells were washed by centrifugation (1300 
rpm, 5 min), and the ones treated with RA+ NPs were either activated or not with a blue laser (405 nm, 
80 mW) for 5 min. NB4 cells (5  106 cells per PDMS construct) were injected subcutaneously in the 
center of the PDMS construct embedded in Matrigel (200 μL, BD Biosciences). Five days after injection 
of the cells, animals were sacrificed by cervical dislocation and cells within the cylindrical construct 
were collected and characterized by flow cytometry. For the in vivo activation studies in the day of the 
experiment, NB4 cells were suspended in serum free medium with (i) no NPs, (ii) with RA+ NPs (10 
g/mL) for 4 h. At the end, cells were washed by centrifugation (1300 rpm, 5 min), and 5  106 NB4 
cells per PDMS construct were injected subcutaneously in the center of the PDMS construct embedded 
in Matrigel (200 μL). One day after injection, experimental groups were either activated or not with a 
blue optical fibre (405 nm, 80 mW) for 5 min. Three days after injection of the cells, animals were 
sacrificed by cervical dislocation and cells within the cylindrical construct were collected and 
characterized by flow cytometry.  
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In vivo study: bone marrow modulation. NOD.CB17-Prkdcscid /J (NOD/SCID) female mice 
(n=12) aged 6-8 weeks were employed in this experiment. Before cell injection, mice received 1.5 Gy 
of total body irradiation from a 137Cs source and were also treated with 200 μg of mouse anti-CD122 
monoclonal antibody (NS122) by intraperitoneal injection. Human THP-1 cells were incubated with 20 
μg/mL of RA+NPs in RPMI medium for 4 hours, followed by extensive wash with PBS to remove non-
internalised NPs. The cells were then resuspended in RPMI medium with 10% FBS and left in the culture 
incubator overnight. On the following day, the cells loaded with RA+NPs were collected and 1  107 
cells /mouse in 200 µL PBS were injected into the NOD/SCID mice intravenously, through the tail vein. 
After 6 days, the mice were randomly divided into two groups: one of the groups was blue laser 
irradiated (n=6) and the other group was not irradiated (n=6). In the blue laser irradiated group, each 
mouse was anesthetized with 3.5% chloral hydrate in PBS and the craniums were exposed to a blue laser 
(405 nm, 80 mWatts) for 5 min. The mice in the non-irradiated group received the same treatment 
without blue laser activation. After 48 or 72 h, the mice were sacrificed, and the long bones/ craniums 
were collected. The long bones including the femurs, tibias and pelvis were crushed in PBS containing 
1% bovine serum albumin (BSA, sigma) and 2 mM EDTA (Invitrogen). The samples were then filtered 
with 70 μm cell strainer and treated with ACK solution to lyse red blood cells. The resulting cells were 
stained using PE conjugated anti-human CD45 antibody (eBioscience). The results were measured by 
flow cytometry and the data were analysed with FlowJo software.  
The mouse craniums were collected for the ex vivo staining examination followed by the traditional 
protocol. Briefly, the mouse craniums were cut into four pieces along the sutures producing one frontal, 
two parietals and one occipital bone. Only parietal bones were used in this experiment. Bone pieces 
were fixed in 4% paraformaldehyde for 30 min, washed twice with PBS, blocked with 2% BSA-0.01% 
Triton X-100 in PBS (BSA buffer) for 1 hr, and incubated with primary antibodies (diluted 1:100 in 
BSA buffer) overnight at 4ºC. After washing with BSA buffer for 2 hr, bones were incubated with 
secondary antibodies (diluted 1:200 in BSA buffer) for 2 hr, washed with BSA buffer for 2 hr, and nuclei 
were stained using DAPI. The primary antibodies included mouse anti-human CD45 antibody (BD) and 
rabbit anti- human CD11b antibody (Abcam). The secondary antibodies included goat anti-mouse 555 
(Invitrogen) and goat anti-rabbit 488 antibodies. The bone pieces were finally examined with a confocal 
microscope (Nikon Eclipse Ti) under FITC/TRITC/DIC signal channel. Images were analysed in 
ImageJ. Analyse Particles was used after thresholding to quantify positive signals and measure the total 
area occupied by these particles. 
 
In vivo study: CRABP2 expression on mouse cranium. NOD.CB17-Prkdcscid /J (NOD/SCID) 
female mice aged 6-8 weeks were employed in this experiment. The mouse craniums were collected 
from the last experiment. In this experiment, we also collected the mouse craniums without any 
treatment as the control. The ex vivo staining examination was followed by the traditional protocol. 
Briefly, the mouse craniums were cut into four pieces along the sutures producing one frontal, two 
parietals and one occipital bone. Only parietal bones were used in this experiment. Bone pieces were 
fixed in 4% paraformaldehyde for 30 min, washed twice with PBS, blocked with 2% BSA-0.01% Triton 
X-100 in PBS (BSA buffer) for 1 h, and incubated with primary antibodies (anti-CRABP2 antibody, 
ab74265, diluted 1:100 in BSA buffer) overnight at 4ºC. After washing with BSA buffer, bones were 
incubated with secondary antibodies (goat anti-rabbit 488 antibodies, diluted 1:200 in BSA buffer) for 
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2 h and then washed with BSA buffer. Nuclei were stained using DAPI. The bone pieces were finally 
examined with a confocal microscope (Nikon Eclipse Ti) under DAPI/FITC/DIC signal channel. Images 
were analysed in ImageJ. Analyse Particles was used after thresholding to quantify positive signals and 
measure the total area occupied by these particles. Comparison between CD11b, CD45 and CRABP2 
positive areas was used as a proxy of the release of RA by NPs and paracrine effect in the parietal bones 
of irradiated and non-irradiated mice. 
 
Statistical analysis. Statistical analyses were performed with GraphPad Prism software. For 
multiple comparisons, a two-way ANOVA followed by a Holm-Sidak post-test was performed. Results 
were considered significant when P< 0.05. Data are shown as mean ± s.e.m. unless other specification. 
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4.1. Abstract 
Great advances have been made in this century in the development of drug delivery systems for 
AML therapy, which improves the application of previously used drugs in clinical practice and also 
opens new venues for new biomolecules to be used in therapy. The use of stem cells as carriers in cell-
mediated drug delivery strategies is an attractive emerging approach to overcome the current limitations 
of conventional medicines. Stem cells can act not only as “shields” for therapeutic agents, but also as 
specific targeting agents by themselves due to their natural tropism for specific tissues, organs and sites 
of injury594,455, with the added advantage of being able to cross biological barriers, such as anatomical 
(e.g. blood brain barrier)563 or physiological barriers (e.g. tumour site heterogeneity). In this chapter we 
further investigate the functional effect of cell-mediated targeted delivery of photo-triggerable NPs to 
the BM niche on MLL-AF9 AML mouse model. We also explored different options regarding cell type 
used as carriers and type of molecule delivered by photo-triggerable NPs. 
Our results indicate that RA can activate different differentiation pathways depending on whether it 
is delivered extra-cellularly, or intracellularly by activation of RA+NPs. RA+NPs can induce AML 
differentiation towards monocytic/macrophage lineage not only in vitro but also in vivo. Also, we have 
shown in vitro evidence that soluble RA and more significantly, activation of RA+NPs, stimulate 
antitumoral M1 macrophage activation. This macrophage induced differentiation in vivo seems to have 
“systemic” anti-leukemic effect within the BM leukemic niche, as we observed a significant reduction 
of leukemic cells in the BM of animals treated with RA+NPs when compared with animals treated with 
empty NPs (RA-NPs). 
We also explored the potential use of this system using healthy HSCs as RA+NP carriers. Our results 
indicate that RA+NPs can be loaded in human UCB CD34+ cells as efficiently as observed in human 
AML CD34+ cell lines (4h internalization). Although, UCB CD34+ cells seem to be more sensitive to 
blue laser irradiation, shorter irradiation time (1 min) at lower laser power level (40mW) was still 
sufficient to trigger RA release from NPs and trigger the expression of CD38 in UCB CD34+cells.  
The drug delivery systems describe here, composed of carrier cells and RA+NPs offer a versatile a 
promising therapeutic strategy for targeting BM not only on hematopoietic malignancies, such as AML 
but also for regenerative medicine, such as HSCT. 
 
4.2. Introduction 
Several drug delivery strategies have been developed to increase the therapeutic efficiency of 
bioactive molecules. However, their clinical translation has been limited due to their poor specificity 
and efficient drug release at desired location. Furthermore, many therapeutic agents can be recognized 
and destroyed in their route to desired sites by host’s immune system, such as the mononuclear 
phagocytic system (MPS)463, thus decreasing their therapeutic potential. 
The use of stem cells as carriers in cell-mediated drug delivery strategies is an attractive emerging 
approach to overcome the current limitations of conventional medicines. Stem cells can act not only as 
“shields” for therapeutic agents, but also as specific targeting agents by themselves due to their natural 
tropism for specific tissues, organs and sites of injury594,455, with the added advantage of being able to 
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cross biological barriers, such as anatomical (e.g. blood brain barrier)563 or physiological barriers (e.g. 
tumor site heterogeneity). Moreover, stem cells themselves can be used as therapeutic agents as they 
can be modified to secret trophic factors to promote the recovery of the damaged tissue and potentially 
differentiate to a wide variety of functional cells and consequently help in the repopulation of their target 
site.  
MSCs and HSCs have high bioavailability and can be harvested readily from bone marrow of 
healthy unaffected individuals or isolated from UCB units599-604. MSCs have been used as NP carriers 
to target brain tumours568,605, in regenerative medicine606 and cancer therapy 604,607. HSCs are also good 
candidates to target NPs to the HSC niche at the bone marrow in regenerative medicine (e.g. 
hematopoietic stem cell transplant – HSTC) and to treat haematological malignancies (e.g. leukemia). 
NPs can modulate HSC paracrine activity and their engraftment in the BM 608,593. NPs can also be used 
to target HSCs into the BM niche or to recruit other cells to the niche548. 
LSC could also potentially be used as NP carriers, as they could serve as targeting agents to 
otherwise difficult access leukemic niches. This constitutes a special environment where LSCs 
responsible for relapses reside and traditional chemotherapy cannot reach. However, the use of LSCs 
should be made with caution as they could potentially have detrimental effects on the host. For example, 
systems using LSC could include the expression of self-destructive suicide genes after it reaches the 
target sites to prevent carrier-derived tumor formation or even go through rounds of genetic correction 
for leukemia mutations, using the recently described CRISPR/ Cas9 gene correction systems. 
HSC transplantation with bone marrow and mobilized peripheral blood is an important therapeutic 
tool in the management of hematological malignancies and some inherited blood disorders137. 
Unfortunately, repopulation of hematopoiesis can be adversely affected by the inability of HSC s to 
home to appropriate marrow niches or poor engrafting efficiency and self-renewal. In addition, 
individuals requiring an allogeneic HSC transplant may have problems to find a suitable matched 
donor260,261. UCB may offer an important resource for such patients; however, individual units of cord 
blood (CB) contain too few HSCs to allow them to be transplanted into adults without a substantial 
delay in engraftment267. Therefore, methodologies to increase the number or engraftment efficiency of 
stem cells could provide substantial clinical benefit. Although strategies to accomplish this goal have 
been developed in the last years such as exogenous treatment of the HSC s with pro-survival/pro-
engraftment factors644,645 and the stimulation of the adult HSC niche646, 623, 596, they have shown limited 
success. 
In the bone marrow, HSC reside within the context of a complex microenvironment of different cell 
types and extracellular molecules that dictate stem cell self-renewal and differentiation 647-650. The direct 
stimulation of the adult HSC niche might be a strategy to improve HSC engraftment. In mouse models, 
the pharmacologic use of PTH increases the number of HSCs mobilized into the peripheral blood for 
stem cell harvests, protects stem cells from repeated exposure to cytotoxic chemotherapy and expands 
stem cells in transplant recipients 647. However, the effect is modest. An alternative to the direct 
manipulation of endogenous HSC niche is to enhance the engraftment of HSCs into the bone marrow 
niche. Several approaches have been described in the last few years to accelerate and improve the 
engraftment of HSCs including inhibition or deletion of CD26 644, exposure to recombinant human NOV 
645, treatment with prostaglandin E2 651 or cholera toxin 652, but these approaches are at pre-clinical stage. 
All the methodologies described so far are based in the exogenous treatment of the stem cells with pro-
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survival/pro-engraftment factors before their intravenous delivery. In most cases, although the stem cell 
treatments contribute for efficient mobilization of the HSC to the bone marrow niche their effect may 
not be enough to promote a successful and rapid engraftment.  
An alternative to the 2 previous approaches is to potentiate both the expansion and engraftment of 
HSCs 653. The transcription factor HOXB4 is a particularly attractive candidate for use in HSC expansion 
and engraftment. Studies have shown that HOXB4 mediates a significant expansion of HSCs and long-
term repopulation potential either in vitro or in vivo 654,655. However, the expression of HOXB4 should 
be in a regulated manner to avoid potential unwanted effects. High expression levels of HOXB4 led to 
a statistically significant reduced engraftment of the transduced cells at the BM 656, reduce the 
differentiation of stem cells into the erythroid cell lineage656, and increases the risk of leukemia 657. 
Furthermore, the stability of HOXB4 protein in physiological conditions has proven to be an obstacle 
to its clinical application658. 
To be used as drug carriers in cell-mediated delivery systems, NPs need to possess some specific 
characteristics. They must be biocompatible, without exerting cytotoxic effects to carrier cells, or 
without affecting their critical stem cell biological characteristics such as, self-renewal, proliferation and 
differentiation capacity as well as their migratory and homing capacity. Also, NPs components need to 
be biodegradable by the normal cell metabolism.  
In this chapter our objective was to explore the potential use of NP-delivery systems not only to 
modulate the diseased HSC BM niche in AML but also healthy HSC BM niches. To achieve this, the 
murine AML disease model MLL-AF9 and intravital microscopy was used to find out how the remote 
release of RA within the BM niche affects the interaction between delivery cells and malignant cells. 
Next, we explored the possibility of using healthy HSCs (e.g UCB CD34+) as delivery cells. Finally, we 
explore the possibility of using NP systems to carry HoxB4 inside HSC during HSCT. We hypothesize 
that transiently increasing the levels of the transcription factor HOXB4 in bone marrow transplanted 
HSCs may increase HSC engraftment and proliferation.  
4.3. Results and discussion 
4.3.1 In vitro effect of RA+NPs in AML mouse model MLL-AF9 
Although humanized murine AML models provide a better experimental setting towards a 
translational use of this NP formulation, it has some limitations when it comes to study fundamental 
biological interactions. Since our main goal was to study the paracrine effect of the release of RA from 
carrier cells and the interaction between carrier cells and BM niche components, we decided to use a 
murine AML disease model, which allows to apply a more straight experimental approach without 
affecting so much normal BM homeostasis, like the normally required procedure of myeloablation, 
which affects the homeostasis of the normal bone marrow (i.e. deterioration of sinusoids by 
irradiation659), and provides more reliable information about the complex niche interactions without the 
“noise” introduced by using cells coming from different species. For this purpose, we decided to use a 
murine AML model which encompasses the fusion oncogene MLL-AF9, similar to the human cell line 
THP-1, used in the previous chapter. In this model, most of the Leukaemia Stem Cells (LSCs) are 
downstream myeloid lineage cells, phenotypically similar to GMP cells660.  
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Like in the other cell types tested, most RA+NPs are internalized by MLL-AF9 blasts after just 4 h 
of treatment (data not shown), so for the in vitro tests we followed the same methodology as before 
(Figure 4.A), 4 hours internalization followed by wash and 5 minutes exposure for blue laser activation, 
after which the differentiation at 72h post treatment was evaluated by flow cytometry (Figure 4.B). 
Interestingly, in these cells, soluble RA and RA delivered by NP activation seem to promote distinct 
differentiation pathways (Figure 4.C). Although to a lesser extent than in other cell lines, soluble RA 
was able to induce differentiation of MLL-AF9 blasts towards granulocyte lineage, more specifically 
towards neutrophil-like cells (CD11b+Ly6G+) as previously reported661. However, when RA was 
delivered intracellularly by photo-activation of RA+NPs, granulocyte differentiation was not significant, 
on the other hand, RA+NPs appear to prime monocyte/macrophage differentiation (CD11b+Ly6G-
F4/80+) (Figure 4.D). Although previous studies have shown differentiation towards 
monocyte/macrophage lineage in vitro when AML cell lines were treated with vitamin D662, which can 
be further enhanced by combining vitamin D treatment with RA, this was the first time to our knowledge 
that monocyte/macrophage differentiation was observed with RA treatment alone.  Furthermore, 
activation of RA+NPs seems to promote the type 1 macrophage polarization (M1) (MHC II+CD206-) 
which has been shown to suppress tumour growth663, and not type 2 macrophages (M2), contrary to 
previous reports for the human AML cell lines HL-60 and THP-1 differentiation in vitro when combined 
RA+VitD treatments were used664. Of note, RA differentiation effect in APL was associated with 
restoration of normal PU.1 gene expression665, a transcription factor essential for macrophage 
differentiation and full neutrophil maturation666. Also, RA has been previously reported to negatively 
regulate neuropeptide Y gene expression667, a widely expressed neuroregulatory peptide, which 
suppresses macrophage activity668. 
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Figure 4.1 – In vitro Differentiation profile of MLL-AF9 YFP blast cells after treatment with soluble RA or 
RA+NPs. (A) Schematic representation of the experiment. MLL-AF9 YFP cells were incubated in serum-free 
RPMI-1640 with RA+NPs (10 μg/mL) for 4 h. Then, cells were washed three times with PBS to remove NPs not 
internalized, activated or not by blue laser (405nm, 80mW) during 5 min, and cultured in complete medium for 
additional 3 days. Alternatively, MLL-AF9 YFP were cultured in complete medium for 3 days having soluble RA 
(3μg/mL). (B) Representative gating strategy for Lin- MLL-AF9 YFP cells treated with RA+NPs. Dead cells 
excluded by DAPI staining. (C-D) Percentages of positive single cells were calculated based in the FMOs controls 
and are shown in each scatter plot. (C) Monocytes (Ly6G-CD11b+), Neutrophil (Ly6G+CD11b+) and Macrophage 
(Ly6G- CD11b+F4/80+) differentiation markers. (D) Percentage of macrophage activation markers for type 1 
(MHC II+CD206-) and type 2 (MHC II-CD206+) polarization. In D and E results are expressed as mean±s.e.m. 
(n=3).  Statistical analyses were performed by two-way ANOVA followed by a Holm-Sidak post-test. *P<0.05, 
**P<0.01, ***P<0.001 and ****P<0.0001. 
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4.3.2 Paracrine effect of RA+NPs in AML mouse model MLL-AF9 leukaemic niche 
 
To better understand the therapeutic potential of RA+NPs it was important to confirm if the same 
type of differentiation could be observed in vivo and how this differentiation in situ - within the 
leukaemic BM microenvironment - could affect the progression of the disease. We also adopted a 
different methodology, closer to the normal disease progression, where we allowed LSC to invade and 
remodel the BM niche in steady state (initiation) before applying our treatment during the progression 
phase of the disease, which was followed by intravital microscopy70. In short, first mTmG MLL-AF9 
blasts were injected in healthy mice to induce disease infiltration. After 12-14 days YFP MLL-AF9 
blasts previously loaded with RA+NPs or empty NPs were injected. One or two days later, after 
confirming by intravital microscopy the homing of YFP blasts to the same niche as mTmG blasts, the 
nanoparticles were activated by exposing the mouse calvaria to the blue laser for 10 minutes. This 
activation was repeated the following day. Three days after the last activation, the progression of the 
disease and MLL-AF9 activity were monitored inside the niche by time-lapse image acquisition (Figure 
4.2A). In the end of the acquisitions, mice were sacrificed, and BM was collected from the calvaria and 
long bones and analysed by flow cytometry (Figure 4.2B).  
The in vivo results allowed to confirm the observations made in chapter 3, where we have shown 
that NP loading of cells did not affect their homing capacity and RA release from NPs could be triggered 
remotely with the blue laser. More importantly, our results show that RA+NP were able to induce a 
reduction of both MLL-AF9 blasts population (YFP+ and mTmG+) in the BM of animal, particularly in 
the calvaria BM, the site of activation (Figure 4.2C). These results suggest that RA+NPs could help to 
decrease the disease burden of the resident mTmG+ MLL-AF9 AML mouse model. Furthermore, when 
looking at differentiation of YFP+ carrier cells (Figure 4.2D), we can observe a small increase in the 
neutrophil population in the calvaria BM of animals treated with RA+NPs. Although this increase is not 
statistically significant, this effect could only be observed at the calvaria BM and not in the long bones, 
suggesting this observation was due to activation of NPs at the calvaria BM. As for macrophage 
differentiation (Figure 4.2E), we did not observe significant differences between treatment groups at 
the whole BM, but by looking at the YFP+ cells differentiation we can observe a significant increase in 
the macrophage population, not only at the calvaria BM, but also at the long bones BM. 
Although we did not explore the mechanisms behind the observed effect and more experiments 
would be necessary to fully understand these results in this experimental setting for AML disease model, 
at least three hypotheses should be considered: the effect of blue laser irradiation (405nm), the impact 
of NPs and their photo-activation by-products, and finally the effect of RA release by carrier cells within 
the leukemic niche.  
Indeed, other studies have reported that blue light exposure can induce reactive oxygen species 
(ROS) generation669,670 and ROS have also been shown to promote macrophage differentiation and 
activation671. Also, ROS have been shown to induce an increase in RARα protein levels672, the main 
RAR isotype involved in RA dependent differentiation in APL 327,328. Furthermore, although in a 
different biological scenario, UV irradiation in skin cells is known to promote the production of vitamin 
D673, a molecule also involved in the promotion of macrophage differentiation662.  
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Figure 4.2 - In vivo activation of AML MLL-AF9 differentiation program by light at the bone marrow. (A) 
Schematic representation of the protocol for the generation murine MLL-AF9 mTmG AML disease model (12 
days infiltration) and treatment with delivery cells MLL-AF9 YFP+ previously transfected with RA-NPs (n=3) or 
RA+NPs (n=3) by tail vein injection. After the homing (1 day) of delivery cells, the NPs were remotely activated 
by irradiating the mouse calvaria with a blue laser (5 min, 405 nm, 80mW) on the following two days. On the fifth 
day after MLL-AF9 YFP injection mouse were sacrificed and BM from the calvaria and long bones isolated for 
flow cytometry analysis. (B) Representative plots of flow cytometry gating strategy analysis for MLL-AF9 YFP+ 
and mTomato+ calvaria and long bone BM composition (C) and MLL-AF9 YFP+ differentiation in (D) neutrophils 
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or (E) macrophages. (C) Percentage of MLL-AF9 YFP+ or mTomato+ cells in BM of the calvaria and in the long 
bones. (D) Percentage of the neutrophil differentiation (CD11b+Ly6G+)  at the calvaria and long bones quantified 
within the GMP population, identified by gating by Lin-Sca1-c-kit+ CD16/32highCD34+ of MLL-AF9 YFP+ cell 
population. (E) Percentages of macrophage differentiation (CD11b+Ly6G-F4/80+) at the calvaria and long bones 
at the hole BM or MLL-AF9 YFP+ population. Dead cells excluded by DAPI staining and percentages of YFP and 
mTmG cells were calculated based on the total BM live cells. Percentages of positive single cells were calculated 
based in the FMOs controls. Results are expressed as mean±s.e.m. (n=3). Statistical analyses were performed by 
two-way ANOVA followed by a Holm-Sidak post-test. ***P<0.001 and ****P<0.0001. 
Also, the mononuclear phagocytic system (MPS) has been shown to be determinant for the systemic 
recognition and clearance of NPs in the organism464. However, the exact mechanisms and the direct 
metabolic effects of NPs in macrophages are still under scrutiny. One of the mechanisms proposed is 
the recognition of polyanions (e.g. dextran sulphate) by folate receptors present in macrophages532,533. 
Also, a recent study has shown that different NP systems can induce different metabolic reprograming 
effects in macrophages, through: increased glycolytic activity, altered tricarboxylic acid cycle, and 
reduced ATP generation, which are consistent with a proinflammatory phenotype (M1) of 
macrophages674. 
These effects that can be mediated by the radiation or directly by the NPs, may have some 
contribution for the results observed in this work. Nevertheless, it must be low because no significant 
effect was seen in vivo when mice were treated with RA-NPs loaded MLL-AF9 blasts and irradiated 
with the blue laser. This suggests that RA release from NPs is the main factor responsible for 
monocyte/macrophage differentiation. 
 
4.3.3 Effect of RA+NPs in CD34+ cells 
 
In a clinical setting, the use of LSC as NP carriers is not desirable for the obvious reasons, so we 
decided to investigate the possibility of using healthy hematopoietic cells as carriers and what would be 
the effect of the NPs and their light-activation in healthy hematopoietic cells.  To do this we decided to 
test the NPs in UCB CD34+ cells, a common cell source used in hematopoietic stem cell transplant 
(HSCT), but as the availability of these cells is scarce, we did the initial tests in a CD34+ immortalized 
AML cell line, the KG1a. 
 
Internalization and cytotoxicity of NP and laser exposure 
The first step was to determine the CD34+ cells uptake of nanoparticles and the conditions of NP 
treatment and activation (laser exposure) which do not affect the viability. Our initial approach was the 
same conditions used during chapter 3. Briefly KG1a cells were treated with different concentrations of 
RA+NPs (0.1, 1 and 10ug/mL) for 4 hours in complete RPMI-1640 media with 1% FBS. After the 
incubation period cells were washed with PBS several times to remove non-internalized NPs and 
replated with complete RPMI-1640 with 10% FBS and irradiated or not with a blue laser (405nm, 5 
minutes at 80mw). After 48h cells were collected and AnexinV/PI (AnV/PI) flow cytometry protocol 
was used to assess the toxicity of the NPs (Figure 4.3A).  
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Figure 4.3 - Cytotoxicity of RA+NPs and light activation at human AML CD34+ cell line (KG1a) and UCB 
CD34+. Cytotoxicity of RA+NPs and laser exposure against human leukaemic cell line KG1a (A, B) and UCB 
CD34+ cells (C-E) and evaluated 48 h post-treatment by Annexin/PI staining followed by flow cytometry analysis. 
Live cells were negative for Annexin V and PI staining. (A) Cells were cultured in medium supplemented with 
different concentrations of RA+NPs for 4 h, washed and exposed or not to a blue laser (5 min, 405nm 80mW). (B) 
Cells were exposed to a blue laser at 80mW for different time periods. (C) Cells were exposed to a blue laser for 
5 minutes at different laser powers. (D) Cells were exposed to a blue laser at 40mW for different time periods. (E) 
Cells were cultured in medium supplemented with different concentrations of RA+NPs for 4 h, washed and 
exposed or not to a blue laser (1 min, 405nm 40mW). All results are expressed as mean±s.e.m (n = 3). Statistical 
analyses were performed by one-way ANOVA (B-D) or two-way ANOVA (A, E) followed by a Holm-Sidak post-
test. *P<0.05, **P<0.01, ***P<0.001. 
 
According to these results, the NPs alone do not show any cytotoxicity in non-irradiated KG1a cells. 
However, we could observe <25% decrease in viability when comparing non-irradiated with irradiated 
pairs in cells without NP treatment and when treated with 10ug/mL NPs. Surprisingly, in cells treated 
with 0.1 and 1 ug/mL of NP we couldn't observe any significant effect in their viability after being 
exposed to blue laser. These results suggest that RA+NPs could exert a protective effect against 
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irradiation, which could be due to irradiation absorption by the photo-responsive element of the NPs, 
DMNC. The next step was to find non-toxic conditions for the laser exposure. To do this, we tested 
different times of laser exposure while maintaining the laser power at 80mW and after 48h in culture 
the viability was assessed again using AnV/PI protocol (Figure 4.3B). These experiments confirm that 
300 seconds (5 minutes) of laser exposure in KG1a cells already have a significant effect in their 
viability, but no toxic effect was observed up to 150 seconds of laser exposure at 80mW.  
With the acquired knowledge regarding the toxicity of NPs and blue laser in KG1a cells, we could 
now start testing the cytotoxicity in UCB CD34+ cells. As the laser exposure seemed to have a higher 
impact in cell viability, we started to test different laser powers (Figure 4.3C) and we could observe 
that using laser powers higher than 20mW for 5 minutes had a significant effect in cell viability. Despite 
the fact that we could already observe a toxic effect using 40mW laser power, reducing the laser power 
would also reduce the amount of released cargo from the NPs, so we tried to find a compromise between 
laser power and exposure time and tested the toxicity of 40mW for different exposure times (Figure 
4.3D). At 40mW laser power, we observed a decrease in viability for laser exposure over 60 seconds. 
Finally, we tested the combined effect of the laser exposure and NP treatment in UCB CD34+ cells 
(Figure 4.3E). Although the laser exposure still seems to have a negative effect in viability in cells 
without NP treatment, just like in KG1a, the toxicity effect is decreased with increased concentrations 
of NP treatment. In fact, no significant toxicity is observed in cells treated with 10µg/mL NPs with or 
without subsequent laser exposure for 60 seconds at 40mW laser power. This could be due to the anti-
apoptotic proprieties of RA675 and/or due to the presence of the photo-sensible antenna (DMNC), which 
could diminish the irradiation effects on cells. 
Next, we wanted to characterize the internalization kinetics and the dilution of internalized NPs 
during extended cell culture periods (Figure 4.4A).  
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Figure 4.4 - Cellular uptake and dilution of RA+NPs in human AML CD34+ cell line (KG1a) and UCB 
CD34+cells. (A, B) Uptake of TRITC-labelled RA+NPs (10 μg/mL) in human AML CD34+ cell line (KG1a) (A) 
and UCB CD34+ cells (B) as determined by FACS. Cells were cultured in medium supplemented with NPs for the 
time defined in the graph, washed and characterized by flow cytometry. The results are expressed as mean±s.e.m 
(n = 3). (C, D) Dilution of TRITC labelled RA+NPs with cell culture. KG1a (C) and UCB CD34+ cells (D), were 
transfected with RA+NPs in serum-free media for 4h, washed with PBS to remove non-internalized RA+NPs and 
cultured in complete media for additional 4h, 3 days and 6 days. After each incubation time cells were washed and 
NP dilution evaluated by flow cytometry. The results are expressed as mean±s.e.m (n=3) (E) Representative 
confocal imaging of 4 h internalization of TRITC-labeled RA+NPs (red) at UCB CD34+ cells stained with the 
membrane marker PKH67 green and nuclear staining DAPI (scale bar 5µm) 
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Similar to what has been done in chapter 3, cells were treated TRITC-labelled RA+NPs for different 
periods of time and after several washes with PBS, internalization levels were assessed by flow 
cytometry (Figure 4.4B). Both KG1a and UCB CD34+ cells show similar internalization kinetics to 
what was observed in other cell lines (chapter 3). Although it only takes 4 hours to have almost all the 
cells with NPs internalised (%TRITC), they seem to continue to accumulate NPs over this time, which 
is shown by the continuous increase in the mean fluorescence intensity (M.F.I) of TRITC in the cells. 
In the case of UCB CD34+ cells, we also observed by confocal microscopy the internalized NPs after 
4h. Surprisingly, we did not observe a homogenous distribution of the NPs in the cell cytoplasm as we 
expected, instead in the case of UCB CD34+ cells, the internalization seems to be polarized. This could 
indicate that NP internalization in these cells is mainly by pinocytosis and not by receptor mediated 
endocytosis, as the observed cytoplasmic deformation only occurs during phagocytosis and 
micropinocytosis internalization, but HSC do not have phagocytic activity.(Figure 4.4E). 
For the dilution experiments, cells were treated with TRITC-labelled RA+NPs for 4 hours after 
which they were extensively washed and replated and cultured for an additional 3 or 6 days. To have a 
baseline, the internalization level was measured after 4h of NP treatment. At the selected time points 
cells were collected and the percentage of NP-loaded cells was evaluated by flow cytometry (Figure 
4.4C). In KG1a cells, after 3 days and 6 days only 15% and 5%, respectively, of the cells retained the 
NPs. When compared to percentage of internalization observed at 4 hours of internalization, these 
reductions represent approximately a 3-fold decrease for every 3 days in culture. In UCB CD34+ cells, 
similar to what we observed in KG1a, there was a 2-fold and 3-fold reduction of nanoparticles after 3 
days and 6 days in culture, respectively.   
 
Biological effect of RA-NPs in CD34+ cells 
Next, we evaluated the differentiation capacity effect of RA+NP in CD34+ cells. We started to test 
the effect of RA+NPs in the differentiation of KG1a cells and also the differentiation potential of 
RA+NPs after 3 and 6 days in culture before activation. The RA+NPs were internalized for 4h hours and 
after being washed with PBS, divided into 3 groups, one where cells were irradiated with the blue laser 
right after wash (4 h activation), in the second and third group cell were cultured for additional 72 h or 
144h, respectively, before laser activation. As a control condition, soluble RA was added to cells at the 
same time of laser activation of each group. In all groups the differentiation was evaluated 3 days after 
activation, by flow cytometry with CD11b/CD13 staining (Figure 4.5A). At 4 hours activation, all 
treatments seem to initiate the differentiation program of KG1a, observed by the decrease in 
CD13+CD11b- population and increase of CD13dimCD11b-/+ populations, however statistical significant 
terminal differentiation (CD13+CD11b+) can only be observed when cells are treated with RA+NPs and 
activated by blue laser (Figure 4.5B). As we observed previously, the percentage of cells that retain 
RA+NPs decreased with culture time (Figure 4.4B), so as expected the differentiation potential of the 
NPs was diminished when NPs were activated only after 72 or 144 h. 
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Figure 4.5 - Differentiation profile of in human AML CD34+ cell line (KG1a) and UCB CD34+cells after 
treatment with soluble RA or RA+NPs. (A, B) KG1a cells were incubated in complete IMDM with 2% serum 
with soluble RA or 10 µg/mL RA+NPs for 4 h. Then, cells were washed three times with PBS to remove NPs not 
internalized and replated in IMDM 20% serum. Cells were irradiated with a blue Laser (405 nm 80mW, 3 min) 
immediately or after 3 or 6 days and then cultured for 3 days after being irradiated. (A) Flow cytometry analysis 
of differentiated KG1a cells cultured for 3 days. Cells were initially gated in an FSC/SSC plot and gated analysed 
for CD13 and CD11b expression levels. Percentages of positive cells were calculated based in the isotype. (A) 
Percentages of CD13+CD11b- CD13+ CD11b+, CD13dimCD11b- and CD13dimCD11b+ in KG1a cells activated 
at 4h, 3 days and 6 days after RA+NP treatment and differentiated for 72 h. (B) KG1a CD13+ CD11b+ 
differentiation profile evolution at different times of activation. (C) UCB CD34+ cells were incubated in complete 
XVIVO15 media (supplemented with Flt3 and SCF). with soluble RA or 1 µg/mL RA+NPs for 4 h. Then, cells 
were washed three times with PBS to remove NPs and irradiated with a blue Laser (405nm 40mW,60 sec). After 
3 days in culture, cells were stained for CD34 and CD38 markers and differentiation analysed by flow cytometry. 
The results are expressed as mean±s.e.m (n=3). Statistical analyses were performed by two-way ANOVA followed 
by a Holm-Sidak post-test. *P<0.05, **P<0.01 and ****P<0.0001. 
Next, we tested the NPs effect on the differentiation of UCB CD34+ cells following a similar 
methodology as previously described, however we only tested activation right after 4 h of 
internalization, and 72h later cells were stained for CD34 and CD38 and differentiation evaluated by 
flow cytometry. Again, cells treated with RA+NPs and activated by light showed the most significant 
increase in CD38 staining when compared to all other conditions. Furthermore, none of the treatments 
had an effect in CD34 expression. These results are in line with previous observations, where soluble 
RA induced CD38 expression in normal hematopoietic progenitor cells and leukemic human cells. 
However, CD38 increased expression was only correlated with terminal differentiation in CD34- 
progenitors and leukemic promyelocytic cell lines (e.g. HL-60).  Conversely, in CD34+ leukemic cell 
lines (e.g. KG1a) and in primary human CD34+ cell cultures derived from AML patients, CD38 
expression and terminal differentiation were not correlated676. 
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Since we have shown that polymeric photo-triggerable NPs could be efficiently loaded in human 
HSC and remotely activated without toxic effects while maintaining their functionality, we decided to 
further explore their potential use to modulate healthy HSC. 
 
4.3.4 Production and characterization of functional TAT-HoxB4 recombinant protein 
To have functional HoxB4 that could be used in this study, we produced a recombinant version of 
HoxB4 fusion protein, TAT-HoxB4. We have used a TAT-HoxB4 expression vector that has a C-
terminal 6xHistag which allows us to purify the protein by affinity and a N-Terminal TAT sequence, 
which facilitates the internalization of the protein677. The protein was produced similarly to what has 
been done in the past655,658. In short, recombinant HoxB4 was produced in E.coli expression system and 
purified by affinity under denaturing conditions (in the presence of Urea) and elution made with 
increasing concentrations of imidazole (Figure 4.6A panel I). Then the protein underwent a second 
purification step using an ionic-exchange chromatography (Figure 4.6A panel II) and finally eluted and 
shock-refolded in a single step by using high concentration of NaCl (Figure 4.6A panel III). Finally, 
the protein was eluted in PBS. As a result of the needed multiple purification, resulting protein 
concentration was very low to be used in our experiments, so we decided to concentrate it by using an 
Amicon 10 kDa. The purity and concentration of the TAT-HoxB4 and fusion protein were determined 
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and detected with 
Coomassie Blue staining. The purified TAT-HoxB4 run as ~37 kDa protein and the concentration was 
estimated by comparison with a BSA protein standard in the same gel.  
To demonstrate that the purified protein had biological activity, we proceeded to an electrophoretic 
mobility shift assay (EMSA). Purified TAT-HoxB4 protein was incubated with an oligo containing the 
HoxB4 consensus sequence (5’-CGAATTGATTGATGCACTAATTGG AG-3’). The detection of the 
shift was done using a DNA/Protein double stain kit and although the shift is not very clear at the protein 
level, when looking at the DNA probe bands it was clear that the produced protein interacts with the 
probe, by the observed shift in the DNA band (Figure 4.6B). To confirm that this shift was not caused 
by unspecific interaction with contaminant proteins present in the TAT-HoxB4 solution, we also 
included a control in which we previously incubated the protein extract with an antibody for HoxB4. 
The increased shift observed in this condition confirms the specificity of the interaction and overall that 
the produced protein is functionally active and able to interact with its target, contrary to the commercial 
HoxB4. 
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Figure 4.6 - Production and validation of biological activity of TAT-HoxB4. (A) Purification of recombinant 
TAT-HoxB4 (~37kDa) by (I) HisTrap affinity followed by (II) cationic exchange and a final step of shock-
refolding by (III) fast dessalting. (B) DNA-Binding competence of produced TAT-HoxB4 assessed by 
electrophoretic mobility shif assay using a probe for the consensus HoxB4-PBX1 binding site oligo sequence (5’ 
CGA ATT GAT TGA TGC ACT AAT TGG 3’). Activity of Hoxb4 confirmed by the shift in the presence of 
double-stranded oligo and further specificity of the reaction confirmed by the supershift in the presence of an anti-
HoxB4 antibody, observed in the increase of intensity of higher bands in both DNA(SYBR Green) and protein 
stain(SYPR Ruby). (C) Schematic representation of the methodology used for cell cycle and G0 determination 
experiments. (D) and (E) Flow cytometry results of the effect of TAT-Hoxb4 on the cell cycle of modified murine 
pro-B cells, BaF3-GATA2. (D) Gating strategy. (E) Percentages of the cell cycle phases determined after 48 h of 
a single treatment with β-ER or TAT-HoxB4 (50nM and 500nM). Statistical analyses were performed by two-way 
ANOVA followed by a Holm-Sidak post-test. *P<0.05, **P<0.01 ***P<0.001 and ****P<0.0001. 
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4.3.5 Effect of TAT-HoxB4 in the cell cycle 
 
Next, we wanted to evaluate if the produced protein was biologically active. Because the quiescence 
of HSCs is a key aspect for the homing and maintenance of stemness of the HSC654, we decided to 
evaluate the influence of TAT-HoxB4 in the cell cycle. Classical flow cytometry cell cycle assays allow 
to determine the different phases of the cycle (G1/0, S, G2/M) only by DNA levels, however it does not 
allow to distinguish between quiescent cells (G0) from active G1 cells as they will have similar DNA 
amounts. By using a RNA fluorescent probe, we can separate G0 and G1 phases, as the dormant G0 
cells will have lower levels of RNA when compared to G1678. 
To validate and optimize the G0 determination protocol we initially used the BaF3 murine cell line 
stably expressing a GATA2-Estrogen Receptor inducible construct (BaF3-GATA2/ER). This cell line 
was previously used to determine the role of GATA2 in the cell cycle of haematopoietic stem and 
progenitor cells, where the addition of β-estradiol (β-ER) to the culture media will activate the 
transcription of GATA2, increasing the quiescence of the cells406.  Also, HoxB4 has been reported as a 
direct downstream target of the GATA2 in human CD34+ cells679. 
For cell cycle assays and G0 determination (Figure 4.6C), BaF3-GATA2 were cultured with RPMI 
culture medium supplemented with murine IL-3 and treated with a single addition of TAT-HoxB4 (50 
and 500 nM) or β-ER (1µm) as an internal control of G0 induction. After 48h in culture, cells were 
stained for DNA (7-AAD) and RNA (Pyronin) and analysed by flow cytometry (Figure 4.6D). Only at 
high concentrations of HoxB4 a similar level of G0 to the one observed in the control conditions (β-ER) 
could be achieved (Figure 4.6E). These results go along with previous observations that HoxB4 protein 
is very unstable in culture medium658, with a reported half -life of 2h and that continuous 
supplementation of fresh HoxB4 is needed to achieve a positive effect in the expansion of HSCs680. 
To better understand the dose effect of TAT-HoxB4 in the cell cycle of HSCs we tested the influence 
of different HoxB4 dosages during cell culture. Although our final objective is to deliver HoxB4 to 
human UCB CD34+, the availability of this cells is scarce, so we decided to use as a model the KG1a681 
cell line, a differentiation-resistant human AML cell line containing a very primitive population of 
CD34+CD38-. For this purpose, we treated KG1a cells with TAT-HoxB4 for 48 h (Figure 4.7A), in one 
experimental group TAT-HoxB4 was renewed after 24h, in the other group was renewed every 8 h. 
After the treatments cells were collected and analysed for cell cycle (G0 arrest) (Figure 4.7B) and for 
gene expression (Figure 4.8B). 
With cell cycle analysis we could observe that only two treatments of HoxB4 are already enough to 
induce quiescence in these cells, however only when multiple treatments are applied that we can see 
most of the cells acquiring a quiescence state (Figure 4.7C). 
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Figure 4.7 - TAT-HoxB4 Dosage effect in the cell cycle of human AML CD34+ cell line KG1a. KG1a cells 
were incubated in complete IMDM supplemented with HoxB4 (500nM). Every 8h or 24h cells were supplemented 
with fresh HoxB4. Cells were collected 48h after the first treatment and stained with 7AAD (DNA) and PyroninY 
(RNA) followed by flow cytometry analysis of the cell cycle and G0 determination. (A) Schematic representation 
of the methodology used. (B) Representative gating strategy for cell cycle analysis. (C) Percentages of the cell 
cycle phases determined after 48 hours of multiple treatments with TAT-HoxB4 (500nM), every 24h or every 8h. 
Results are expressed as mean±s.e.m (n=3). Statistical analyses were performed by two-way ANOVA followed 
by a Holm-Sidak post-test. *P<0.05, **P<0.01 ***P<0.001 and ****P<0.0001. 
Next, we monitored the effects of the different TAT-HoxB4 treatments on the transcriptional 
regulation of key genes related with HoxB4 regulation cascade (HEMGN, GATA2, CUL4 and PBX1) 
and cell-cycle associated genes CDC20 and CDK2 (Figure 4.8). Consistent with the cell cycle data, the 
strongest upregulation of HoxB4 related genes was observed in the 8 hours treatments, with PBX1, a 
transcriptional co-factor of HoxB4, being the most upregulated; followed by the Hoxb4 direct targets 
HEMGN and GATA2. Also, not surprisingly, we could observe high levels of expression of CUL4, a 
ubiquitin ligase protein, previously associated with the high levels of cellular degradation of HoxB4658. 
As for CDC20 and CDK2, cell cycle regulators in cell division (M phase) and S phase entry, we could 
observe an increase with HoxB4, but no significant difference was observed with different HoxB4 
treatments. This data supports the double role of HoxB4 in the maintenance of HSC stemness by 
promoting an accumulation in G0 without a full cell cycle arrest, allowing the expansion of HSCs. 
CHAPTER 4 - Prospective studies on nanoformulations that are able to modulate healthy and leukemic niches 
114 
 
 
Figure 4.8 - Genes modulated by HoxB4 during G0 induction in KG1a cells as assessed by qRT-PCR 
analyses. (A) Gene expression profile of KG1a cells 2 h, 4 h and 8 h after treatment with 500nM HoxB4. (B) Gene 
expression of KG1a cells after 48 h of treatment with HoxB4 (500nM), with HoxB4 renewal every 24h or every 
8h. In each run, the expression of each gene was normalized by GAPDH gene. Gene expression in each 
experimental group was normalized by the corresponding gene expression observed in nontreated KG1a cells. 
Results are expressed as mean±s.e.m (n=3). Statistical analyses were performed by two-way ANOVA followed 
by a Holm-Sidak post-test. *P<0.05, **P<0.01 ***P<0.001 and ****P<0.0001. 
 
4.3.6 Immobilization of HoxB4 in NPs 
Next, we hypothesized that if we could encapsulate or immobilize the TAT-HoxB4 in a nanoparticle 
system, we could improve not only the stability of the protein, but also take advantage of the light-
activatable NP platforms developed in our group which would allow us to control with higher precision 
the time, location and dosage of the release. Our first approach was to try to encapsulate TAT-HoxB4 
by replacing RA with the TAT-HoxB4 in PEI-DMNC:DS nanoparticles (Figure 4.9A). However, 
despite many attempts using different concentrations of HoxB4 we could not detect any protein 
associated with the NPs using Coomassie (Figure 4.9B). In fact, all the protein seems to be lost during 
the first centrifugation at 350g. In normal conditions, we can only achieve sedimentation of soluble 
proteins with >10000g forces, so this sedimentation of TAT-HoxB4 at 350g may indicate that the protein 
is losing solubility either by forming aggregates with itself and/or with dextran sulphate, the polyanion 
block of the nanoparticles.  
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Figure 4.9 - HoxB4 ligation to light sensitive NP platforms. (A, B) Characterization of the encapsulation of 
TAT-HOXB4 in PEI-DMNC:DS NPs. Size, zeta potential and number of NPs (Kcps) of NPs in an aqueous 
suspension exposed or not to UV light (5min 100W). (B) Evaluation of encapsulation efficiency by SDS-PAGE. 
(C) Schematic representation of procedure to test the covalent ligation of TAT-HOXB4 (positively charged) to the 
PCL of up-conversion nanocrystals (negatively charged) SDS was used to eliminate electrostatic interactions. (D) 
SDS-PAGE evaluation of supernatants (SN) and pellets (P) from the different steps. 
 
As the physical encapsulation did not seem to be feasible with the DS:PEI-DMNC NP system we 
decided to try a different approach. In this second approach we used an up-conversion nanocrystal (NC) 
system developed in our group, which can convert infrared irradiation to UV irradiation. These NCs 
were functionalized with a photocleavable linker (PCL), sensible to the UV, which allows to covalently 
bond proteins by their C-terminal; in the case of our recombinant HoxB4 this is especially relevant as 
the TAT-sequence is at the N-terminal. In this way, we could maintain the full functionality of TAT-
HoxB4 and still use light stimulus to control the release. After confirming the functionalization of the 
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NCs with the PCL, the carboxylic group of TAT-HoxB4 was activated and the ligation made by click-
chemistry. To confirm the ligation reaction (Figure 4.9C), we run both pellets and supernatants (Figure 
4.9D, SN-1) of a 5000g centrifugation of TAT-HoxB4+NC suspension, before (Figure 4.9D, P-1 and 
SN-1) and after 10 minutes irradiation with UV (Figure 4.9D, P-2 and SN-2). Despite we could detect 
almost all the protein with the NCs pellet before irradiation, we were unable to detect protein in the 
supernatant after UV irradiation of the NC suspension. As the NCs are negatively charged and the TAT-
HoxB4 has a positive isoelectric point (pI.~10), we hypothesized that TAT-HoxB4 could be interacting 
electrostatically with the NC surface instead of being covalently bound by the PCL. To test this, we 
incubated the TAT-HoxB4+NCs with a 10%SDS PBS solution for 10 minutes before proceeding to the 
centrifugation. By using a detergent, we expect to reduce the electrostatic interactions. In fact, by doing 
this most of the protein was detected in the supernatant of the solution (Figure 4.9D, SN-3) Although 
some protein could be detected in the pellet fraction (Figure 4.9D, P-3), this was likely to be still either 
some carryover from the protein in the SN or still protein electrostatically bound to the NC. 
While we were able to produce biological active HoxB4 protein, which can regulate HSC self-
renewal, conjugation of HoxB4 to a nanoplatform showed to be more challenging than expected and 
further work is need to overcome the obstacles found during the development of this work. 
 
 
4.4. Conclusions 
In this chapter we were able to demonstrate that athe feasibility in AML therapy of targeted spatio-
temporal controlled drug release system, composed by LSCs and photo triggerable RA+NPs, can be 
successfully used in an AML disease model. Our results   show that, instead of alternately to soluble RA 
treatments, RA+NPs can be used to induce AML differentiation towards monocytic/macrophage lineage 
not only in vitro but also in vivo in an MLL-AF9 mouse model of AML. Also, we have shown in vitro 
evidence that soluble RA and more significantly, activation of RA+NPs, stimulate antitumoral M1 
macrophage activation. This macrophage induced differentiation in vivo seems to have “systemic” anti-
leukemic effect within the BM leukemic niche, as we observed a significant reduction of leukemic cells 
in the BM of animals treated with RA+NPs when compared with animals treated with empty NPs (RA--
NPs). 
We also explored the potential use of this system using healthy HSCs as RA+NP carriers. Our results 
indicate that RA+NPs can be loaded in human UCB CD34+ cells as efficiently as observed in human 
AML CD34+ cell lines (4h internalization). Although, UCB CD34+ cells seem to be more sensitive to 
blue laser irradiation, shorter irradiation time (1 min) at lower laser power level (40mW) was still 
sufficient to trigger RA release from NPs and trigger the expression of CD38 in UCB CD34+cells. 
In the final part of this chapter, we were able to produce biologically functional HOXB4, which we 
were able to show it is capable to induce a quiescent state in human AML CD34+ cell lines. 
Unfortunately, HOXB4 loading or surface ligation in NP proved to be difficult, probably due to its 
intrinsic physico-chemical properties (e.g. size, charge, conformation). 
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4.5. Materials and Methods 
 
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis. Total 
RNA was extracted and purified using RNeasy Micro Kit (Qiagen) and immediately stored at -
80ºC. Total RNA was quantified in a NanoDrop ND-1000 Spectrophotometer (NanoDrop 
Technologies, Inc., USA) by spectrophotometry at 260 nm. The cDNA was reverse transcribed 
from 0.5 μg of total RNA, using TaqMan Reverse Transcription Reagents kit (Invitrogen) according 
to the manufacturer’s instructions. The cDNA obtained was stored at -20ºC until further analysis 
by qRT-PCR using SYBR Green technology and qRT-PCR analyses were performed using the ABI 
PRISM 7500 Fast System (Applied Byosystems). Quantification of target genes was performed 
relative to GAPDH gene according to the equation: 2[–(Ct sample –Ct GADPH)]. The mean minimal cycle 
threshold values (Ct) were calculated from quadruplicate reactions.  
 
 
RA+NPs internalization by MLL-AF9 blasts and differentiation - MLL-AF9 YFP cells were 
incubated in serum-free RPMI-1640 with RA+NPs (10 μg/mL) for 4 h. Then, cells were washed three 
times with PBS to remove NPs not internalized, activated or not by blue laser (405nm, 80mW) during 
5 min, and cultured in complete medium for additional 3 days. Alternatively, MLL-AF9 YFP were 
cultured in complete medium for 3 days having soluble RA (3μg/mL). The differentiation at 72h post 
treatment was evaluated by flow cytometry: GMPs (Ly6G+CD11b-), Neutrophil (Ly6G+CD11b+) and 
Macrophage (Ly6G- CD11b+F4/80+) differentiation markers. Percentage of macrophage activation 
markers for type 1 (MHC II+CD206-) and type 2 (MHC II-CD206+) polarization. Percentage of 
myelocytic differentiation MLL-AF9 cells in neutrophils or macrophages and percentage of type 1 and 
type 2 macrophage polarization. 
Intravital microscopy to monitor cell activity inside the calvaria BM niche. First mTmG MLL-
AF9 blasts were injected in healthy mice to induce disease infiltration. After 12-14 days YFP MLL-AF9 
blasts previously loaded with RA+NPs or empty NPs were injected. One or two days later, after 
confirming by intravital microscopy the homing of YFP blasts to the same niche as mTmG blasts, the 
nanoparticles were activated by exposing the mouse calvaria to the blue laser for 10 minutes. This 
activation was repeated the following day. Three days after the last activation, the progression of the 
disease and MLL-AF9 activity were monitored inside the niche by time-lapse image acquisition. In the 
end of the acquisitions, mice were sacrificed and BM was collected from the calvaria and long bones 
and analysed by flow cytometry. 
 
Treatment with delivery cells MLL-AF9 YFP+ previously transfected with RA-NPs (n=3) or 
RA+NPs (n=3) by tail vein injection. After the homing (1 day) of delivery cells, the NPs were remotely 
activated by irradiating the mouse calvaria with a blue laser (5 min, 405 nm, 80mW) on the following 
two days. On the fifth day after MLL-AF9 YFP injection mouse were sacrificed and BM from the 
calvaria and long bones isolated for flow cytometry analysis. 
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NPs in UCB CD34+ cells Internalization and Cytotoxicity of RA+NPs and light activation at 
human AML CD34+ cell line (KG1a) and UCB CD34+ Briefly KG1a cells were treated with different 
concentrations of RA+NPs (0.1, 1 and 10ug/mL) for 4 hours in complete RPMI-1640 media with 1% 
FBS. After the incubation period cells were washed with PBS several times to remove non-internalized 
NPs and replated with complete RPMI-1640 with 10% FBS and irradiated or not with a blue laser 
(405nm, 5 minutes at 80mw). After 48h cells were collected and AnV/PI flow cytometry protocol was 
used to assess the toxicity of the NPs. To find non-toxic conditions for the laser exposure, cells were 
exposed to a blue laser at 80mW for different time periods…… 
 
Cellular uptake and dilution of RA+NPs in human AML CD34+ cell line (KG1a) and UCB 
CD34+cells. Uptake of TRITC-labelled RA+NPs (10 μg/mL) in human AML CD34+ cell line (KG1a) 
and UCB CD34+ cells was determined by FACS. Cells were cultured in medium supplemented with 
NPs, washed and characterized by flow cytometry. Dilution of TRITC labelled RA+NPs with cell 
culture. KG1a and UCB CD34+ cells were transfected with RA+NPs in serum-free media for 4h, washed 
with PBS to remove non-internalized RA+NPs and cultured in complete media for additional 4h, 3 days 
and 6 days. After each incubation time cells were washed and NP dilution evaluated by flow cytometry.  
 
Differentiation capacity of RA+NP in KG1a e UCB CD34+ cells. The RA+NPs were internalized 
for 4h hours and after being washed with PBS, divided into 3 groups, one where cells were irradiated 
with the blue laser right after wash (4 h activation), in the second and third group cell were cultured for 
additional 72 h or 144h, respectively, before laser activation. As a control condition, soluble RA was 
added to cells at the same time of laser activation of each group. In all groups the differentiation was 
evaluated 3 days after activation by flow cytometry by CD11b/CD13 staining 
 
TAT-HoxB4 production. Recombinant HoxB4 was produced in E.coli expression system and 
purified by affinity using an HisTrap HP chromatography column (GE Healthcare) under denaturing 
conditions (in the presence of 8M Urea) and elution made with increasing concentrations of imidazole 
(Figure 4.6A panel I). Then the protein underwent a second purification step using an ionic-exchange 
chromatography (HiTrap SP HP, GE Healthcare ) (Figure 4.6A panel II) and finally eluted and shock-
refolded in a single step by using 20mM HEPES supplemented with 1M NaCl (Figure 4.6A panel III). 
At this point, the sample buffer was then exchanged to PBS, using an HiTrap desalting column and as 
the resulting eluted protein concentration was low, purified recombinant HoxB4 was concentrated using 
and Amicon 10 kDa. The purity and concentration of the TAT-HoxB4 and fusion protein were 
determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and detected 
with Coomassie Blue staining. The purified TAT-HoxB4 run as ~37 kDa protein and the concentration 
was estimated by comparison with a BSA protein standard in the same gel. 
 
Validation of biological activity of TAT-HoxB4. An electrophoretic mobility shift assay (EMSA) 
was used. Purified TAT-HoxB4 protein was incubated with an oligo containing the HoxB4 consensus 
sequence (5’-CGAATTGATTGATGCACTAATTGG AG-3’) for 1hour and then loaded in a 6% non-
denaturing polyacrylamide gel. The detection of the shift was done using a DNA/Protein double stain 
kit  
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Effect of TAT-HoxB4 in cell cycle. Classical flow cytometry cell cycle assays allow to determine 
the different phases of the cycle (G1/0, S, G2/M) only by DNA levels, however it does not allow to 
distinguish between quiescent cells (G0) from active G1 cells as they will have similar DNA amounts. 
By using a RNA fluorescent probe, we can separate G0 and G1 phases, as the dormant G0 cells will 
have lower levels of RNA when compared to G1. BaF3 murine cell line stably expressing a GATA2-
Estrogen Receptor inducible construct (BaF3-GATA2/ER). For cell cycle assays and G0 determination, 
BaF3-GATA2 were cultured with RPMI culture medium supplemented with murine IL-3 and treated 
with a single addition of TAT-HoxB4 (50 and 500 nM) or β-ER (1µm) as an internal control of G0 
induction. After 48h in culture cells were stained for DNA (7-AAD) and RNA (Pyronin) and analysed 
by flow cytometry. 
 
TAT-HoxB4 Dosage effect in the cell cycle of human AML CD34+ cell line KG1a. KG1a cells 
were incubated in complete IMDM supplemented with HoxB4 (500nM). Every 8h or 24h cells were 
supplemented with fresh HoxB4. Cells were collected 48h after the first treatment and stained with 
7AAD (DNA) and PyroninY (RNA) followed by flow cytometry analysis of the cell cycle and G0 
determination.  
 
Immobilization or Encapsulation of HoxB4. Encapsulate TAT-HoxB4 by replacing RA with the 
TAT-HoxB4 in PEI-DMNC:DS nanoparticles. Detect protein associated with the NPs using Coomassie. 
Encapsulation efficiency by SDS-PAGE. Covalent ligation of TAT-HOXB4 (positively charged) to the 
PCL of up-conversion nanocrystals… 
 
Statistical analysis. Statistical analyses were performed with GraphPad Prism software. For 
multiple comparisons, a two-way ANOVA followed by a Holm-Sidak post-test was performed. Results 
were considered significant when P< 0.05. Data are shown as mean ± s.e.m. unless other specification. 
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General conclusions and Future work 
In conclusion, with this work we were able to develop a naturally targeted drug delivery system for 
AML therapy, featuring a high degree of precision in the spatio-temporal control of drug release and 
delivery. 
To achieve this, we developed a biocompatible photo-triggerable NP system to deliver RA 
intracellularly. Photo-triggerable RA+NPs can be quickly internalized and avoid cellular degradation by 
lysosomal escape, which allows a prolonged intracellular accumulation of functional NPs inside LSC400. 
Our nanoformulation, allowed us to explore the natural tropism of LSCs (as a targeting strategy) to 
deliver RA+NPs in leukaemic niches of the BM in a stealthy manner, as cell carriers avoid systemic 
immunological recognition and response. We would also expect this system to have less off-target 
accumulation and side effects, when compared with other targeted drug delivery systems. Although we 
did not evaluate the systemic distribution in the whole animal, we believe the great majority of RA+NP 
loaded cells would naturally accumulate at the BM. Furthermore, our photo-triggerable system allowed 
us to choose, with precision, the time and location (i.e. calvarium bone) of RA release from NPs by an 
external stimulus (i.e. blue laser irradiation – 405nm). 
We also observed that RA+NPs can help to reduce leukaemia burden in MLL-AF9 AML mouse 
model and promote macrophage differentiation of carrier cells in vitro and in vivo. However, further 
investigation is necessary to clarify our observations. Although it was not possible to analyse before the 
submission of this thesis, we also used intravital microscopy imaging techniques70 to acquire calvaria 
tilescans, and 3h time-lapses of calvarium BM before and after exposure to blue laser in animals treated 
with NP-loaded MLL-AF9 cells. Intravital imaging was performed in the same animals used in flow 
cytometry characterization of BM cell composition in animals treated with empty NP (RA-NPs) and 
RA+NPs. We are now conducting image analyses in order to better understand the mechanism. This kind 
of analysis would allow to observe biological events to support our results, such as: phagocytic events 
from carrier cells, apoptotic events from either carrier cells or resident leukaemic cells. We could also 
investigate the different migration patterns of both MLL-AF9 blasts used in this experiment. We would 
expect to find the majority of YFP+ to migrate preferentially to the vicinity of mTmG MLL-AF9 cells 
expanding in the BM of treated mice. 
Preliminary data obtained by particle analysis, showed that we could potentially use two-photon 
laser to activate RA+NPs with high precision, which coupled with intravital imaging could allow us to 
study, in deeper detail, the interaction promoted by our system within the bone marrow niche. For 
example, we could activate carrier cells preferentially located at different niches (endosteal v.s. 
perivascular niche) and follow the promoted effects by intravital time-lapse imaging.  
Our observations could be further improved towards a potential clinical application by: 
1) doing a better characterization of BM cells, either by a better choice of antibody panel choice 
which could better identify macrophages and type of activation, or by better discrimination of different 
BM fractions (e.g. flushing central marrow diaphysis and trabecular-rich areas by crushing metaphysis 
area682; 
2) testing the impact of RA+NPs related LSC clearance in the survival; 
CHAPTER 5 - General Conclusions and Future Work 
124 
 
3) using in a combined therapy approach, with other therapeutic agents683; for example, RA+NPs 
could be used in combination anti-CD38-based therapeutic agent (Mol Cancer Ther. 2004 Mar;3(3):345-
52). 
RA is a signalling molecules with pleiotropic effects, serving as key modulator in different parts of 
the organism. in the modulation of haematopoiesis, while it induces LSC differentiation in APL or in 
HSPCs, it can also be involved in the regulation of HSC self-renewal and maintenance380. Making 
RA+NPs a good candidate to be tested in HSCT therapy used during remission therapy. Although we 
did not fully explore this option, our results indicate that HSC could be a good candidate to be the carrier 
cell on our drug delivery system, as we showed that RA+NPs can be loaded and activated efficiently in 
UCB CD34+. Also, a fast NP internalization protocol can decrease the exposure of HSC to normoxia 
atmospheric conditions, which compromises HSC recovery from the BM and cord blood274. 
Besides AML, RA+NPs could potential be explored in other types of cancer therapy, such as brain 
tumours, or other hematopoietic malignancies specially in other leukaemia, bone metastasis and also in 
regenerative therapy. For example, we could take advantage of the small RA passive release (leakiness 
of the NPs) to help in maintaining HSC functionality during transplantation. This would probably 
potentiate a higher efficiency in terms of numbers of HSCs that reach the niche. On the other hand, due 
to the rarity and difficulty to isolate HSCs in high numbers for experimental purposes, maybe by using 
cells with higher availability as NP carriers would be more rewarding; such as: MSC, 
Macrophages/Monocytes, T cells, NK cells. 
NP delivery systems are attractive for the delivery of protein and in particular transcription factors. 
They can help in stabilizing and protecting proteins from degradation and also because they can serve 
as an intracellular delivery system, important in transcription factors delivery as they often require post-
translational modifications in order to become biologically active. In this work, the conjugation of 
functional HOXB4 with a NP-delivery system failed and we are actively looking for other alternatives. 
In the meantime, further NP improvements have been made in our group which would allow a higher 
diversity of applicability either by allowing for an easier conjugation/loading of proteins, small 
molecules or nucleic acids684-686, or by using light wavelengths which allow higher body penetration and 
less toxic effect than 405nm laser irradiation. In particular, Jimenez-Balsa A et al NP systems would be 
specially interesting as it could possibly allow for a double delivery system, by encapsulating a small 
molecule and conjugate any other type of biomolecule to the photo-cleavable linker. 
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